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 Abstract		
Background:	 Adolescent	 girls	 and	 young	 women	 (AGYW)	 are	 at	 high	 risk	 for	 HIV	infection,	 particularly	 in	 Southern	 Africa.	 In	 addition,	 some	 hormonal	 contraceptives	(HC),	 such	 as	progestin	 only-injectable	 contraceptives	 DMPA	 and	NET-EN,	 have	 been	associated	with	 significantly	 increased	 risk	 for	HIV	 infection.	 These	HC	 together	with	sexual	 immaturity	may	 increase	activation	of	CD4+	T	cells	 in	 the	 female	 reproductive	tract	 (FRT),	 which	 are	 target	 cells	 for	 HIV	 infection.	 NuvaRing,	 also	 a	 long-acting	progestin-containing	contraceptive	albeit	topical,	has	recently	been	introduced	to	South	Africa,	and	may	offer	an	improved	safety	profile	over	NET-EN	and	DMPA	in	terms	of	HIV	risk	 for	 young	women.	 Recently,	 Th17	 cells	 have	 been	 found	 to	 be	 disproportionally	susceptible	to	HIV	infection	compared	to	the	other	T	helper	subsets	although	the	impact	of	HC	use	 on	Th17	 cell	 frequency	 and	 activation	 has	 not	 been	 investigated.	Here,	 the	impact	 of	 NuvaRing,	 NET-EN	 and	 combined	 oral	 contraceptive	 pills	 (COCPs)	 on	 the	vaginal	microenvironment	of	the	FRT	in	AGYW	was	investigated	as	this	relates	to	HIV	risk,	 with	 particular	 focus	 on	 cervical	 Th17	 cells	 and	 their	 related	 cytokines	 (Th17-related	cytokines).	
	
Methods:	One	hundred	and	thirty	HIV-negative	adolescent	girls	between	the	age	of	15	and	19	years	were	enrolled	 into	a	 randomized,	 controlled	crossover	 study	comparing	NuvaRing	 (n=45),	 NET-EN	 (n=45),	 and	 COCPs	 (n=40)	 for	 16	 weeks	 (~4	 menstrual	cycles).	 At	 crossover	 (16	 weeks),	 the	 AGYW	 changed	 to	 another	 method	 for	 the	following	 16	 weeks:	 23	 of	 those	 who	 used	 NuvaRing	 changed	 to	 NET-EN	 while	 8	changed	 to	 COCPs;	 23	 of	 those	 who	 used	 NET-EN	 and	 24	 of	 those	 who	 used	 COCPs	changed	 to	 NuvaRing.	 The	 protocol	 included	 three	 study	 visits	 in	 total	 (screening,	crossover,	study	completion	visits).	Of	the	130	adolescents	enrolled,	107/130	reached	the	 crossover	 visit	 and	 92/130	 reached	 the	 study	 exit	 visit.	 All	 adolescents	 were	screened	 for	 STIs	 (multiplex	 PCR	 for	 Chlamydia	 trachomatis,	 Neisseria	 gonorrhoeae,	
Trichomonas	vaginalis	and	Mycoplasma	genitalium),	BV	(by	Nugent	scoring),	and	yeast	(visible	hyphae	on	gram	stain)	at	all	study	visits.	Data	on	relative	abundance	of	vaginal	microbial	community	types	(CTs)	from	ectocervical	swabs	was	available	for	this	study,	determined	 by	 16S	 rRNA	 sequencing	 of	 the	 V4	 region.	 Several	 genital	 samples	 were	
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collected,	including	Digene	cervical	cytobrushes	(for	flow	cytometry	of	cervical	T	cells)	and	 menstrual	 cups	 at	 each	 study	 visit	 (for	 measurement	 of	 genital	 cytokine	concentrations).	 Multiparameter	 flow	 cytometry	 was	 performed	 on	 cytobrushes	 to	determine	 the	 frequency	 and	 activation	 status	 (CD38	 and	 HLA-DR)	 of	 Th17	 cells	(defined	 by	 expression	 of	 CCR6+CCR10-),	 total	 CD3+CD4+	 T	 cells	 and	 CD3+CD8+	including	Tc17	cells	 (CD8+	CCR6+).	A	panel	of	 fifteen	Th17-related	cytokines	(IL-17A,	IL-17F,	IL-21,	IL-22,	IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α,	IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ	and	sCD40L)	were	measured	in	genital	secretions	by	Luminex.	Results	have	been	presented	as	an	intention	to	treat	(ITT)	and	per	protocol	(PP;	which	accounted	for	early	switching	of	 HC	 products	 prior	 to	 the	 crossover	 visit).	 Unless	 otherwise	 stated,	 all	 statistical	testing	 was	 non-parametric,	 and	 P≤0.05	 were	 considered	 significant.	 The	 Benjamini-Hochberg	method	was	used	to	adjust	for	multiple	comparisons.	
	
Results:	 In	 the	 FRT	 of	 adolescents	 at	 baseline	 (before	 randomization),	 Th17	 cells	(CCR6+CCR10-)	were	found	to	be	the	major	CD4+	T	cell	subset	in	cytobrushes	(median	54.4%,	 IQR	 43.7%	 -	 64.3%)	 compared	 to	 CCR6-CCR10-	 (median	 42.2%,	 IQR	 33.5%	 -	52.6%),	 CCR6+CCR10+	 (median	 1.2%,	 IQR	 0.4%	 -	 2.8%)	 and	 CCR6-CCR10+	 (median	0.8%,	IQR	0.2%	-	1.9%).	Higher	frequencies	of	Th17	cells	expressed	CCR5	compared	to	CCR6-CCR10-	CD4+	T	cells	(median	68.0%	vs	56.2%	respectively,	p<0.0001).	However,	Th17	 cell	 frequencies	 did	 not	 correlate	 with	 genital	 tract	 Th17-related	 cytokines	 at	baseline.	The	presence	of	BV	or	STIs	did	not	appear	to	influence	either	the	frequencies	or	activation	status	of	cervical	Th17	cells.	Although	BV	(Nugent	7-10)	and	having	a	non-
Lactobacillus-dominated	 vaginal	 microbiome	 (C1)	 was	 associated	 with	 increased	concentrations	 of	 all	 Th17-related	 cytokines	 (IL-17A,	 IL-17F,	 IL-21,	 IL-22,	 IL-6,	 IL-1β,	IL-23,	 IL-33,	 TNF-α,	 IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ	 and	 sCD40L)	 compared	 to	 those	without	 BV	 (Nugent	 0-3)	 or	 C2/3,	 while	 adolescents	 with	 any	 STI	 had	 increased	concentrations	 of	 IL-1β	 and	 IL-17A	 compared	 to	 those	 without	 an	 STI.	 After	 being	randomized	 on	 to	 HC	 for	 16	 weeks,	 cervical	 cytobrush-derived	 immune	 cells	 were	analysed	within	 individuals	 in	each	arm	(intra-individual)	 and	between	 individuals	 in	the	 three	 contraceptive	 arms,	 using	 both	 ITT	 and	 PP	 approaches.	 Although	 the	frequency	and	activation	status	of	cervical	Th17	cells	was	similar	across	 the	 three	HC	arms,	 adolescents	 using	 NuvaRing	 and	 NET-EN	 had	 significantly	 increased	 activation	(CD38+HLA-DR+)	 on	 Th17	 cells	 compared	 to	 their	 respective	 baselines	 (p=0.02	 and	
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p=0.03,	 respectively),	 which	 was	 not	 evident	 in	 those	 using	 COCPs.	 Furthermore,	adolescents	 using	 NuvaRing	 had	 reduced	 frequencies	 of	 Th17	 cells	 compared	 to	baseline	(p=0.001),	which	was	not	evident	in	those	using	NET-EN	or	COCPs.	Although	it	was	 hypothesized	 that	 NuvaRing	would	 offer	 some	 safety	 advantage	 over	 NET-EN	 in	terms	 of	 mucosal	 HIV	 target	 cell	 activation,	 intra-individual	 analysis	 showed	 a	significant	 increase	 in	 the	 frequency	 of	 highly	 activated	 cervical	 Th17	 cells	 in	 those	adolescents	 who	 started	 using	 the	 ring.	 A	 significant	 increase	 in	 genital	 tract	concentrations	of	several	Th17-related	cytokine	concentrations	(including	IL-21,	IL-1β,	IL-33,	TNF-α,	 IL-4,	 IFN-γ	and	sCD40L)	was	noted	in	adolescents	assigned	to	NuvaRing	after	16	weeks	of	use,	suggesting	that	the	presence	of	the	vaginal	ring	likely	increased	genital	cytokine	responses.	Although	the	frequency	and	activation	of	CD8+	T	cells	was	similar	 across	 HC	 arm,	 intra-individual	 analysis	 showed	 changes	 in	 the	 frequency	 of	activation	markers	on	CD8+	T	cells	in	all	HC	arms.	Moreover,	frequencies	of	Tc17	cells	were	 significantly	 reduced	 after	 4	 months	 of	 contraceptive	 use	 in	 each	 HC	 arm	compared	to	baseline	frequencies.	
	
Conclusion:	 In	 summary,	 CCR6+CCR10-	 Th17	 cells	 were	 confirmed	 to	 be	 the	 major	CD4+	 T	 cell	 subset	 in	 the	 FRT	 of	 young	 adolescents.	 The	 use	 of	 NuvaRing	 led	 to	decreased	 frequencies	 of	 Th17	 cells	 which	 were	 highly	 activated,	 and	 was	 also	associated	with	an	increase	in	Th17-related	cytokines	compared	to	NET-EN	and	COCPs.	All	HC	altered	activation	of	cervical	CD8+	T	cells	and	reduced	the	 frequencies	of	Tc17	cells.	 The	 dramatic	 alterations	 observed	 in	 cervical	 immune	 cells	 associated	with	 the	use	of	NuvaRing	compared	to	NET-EN	and	COCPs	warrant	further	investigations.						
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1.1 Introduction	
Despite	 some	 remarkable	 advances	 in	 treatment	 and	 more	 modest	 advances	 in	prevention,	 HIV-1	 continues	 to	 be	 a	 global	 epidemic	 and	 AIDS	 has	 claimed	 an	estimated	35	million	lives.	By	the	end	of	2016,	UNAIDS	estimated	that	around	40	million	 people	were	HIV-infected,	 and	 1.8	million	 people	 became	newly	 infected	globally	(UNAIDS,	2017).	While	HIV	is	a	global	health	emergency,	African	countries	bear	the	highest	burden,	with	approximately	19	million	people	in	this	region	living	with	HIV,	and	approximately	7	million	are	living	in	South	Africa	(SA).	Sub-Saharan	Africa	(SSA)	accounts	for	about	43%	of	the	global	total	new	infections.	The	scale	up	of	 antiretroviral	 therapy	 (ART)	 in	 eastern	 and	 southern	 Africa,	 together	 with	improved	 public	 health	 measures	 such	 as	 male	 circumcision	 programs,	 have	contributed	 to	a	decline	of	up	 to	29%	of	new	 infections	between	2010	and	2016	(UNAIDS,	 2017).	 In	 lower	 HIV	 prevalence	 settings,	 the	 key	 risk	 populations	continue	 being	men	who	 have	 sex	with	men	 (MSM),	 sex	workers,	 prisoners	 and	injectable	 drug	 users.	 In	 high-prevalence	 settings,	 adolescent	 girls	 and	 young	women	(AGYW)	between	the	ages	of	15-24	are	the	key	risk	population,	with	80%	of	 young	women	who	become	 infected	 residing	 in	 SSA.	 Even	 in	 the	 era	 of	ARTs,	AIDS-related	 illness	remains	 the	second	 leading	cause	of	death	among	women	of	reproductive	 age	 in	Africa	 because	 of	 poor	 access	 to	 or	 uptake	 of	HIV	 screening	and/or	drugs	(UNAIDS,	2017).		This	dissertation	will	focus	on	HIV-1	risk	factors	in	AGYW	living	in	Southern	Africa.		
1.2 Sub-Saharan	African	young	women	and	HIV	risk	
Women	make	up	the	fastest-growing	group	of	people	living	with	HIV-1,	especially	in	SSA	(Cowan	and	Pettifor,	2009).	The	majority	of	new	HIV	infections	in	SSA	are	by	 heterosexual	 transmission,	with	 younger	 females	 carrying	 a	 disproportionate	burden	of	HIV	infection.	AGYW	in	SSA	aged	15-24	years	currently	represent	25%	of	new	 infections,	being	at	 approximately	eight	 fold	higher	 risk	 for	HIV	 infection	than	males	in	the	same	age	groups	(UNAIDS,	2017).	It	has	also	been	reported	that	these	 younger	 women	 acquire	 HIV	 5-7	 years	 earlier	 than	 their	 male	 peers	
	
 
3	
(Kharsany	and	Karim,	2016).	Like	countries	within	SSA,	the	gender	discrepancy	in	HIV	 prevalence	 is	 observed	 across	many	 African	 countries.	 South	 Africa	 has	 the	highest	 HIV	 prevalence	 amongst	 15-24	 year	 old	 females	 (13%)	 and	 the	 largest	gender	discrepancy	(difference	of	9%;	Dellar	et	al.,	2015).	Figure	1.1	summarizes	the	prevalence	of	HIV	according	to	gender	in	southern	African	countries.			
	
Figure	 1.1.	 HIV	 prevalence	 in	 selected	 Southern	 African	 countries	 among	 females	
(pink	bars)	and	males	 (blue	bars)	between	15-24	years	old	 in	2013.	 Adapted	 from	data	reported	by	Kharsany	and	Karim,	2016.	Graph	drawn	by	Iyaloo	Konstantinus.			Although	almost	certainly	multi-factorial	 in	cause,	the	disproportionate	impact	of	the	 HIV	 epidemic	 on	 African	 women	 has	 been	 attributed	 to	 various	 cultural,	behavioral,	 social,	 economic	 and	 biological	 factors	 (Ramjee	 and	 Daniels,	 2013;	Mabaso	et	al.,	2018).	Women	in	SSA	in	some	African	cultures	are	not	empowered,	and	do	not	play	a	major	 role	 in	decision-making	about	 sex	 (Jewkes	et	 al.,	 2010).	Some	 traditions	 in	Africa	 still	 allow	marriage	 for	 girls	 as	 young	 as	 10	 years	 old,	which	 are	 frequently	 arranged	 and	 sometimes	 associated	 with	 violence	 within	
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marriage	(Wadesango	et	al.,	2011;	Lilian	et	al.,	2015).	Moreover,	the	illegal	cultural	practice	of	genital	 female	mutilation	that	are	practiced	 in	some	African	countries	have	 been	 associated	with	 increased	 risk	 for	HIV	 transmission	 (Olaniran,	 2013).	Other	 cultural	 practices	 that	 may	 influence	 HIV	 acquisition	 within	 the	 African	continent	include	polygamy	and	the	practice	of	dry	sex	(Mswela,	2009;	Ramjee	and	Daniels,	2013).		Poverty	has	also	been	suggested	as	an	important	driver	of	HIV	risk	in	women,	as	some	 resort	 to	 transactional	 sex	 (Muula,	 2008).	 Young	 girls	 from	socioeconomically	deprived	families	are	sometimes	forced	or	coerced	into	having	sexual	 relationships	 with	 older	 men,	 also	 known	 as	 “blessers”	 in	 South	 Africa	(Mampane,	2018).	As	a	function	of	the	age	and	economic	disparity	between	young	girls	and	their	older	partners,	the	AGYW	cannot	negotiate	safe	sex	options.	Other	behavioral	factors	(like	alcohol	consumption	and	drug	abuse,	unprotected	sex	and	early	 sexual	 debut)	 or	 cleansing	 and	 sexual	 practices	 (like	 vaginal	 cleansing	 or	douching,	or	use	of	sex	enhancers	inserted	into	the	vagina)	have	also	been	shown	to	 increase	 women’s	 risk	 for	 HIV	 infection	 (Muula,	 2008;	 Ramjee	 and	 Daniels,	2013,	 Idele	 et	 al.,	 2014).	 Due	 to	 the	 high	 prevalence	 of	HIV	 in	 SSA,	 these	 young	women	 are	 likely	 to	 be	 exposed	 frequently	 to	 HIV,	 making	 them	 a	 highly	susceptible	group.			
1.3 Structure	and	immunity	of	the	female	reproductive	tract	
The	female	reproductive	tract	(FRT)	has	two	main	functions:	to	maintain	a	healthy,	growing	fetus;	and	to	protect	against	pathogens	(Wira	et	al.,	2005a).	The	FRT	can	be	 divided	 into	 upper	 and	 lower	 sections.	 The	 upper	 FRT	 is	 comprised	 of	 the	endocervix,	uterus,	fallopian	tubes	and	ovaries	(Figure	1.2).	The	lower	FRT	is	made	up	of	the	vagina	and	the	ectocervix.	Both	innate	and	adaptive	immunity	protect	the	FRT	 (Hickey	 et	 al.,	 2011).	 Innate	 immune	 mechanisms	 include	 the	 epithelium,	innate	 immune	 cells	 (neutrophils	 and	 natural	 killer	 [NK]	 cells),	 mucus,	complement,	 antimicrobial	 peptides	 (AMPs)	 and	 low	 pH,	 which	 are	 critical	 in	preventing	penetration	of	pathogens.		
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Figure	1.2.	Anatomy	and	 immune	cells	 in	 the	 female	reproductive	 tract.	 The	upper	FRT	 including	 the	uterus	 and	 endocervix	 is	 lined	by	 a	 simple	 columnar	 epithelium.	The	lower	 FRT	 including	 the	 vagina	 and	 ectocervix	 is	 lined	 by	 the	 stratified	 squamous	epithelium.	 Target	 cells	 including	 macrophages	 and	 T	 cells	 are	 found	 in	 the	 lamina	propria.	 Other	 immune	 protection	mechanisms	 found	 in	 the	 vaginal	 epithelium	 include	mucus,	 lactobacilli,	 AMPs,	 tight	 junctions,	 antibodies	 such	 as	 IgA	 and	 IgG.	 Lymphoid	aggregates	 composed	 of	 B	 cells	 (inner)	 and	 CD8+	 T	 cells	 (outer)	 are	 found	 in	 the	endometrium,	 and	 they	 can	 be	 found	 surrounded	 by	 NK	 cells	 and	 CD4+	 T	 cells.	 Figure	taken	from	Wessels	et	al.,	(2018).		The	 epithelium	 provides	 a	 physical	 barrier	 to	 potential	 pathogens	 in	 the	environment,	 without	 compromising	 critical	 reproductive	 functions	 like	fertilization	 (Wira	 et	 al.,	 2005b).	 The	 upper	 FRT	 is	 lined	 with	 a	 monolayer	 of	
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columnar	 epithelial	 cells,	 which	 are	 tightly	 apposed	 to	 one	 another	 by	 tight	junctions	(Figure	1.2).	This	region	of	the	FRT	was	originally	thought	to	be	sterile,	and	 that	 infections	 are	 the	 result	 of	 ascending	 pathogens	 from	 the	 lower	 FRT.	However,	a	more	recent	study	in	macaques	showed	that	SIV	could	also	infect	CD4+	cells	in	the	ovaries	and	other	regions	of	the	upper	reproductive	tract	(Stieh	et	al.,	2016).	 In	 addition,	 commensal	 bacteria	 have	 been	 detected	 in	 the	 uterus	 and	fallopian	tubes	of	healthy	women	(Chen	et	al.,	2017).	In	contrast	to	the	upper	FRT,	the	 lower	 FRT	 is	 lined	 by	 the	 multi-layer	 non-keratinized	 stratified	 squamous	epithelium	(Wira	et	al.,	2005b).	The	region	of	the	lower	FRT	where	the	multi-layer	squamous	 epithelium	 of	 the	 ectocervix	 intersects	 with	 the	 simple	 columnar	epithelium	of	the	endocervix	 is	known	as	the	transformation	zone	(Pudney	et	al.,	2005).	The	multi-layer	squamous	epithelium	of	the	lower	FRT	and	ectocervix	also	functions	as	a	protective	barrier	against	pathogens.			Epithelial	cells	making	up	the	simple	columnar	and	squamous	epithelium	express	pattern	 recognition	 receptors	 (PRRs)	 which	 are	 important	 host	 receptors	 to	initiate	 immune	 responses	 against	 pathogens,	 and	 include	 Toll-like	 receptors	(TLRs)	 and	nucleotide-binding	oligomerization	domain	 (NOD)	 receptors	 (Pioli	 et	al.,	 2004;	 Ghosh	 et	 al.,	 2013b).	 In	 addition	 to	 providing	 a	 physical	 barrier	 to	pathogens,	in	vitro	studies	have	shown	that	epithelial	cells	can	produce	a	variety	of	cytokines	 and	 chemokines	 (chemotactic	 cytokines)	 that	 recruit	 immune	 cells	 to	mucosal	 surfaces.	 In	 addition,	 they	 produce	 anti-proteases	 and	 antimicrobial	peptides	(small	peptides	with	the	ability	to	directly	neutralize	and	kill	pathogens)	which	 are	 important	 innate	 factors	 in	 immune	 defense	 and	 protecting	 epithelial	cells	 from	 damage	 caused	 by	 inflammation	 (Fichorova	 et	 al.,	 2002;	 Wira	 et	 al.,	2005a;	Nguyen	et	al.,	2014;	Burgener	et	al.,	2015;	Nazli	et	al.,	2018).	Of	the	AMPs	found	 in	 cervicovaginal	 secretions,	 the	 α-	 and	 β-defensins	 have	 been	 the	 best	described	 (Dasari	 et	 al.,	 2007;	 Fan	 et	 al.,	 2008).	 Mucus,	 secreted	 by	 Bartholin	glands	in	the	vagina	(located	posterior	and	to	the	 left	and	right	of	the	opening	of	the	 vagina)	 and	 goblet	 cells	 in	 endocervical	 crypts,	 provides	 a	 natural	 physical	barrier	 that	 can	 trap	 HIV	 and	 prevent	 the	 virus	 from	 penetrating	 through	 the	epithelial	cell	 layer	(Fahey	et	al.,	2005;	Ferreira	et	al.,	2014;	Nguyen	et	al.,	2014).	The	mucus	also	lubricates	the	vagina	(primarily	from	Bartholin	glands)	to	protect	
	
 
7	
against	 damage	 to	 the	 epithelial	 layer	 during	 sexual	 intercourse.	 Another	important	component	of	cervicovaginal	mucus	 is	 its	acidic	pH	(pH	<4.5)	 that	has	been	shown	to	slow	down	the	rate	of	HIV	diffusion	(Lai	et	al.,	2009).	Lactobacillus	species	found	in	the	healthy	lower	FRT	produce	lactic	acid	and	hydrogen	peroxide	(H2O2),	as	bi-products	of	glycogen	metabolism,	are	needed	to	maintain	this	acidic	environment	of	 the	vagina	(Antonio	et	al.,	1999;	Mirmonsef	et	al.,	2011;	Ravel	et	al.,	2011).			Macrophages,	 NK	 cells,	 neutrophils	 and	 dendritic	 cells	 (DCs)	 are	 distributed	 in	both	 the	 upper	 and	 lower	 FRT	 (Wira	 et	 al.,	 2005a).	 Macrophages	 tend	 to	 be	detected	 at	 higher	 concentrations	 in	 the	 endometrium	 and	 myometrial	 tissues,	while	 DCs	 tend	 to	 be	 found	 in	 the	 epithelial	 layer	 (Reis	 Machado	 et	 al.,	 2014).	Neutrophils	 concentrations	 are	 reported	 to	 be	 higher	 in	 fallopian	 tubes	 (upper	FRT)	 and	 decrease	 in	 concentration	 towards	 the	 vagina,	 where	 they	 respond	 to	pathogens	by	phagocytosing	them	and/or	by	producing	AMPs	(Wira	et	al.,	2005a).		Beneath	 the	 squamous	 epithelium	 is	 a	 structural	 layer	 made	 up	 of	 stromal	fibroblasts	 that	 supports	 the	 tissues.	 These	 stromal	 cells	 contain	 a	 diverse	population	of	immune	cells,	of	which	CD3+	T	lymphocytes	are	the	most	abundant	(Givan	 et	 al.,	 1997;	 Nguyen	 et	 al.,	 2014;	Wessels	 et	 al.,	 2018).	 CD4+	 T	 cells	 are	distributed	 throughout	 the	 FRT	 (lower	 and	 upper;	 Stieh	 et	 al.,	 2014),	 although	earlier	studies	suggested	 that	 these	were	present	at	higher	concentrations	 in	 the	cervical	 transformation	 zone	 than	 the	 vagina	 (Pudney	 et	 al.,	 2005).	 CD4+	T	 cells	have	 been	 further	 sub-divided	 into	 several	 T	 helper	 (Th)	 subsets,	 including	 Th1	(which	 are	 defined	 by	 their	 ability	 to	 produce	 IFN-γ,	 IL-2	 and	 TNF-α),	 Th2	(producing	IL-4,	IL-5	and	IL-13),	Th17	(producing	cytokines	like	IL-17A,	IL-17F,	IL-21	 and	 IL-22)	 and	 T	 regulatory	 (Treg)	 cells	 (producing	 IL-10,	 IL-9	 and	 TGF-β;	Hirahara	and	Nakayama,	2016).	The	differentiation	of	CD4+	T	 cells	 is	directly	or	indirectly	 mediated	 by	 cytokines	 and	 is	 influenced	 by	 a	 number	 of	 factors,	including	antigen	stimulation	(Zhu	and	Paul,	2008;	Golubovskaya	and	Wu,	2016).			
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1.3.1 HIV-1	infection	within	the	FRT	
Although	it	was	generally	thought	that	HIV	infection	of	CD4+	cells	within	the	FRT	occurs	 through	 the	 vagina,	 ectocervix	 or	 endocervix	 (Shen	 et	 al.,	 2012),	 more	recent	evidence	suggests	that	this	can	happen	throughout	the	FRT,	including	CD4+	T	 cells	 resident	 in	 the	 ovaries	 and	 the	 fallopian	 tubes	 (Stieh	 et	 al.,	 2014,	 2016).	Experiments	 in	 macaques	 have	 suggested	 that	 vaginal	 SIV	 infection	 can	 be	mediated	by	both	cell-free	and	cell-associated	viruses	(Hladik	and	McElrath,	2008;	Barreto-de-souza	 et	 al.,	 2014;	Kolodkin-Gal	 et	 al.,	 2013),	 although	 little	 evidence	exists	for	the	latter.			HIV	has	been	proposed	to	cross	the	FRT	mucosal	barrier	through	micro-abrasions	in	the	FRT	squamous	epithelium,	allowing	direct	infection	of	sub-mucosal	CD4+	T	cells,	or	via	transcytosis	of	the	virus	across	the	columnar	epithelium	of	the	upper	FRT	 (Nguyen	 et	 al.,	 2014).	 Other	mechanisms	 that	 have	 been	 suggested	 include	diffusive	percolation	in	the	squamous	epithelium	(Zhang	et	al.,	1999;	Carias	et	al.,	2016).	Following	entry,	HIV	gains	access	to	CD4+	immune	cells	like	macrophages,	DCs,	 Langerhans	 cells	 and	 T	 cells	 (Shattock	 and	 Moore,	 2003).	 HIV	 primarily	establishes	 infection,	 following	sexual	exposure,	 through	CD4+	T	cells	expressing	chemokine	 receptor	CCR5	 (Berges	et	 al.,	 2008;	Grivel	 et	 al.,	 2010).	HIV	has	been	shown	to	infect	and	replicate	in	sub-epithelial	CD4+	mononuclear	cells,	after	which	these	 traffic	 to	 draining	 lymph	 nodes	 and	 subsequently	 are	 thought	 to	 spread	systemically	(Haase,	2011;	Shen	et	al.,	2012).			
1.4 Th17	cells	and	Th17-related	cytokines	
Th17	 cells	were	 first	 described	 in	mice,	 and	 later	 in	 humans	 (Park	 et	 al.,	 2005).	They	have	been	characterized	by	the	expression	of	cell	surface	markers	(like	CCR6,	CCR4,	 CD161,	 and	 IL-23R),	 transcription	 factors	 (like	 RORγt	 or	 RORC2),	 and	production	 of	 cytokines	 (like	 IL-17;	 Annunziato	 et	 al.,	 2007;	 Singh	 et	 al.,	 2008).	Th17	cells	have	been	shown	to	play	an	important	role	 in	both	anti-microbial	and	fungal	immunity	(Feinen	et	al.,	2010;	Conti	and	Gaffen,	2015;	Li	et	al.,	2018).	Th17	cells	recruit	neutrophils	and	myeloid	cells	to	effector	sites	by	producing	cytokines,	
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and	they	are	also	important	in	epithelial	regeneration	in	mucosal	tissues	(Pelletier	et	 al.,	 2014;	Brockmann	et	al.,	 2017).	Th17	cells	differentiate	 from	naïve	CD4+	T	cells	following	antigen	priming,	in	the	presence	of	cytokines	like	interleukin	(IL)-6,	IL-21,	IL-23,	IL-1β,	IL-33,	tumor	necrosis	factor	(TNF)-α	and	transforming	growth	factor	(TGF)-β	(Khader	et	al.,	2009;	Korn	et	al.,	2009).	The	functions	of	cytokines	involved	 in	 Th17	 differentiation	 (called	 Th17-related	 cytokines)	 have	 been	 best	described	 in	 the	mouse	model	 (Harrison	 et	 al.,	 2008;	 Patel	 and	 Kuchroo,	 2015;	Wacleche	 et	 al.,	 2017).	 Both	 IL-6	 and	 TGF-β	 are	 necessary	 to	 initiate	 Th17	differentiation	 (Sutton	 et	 al.,	 2006).	 IL-21	 promotes	 Th17	 differentiation,	 but	 is	also	produced	by	differentiated	Th17	cells	to	regulate	immune	responses	(Wei	et	al.,	2007).	IL-23	further	commits	the	differentiated	cells	to	the	Th17	lineage	(Revu	et	 al.,	 2018).	 IL-1β,	 in	 combination	 with	 IL-6	 and	 IL-23,	 is	 involved	 in	differentiating	CD4+	T	cells	 into	Th17	cells	(Lasigliè	et	al.,	2011).	The	function	of	IL-33,	although	not	well	defined,	enhances	Th17	cell	differentiation	by	inducing	DC	maturation	(Park	et	al.,	2017).	Overall,	these	cytokines	also	induce	the	expression	of	 the	 transcription	 factors	 RORγt	 and	 RORα	 which	 are	 needed	 for	 Th17	differentiation	(Awasthi	and	Kuchroo,	2009).			Studies	of	Th17	cells	in	the	gut	have	suggested	that	differentiation	of	Th17	cells	is	influenced	by	the	gut	microbiota	and	the	prevailing	cytokine	environment	(Ivanov	et	al.,	2008).	Germ-free	mice	have	reduced	Th17	cells,	although	numbers	of	Th17	cells	can	be	increased	by	colonizing	their	gut	with	conventional	microbiota	(Ivanov	et	al.,	2008).	Therefore,	the	composition	of	gut	microbiota	can	directly	or	indirectly	influence	the	development	and	phenotype	of	Th17	cells.		Th17	cells	are	characterized	by	their	ability	to	produce	IL-17A,	IL-17F,	IL-21	and	IL-22	 (Bettelli	 et	 al.,	 2008).	 Th17	 cells	 producing	 IL-17	 are	 the	 best	 described.	Cytokines	produced	by	Th17	cells	have	broad	effects	and	can	act	 in	synergy	with	various	 other	 inflammatory	 cytokines	 (Korn	 et	 al.,	 2009).	 IL-17A	 and	 IL-17F	 are	important	 in	 host	 defence	 and	 inflammation	 by	 inducing	 pro-inflammatory	cytokine,	 chemokine	 and	 metalloproteinase	 production	 in	 various	 tissues	(Hymowitz	et	al.,	2001;	Schofield	et	al.,	2016).	Moreover,	IL-17A	and	IL-17F	share	a	50%	amino	acid	 sequence	homology	and	bind	 to	 the	 same	 IL-17	 receptor,	 and	
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have	similar	biological	functions	(Ishigame	et	al.,	2009;	Ouyang	et	al.,	2012).	Both	of	these	IL-17	cytokines	induce	production	of	IL-6,	several	chemokines	(like	CXCL1	[GRO-1],	 CXCL2	 [macrophage	 inflammatory	 protein	 {MIP}-2a],	 and	 CXCL5	[epithelial-derived	 neutrophil-activating	 {ENA}	 peptide	 78])	 and	 cytokines	including	 granulocyte	 stimulating	 factors	 (granulocyte	 colony	 stimulating	 factor	[G-CSF],	 granulocyte/macrophage	 colony	 stimulating	 factors	 [GM-CSF]).	 The	released	 cytokines	 and	 chemokines	 promote	 different	 functions	 including	 the	activation	and	migration	of	neutrophils	to	sites	of	inflammation	(Bradley	Forlow	et	al.,	2001;	Miyamoto	et	al.,	2003).	IL-17A	and	IL-17F	also	induce	AMPs	production	including	lipocalin	and	the	β-defensins	that	prevent	infection	at	mucosal	surfaces	(Liang	et	al.,	2006;	Aujla	et	al.,	2008;	Monteleone	et	al.,	2011).	Both	are	important	for	 the	 clearance	 of	 extracellular	 bacteria	 such	 as	 Staphylococcus	 aureus	 and	
Citrobacter	rodentium	(Ishigame	 et	 al.,	 2009;	 Jin	 and	 Dong,	 2013).	 Despite	 their	similarity,	IL-17F	has	a	much	lower	cytokine-inducing	potency	than	IL-17A	(Sueki	et	al.,	2008;	Ouyang	et	al.,	2012;	Brembilla	et	al.,	2018).		If	not	regulated,	the	inflammatory	nature	of	Th17	cells	cause	pathology	and	Th17	cells	 have	 been	 associated	 with	 the	 development	 of	 autoimmune	 diseases	 and	chronic	inflammation	(Kuwabara	et	al.,	2017).	Cytokines	known	to	regulate	Th17	cells	include	IL-25,	IL-31,	soluble	CD40-ligand	(sCD40L),	IL-4,	IL-10	and	interferon	(IFN)-γ	 (Martinez	 et	 al.,	 2008;	Brockmann	 et	 al.,	 2017).	 Some	of	 these	 cytokines	regulate	 Th17	 cells	 by	 increasing	 or	 decreasing	 their	 differentiation	 pathway	signals.	 For	 example,	 sCD40L	 regulate	 Th17	 cell	 differentiation	 by	 providing	 the	optimal	 cytokine	 environment	 (Iezzi	 et	 al.,	 2009).	 IL-10,	 in	 contrast,	 directly	suppresses	cytokine	secretion	by	T	cells	and	macrophages,	including	IL-17	(Gu	et	al.,	 2008).	 IFN-γ	 and	 IL-4	negatively	 regulate	Th17	 responses	 by	promoting	Th1	and	Th2	responses,	respectively	(Harrington	et	al.,	2005).	Furthermore,	IL-25	has	been	shown	to	suppress	Th17	 immune	responses	by	upregulating	Th2	cytokines	like	IL-4	(Liu	et	al.,	2016).	IL-31,	mainly	produced	by	Th2	and	mast	cells	(Zhang	et	al.,	2008),	has	been	found	to	affect	the	differentiation	of	Th17	cells.	Still	considered	a	novel	cytokine	(described	for	the	first	time	in	2004;	Dillon	et	al.,	2004),	IL-31	has	been	 shown	 to	 limit	 Th2	 inflammatory	 processes	 and	 secretion	 of	 IL-31	 is	triggered	by	IL-4	(Di	Salvo	et	al.,	2018).	Furthermore,	IL-31	is	thought	to	regulate	
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cell	proliferation,	and	to	be	involved	also	in	tissue	remodeling	(Zhang	et	al.,	2008).	Th17-related	cytokines	are	summarized	in	Figure	1.3	below.			
	
Figure	1.3.	Cytokines	considered	to	be	related	to	Th17	cells	and	how	they	interact	
with	 Th17	 cells.	 Naïve	 CD4+	 T	 cells	 are	 primed	 by	 a	 combination	 of	 cytokines	 to	differentiate	into	Th17	cells	(including	TGF-β,	IL-6,	IL-1β,	IL-21,	IL-23,	IL-33,	and	sCD40L).	IL-21,	IL-1β	and	IL-23	further	promote	expansion,	maintenance	and	survival	of	Th17	cells.	Differentiation	can	be	inhibited	by	IL-25,	IL-4	and	IFN-γ	that	favor	Th2	and	Th1	responses,	respectively.	 Th17	 cells	 directly	 produce	 IL-17A,	 IL-17F,	 IL-21	 and	 IL-22,	 and	 the	production	of	 these	cytokines	can	be	directly	 inhibited	by	IL-10.	Figure	drawn	by	Iyaloo	Konstantinus.			
1.4.1 The	role	of	Th17	cells	at	mucosal	surfaces	
Mucosal	surfaces	connect	the	human	host	with	their	environment,	consisting	of	the	respiratory,	 gastrointestinal,	 and	 genital	 tract	mucosa.	 The	 role	 of	 Th17	 cells	 in	gastrointestinal	 and	 respiratory	 immunity	 has	 been	 well	 described	 in	 mice	(Infante-Duarte	et	al.,	2000;	Khader	et	al.,	2007;	Atarashi	et	al.,	2008;	Ivanov	et	al.,	2008).	Th17	cells	promote	the	formation	of	tight	junctions	between	epithelial	cells	
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needed	to	maintain	the	mucosal	barrier	integrity	(Blaschitz	and	Raffatellu,	2010),	and	 loss	 of	 Th17	 cells	 have	 been	 linked	 with	 compromised	 mucosal	 barrier	integrity	(Kanwar	et	al.,	2010;	Hartigan-O’Connor	et	al.,	2011;	He	et	al.,	2011).	IL-17-producing	cells	are	abundant	in	lamina	propria	of	the	small	intestine	(Ivanov	et	al.,	2008).	AMPs,	like	defensins,	are	induced	through	signaling	pathways	triggered	by	IL-17A	and	IL-17F	at	the	intestinal	mucosal	surface,	which	have	been	shown	to	protect	mice	against	enteric	infections	caused	by	bacteria	(Rubino	et	al.,	2012).	In	the	lungs,	 IL-17	is	 important	 in	protection	against	airborne	diseases,	with	IL-17A	playing	a	role	in	the	defense	against	extracellular	pathogens	such	as	Pseudomonas	
aeruginosa	and	Klebsiella	pneumoniae	in	the	airways	(Ye	et	al.,	2001;	Kudva	et	al.,	2011).	 In	 the	 oral	 mucosa,	 Th17	 cells	 and	 IL-17	 receptor	 signaling	 has	 been	identified	 to	 be	 important	 in	 defense	 against	 oral	 candidiasis	 (Conti	 and	 Gaffen,	2010).			In	the	genital	tract,	Th17	immunity	in	mice	has	been	shown	to	play	an	important	role	 in	 protection	 against	 fungal	 and	 bacterial	 infections	 including	 chlamydia,	gonorrhoea	and	candida	(Feinen	et	al.,	2010;	Pietrella	et	al.,	2011;	Gladiator	et	al.,	2013;	 Conti	 and	 Gaffen,	 2015;	 Vicetti	 Miguel	 et	 al.,	 2016).	 Ex	vivo	 studies	 using	human	T	cells	showed	that	C.	albicans	primed	Th17	cells	produce	IL-17	and	IFN-γ	under	 the	 regulation	 of	 IL-1β	 (Zielinski	 et	 al.,	 2012).	 Th17	 immunity	might	 also	mediate	protection	following	intravaginal	HSV-2	challenge	(Anipindi	et	al.,	2016).	The	role	of	Th17	immunity	in	the	reproductive	tract	of	women	is	not	well	defined,	however,	 and	 more	 studies	 are	 needed	 to	 investigate	 the	 protective	 properties	offered	by	these	cells.		
1.4.2 The	role	of	Th17	cells	in	HIV	infection	
Th17	 cells	 have	 been	 described	 to	 be	 the	 subset	 predominantly	 infected	 by	HIV	and	SIV	in	rhesus	macaques	(Favre	et	al.,	2009;	Hed	et	al.,	2010;	Stieh	et	al.,	2016).	In	macaques	vaginally	challenged	with	SIV,	approximately	85%	of	all	SIV-infected	CD4+	T	cells	immediately	after	infection	expressed	the	chemokine	receptor	CCR6,	which	 binds	 to	 the	 cytokine	MIP-3a	 (Stieh	 et	 al.,	 2016).	 Moreover,	 CCR6+	 Th17	cells	have	been	shown	to	harbour	more	HIV	DNA	compared	to	CCR6-	CD4+	T	cells	
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(Gosselin	et	al.,	2010).	Studies	 in	HIV	chronically	 infected	adults	have	 found	 that	gastrointestinal	 tract	Th17	 cells	were	depleted	 compared	 to	 those	 found	 in	HIV-uninfected	individuals	(Prendergast	et	al.,	2010).	Since	CCR6	is	a	mucosal	homing	receptor,	one	of	 the	explanations	 for	 the	 increased	susceptibility	of	 these	cells	 to	HIV	 infection	might	be	due	to	 their	migration	to	areas	where	HIV	readily	 infects,	such	 as	 the	 genital	 tract	 (Rodriguez-Garcia	 et	 al.,	 2014;	 Stieh	 et	 al.,	 2016).	 Their	role	 in	 mucosal	 epithelial	 repair	 also	 places	 them	 where	 barrier	 integrity	 is	weakened,	which	are	points	at	which	HIV	can	easily	enter.			
Ex	vivo	experiments	using	mixed	cell	suspensions	from	tissues	taken	from	the	FRT	of	women	 found	 the	highest	number	of	HIV-infected	Th17	cells	 in	 the	ectocervix	compared	 to	 endocervix	 and	 endometrium	 (Rodriguez-Garcia	 et	 al.,	 2014).	Interestingly,	 Th17	 cells	 at	 all	 the	 three	 sites	 expressed	 higher	 levels	 of	 CCR5	compared	 to	 CCR6-	 CD4+	 T	 cells.	 Expression	 of	 CCR5	 together	 with	 mucosal	integrin	α4β7,	which	binds	to	HIV-1	gp120	and	enhances	viral	dissemination,	may	increase	susceptibility	to	HIV	(Sivro	et	al.,	2018).	Th17	cells	were	also	dramatically	depleted	 in	 the	 cervical	 mucosa	 after	 HIV	 infection,	 suggesting	 preferential	infection	(McKinnon	et	al.,	2011;	Masson	et	al.,	2015b).	Given	the	susceptibility	of	Th17	 cells	 to	 HIV	 infection,	 there	 is	 a	 need	 to	 study	 the	 factors	 influencing	 the	characteristics	of	this	CD4+	T	cell	subset,	especially	in	key	risk	groups	like	AGYW.			
1.5 Biological	factors	associated	with	HIV	infection	in	the	FRT	
Women	have	been	suggested	to	be	more	biologically	susceptible	 to	HIV	 infection	than	men,	because	of	their	 larger	mucosal	surface	area	of	the	lower	FRT	that	can	be	exposed	 to	HIV	 (Ramjee	and	Daniels,	2013;	Carias	et	 al.	2013).	During	 sexual	intercourse,	 the	 vagina	 is	 also	 exposed	 to	 infectious	 fluids	 and	 pathogens	 for	longer	periods	of	time	compared	to	the	penis	(Hladik	and	Hope,	2009).	The	act	of	sex	 itself	 is	 also	more	 likely	 to	 cause	 tissue	 injury	 in	women	 than	men,	 thereby	facilitating	greater	exposure	of	 target	 cells	 to	pathogens	 including	HIV	 (Ghosh	et	al.,	 2013a).	 Other	 biological	 factors	 that	 may	 influence	 HIV	 acquisition	 risk	 in	women	 include	 endogenous	 and	 exogenous	 hormones,	 hormonal	 contraceptives	
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(HCs),	 genital	 inflammation,	 sexually	 transmitted	 infections	 (STIs),	 and	 bacterial	vaginosis	(BV).	These	will	be	discussed	in	the	subsequent	sections.		
1.5.1 Inflammation	and	immune	activation	
Inflammation	 is	 a	 natural	 response	 to	 harmful	 pathogens	 or	 tissue	 damage	(Helming,	 2011;	 Leick	 et	 al.,	 2014).	 The	 inflammatory	mechanism	 is	 needed	 for	activating	 and	 recruiting	 immune	 cells	 to	 the	 affected	 area,	 to	 help	 fight	 the	harmful	organisms,	or	repair	tissue	damage.	In	addition	to	recruiting	immune	cells	to	 an	 affected	 site,	 inflammation	 also	 promotes	 cellular	 activation	 and	differentiation	 (Pape	 et	 al.,	 1997;	 Newton	 et	 al.,	 2012).	 Cytokines	 such	 as	 IL-17	contribute	to	various	aspect	of	inflammation	(Kolls	and	Lindén,	2004).	IL-17	play	a	role	 in	recruiting	 immune	cells	 to	 the	site	of	 infection	(including	neutrophils	and	Th17	cells),	and	the	recruited	cells	continue	to	produce	cytokines	and	chemokines	(Roussel	et	al.,	2010;	Ouyang	et	al.,	2012).	Hence,	IL-17	and	Th17	cells	have	been	associated	with	 inflammatory	diseases	 (Miossec	 and	Kolls,	 2012;	 Schofield	 et	 al.,	2016;	Kuwabara	et	al.,	2017).			Genital	inflammation	has	been	linked	to	increased	HIV	risk	in	women	(Roberts	et	al.,	 2012;	 Masson	 et	 al.,	 2015).	 Women	 with	 elevated	 chemotactic	 cytokines	including	 IP-10,	 MIP-1α	 and	 MIP-1β	 in	 the	 genital	 tract	 were	 found	 to	 be	 at	 a	heightened	 risk	 of	 HIV	 acquisition	 (Mlisana	 et	 al.,	 2012;	 Morrison	 et	 al.,	 2014;	Masson	et	al.,	2014;	McKinnon	et	al.,	2018).	Immune	cells	are	elevated	in	women	with	 high	 concentrations	 of	 inflammatory	 cytokines	 and	 chemokines	 in	 the	 FRT,	including	neutrophils,	CD4+	and	CD8+	T	cells	(Pudney	et	al.,	2005;	Nkwanyana	et	al.,	2009).	In	macaques,	it	has	been	shown	that	chemokines	recruit	activated	CD4+	T	 cells	 targeted	 by	 SIV	 to	 the	 vagina	 (Miller	 et	 al.,	 2005;	 Haase,	 2011).	 Earlier	studies	 suggested	 that	 “healthy”	 vaginal	 mucosal	 surfaces	 (in	 the	 absence	 of	inflammation)	are	predominantly	populated	by	resting	CD4+	T	cells,	which	do	not	support	HIV	 replication	 (Tang	 et	 al.,	 1995).	 Activated	 CD4+	 T	 cells	 express	 high	levels	of	HLA-DR	and	glycoprotein	CD38	on	their	surface.	Expression	of	both	HLA-DR	 and	 CD38	 on	 CD4+	 T	 cells	 have	 been	 associated	with	 high	 levels	 of	 HIV	 co-receptor	expression	(CCR5)	in	lymph	nodes	(Meditz	et	al.,	2011).	
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	A	number	of	conditions	and	practices	contribute	to	genital	inflammation,	including	STIs	 (section	 1.5.2)	 and	 BV	 (section	 1.5.3),	 douching,	 cleansing,	 using	 vaginal	drying	 agents	 and	 lubricants	 (Myer	 et	 al.,	 2005;	 Alcaide	 et	 al.,	 2016),	 normal	hormone	cycling	(section	1.6)	and	the	use	of	HCs	(section	1.7;	Jabbour	et	al.,	2009;	Morrison	et	al.,	2014;	Guthrie	et	al.,	2015;	Tasker	et	al.,	2017).		
1.5.2 Sexually	transmitted	infections	
STIs	have	been	linked	with	a	heightened	risk	of	HIV	acquisition	(Steen	et	al.,	2009;	Ward	and	Rönn,	2011).	Recently,	SA	adolescent	girls	were	shown	to	bear	a	higher	burden	of	STIs	compared	to	their	male	counterparts	(Francis	et	al.,	2018).	A	meta-analysis	done	in	SSA	also	reported	a	higher	prevalence	of	STIs	in	AGYW	aged	15-24	years	than	older	women	(Torrone	et	al.,	2018).	SA	and	most	countries	in	SSA	have	adopted	 the	 WHO	 guidelines	 of	 syndromic	 management	 of	 STIs,	 in	 which	 only	symptomatic	 STIs	would	 be	 treated	with	 antibiotics	 (WHO,	 2004).	However,	 the	majority	of	STIs	in	women	in	particular	are	asymptomatic	and	therefore	would	not	be	 treated	 (Barnabas	 et	 al.,	 2017).	 In	 most	 cases	 in	 resource-limited	 African	countries,	 both	 symptomatic	 and	 asymptomatic	 STIs	 remain	 undiagnosed	 and	therefore	 untreated	 (Barnabas	 et	 al.,	 2017;	 Torrone	 et	 al.,	 2018).	 In	 addition	 to	increasing	HIV	acquisition	risk,	untreated	STIs	may	result	in	several	other	adverse	consequences	 including	 pelvic	 inflammatory	 disease	 (PID),	 adverse	 pregnancy	outcomes	and	infertility.			Different	 pathogens	 cause	 STIs,	 including	 various	 bacterial	 (such	 as	 Chlamydia	
trachomatis,	Mycoplasma	genitalium,	 Treponema	pallidum	 [causing	 syphilis]	 and	
Neisseria	 gonorrhoeae),	 protozoal	 (Trichomonas	 vaginalis),	 and	 viral	 pathogens	(herpes	simplex	virus	[HSV]-2,	human	papilloma	virus	[HPV],	and	HIV).			Of	 the	 bacterial	 STIs,	 C.	trachomatis	 is	 probably	 the	most	 common	 bacterial	 STI	worldwide,	especially	in	younger	women	<25	years	of	age	(Newman	et	al.,	2015).	Despite	being	so	prevalent	and	recurrent,	it	causes	a	“silent	epidemic”	because	up	to	 70%	 of	 cases	 in	 women	 appear	 to	 be	 clinically	 asymptomatic	 despite	 C.	
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trachomatis	 causing	 severe	 damage	 to	 the	 upper	 FRT,	 including	 infertility.	Infection	with	chlamydia	initiates	both	innate	and	adaptive	immune	responses	in	the	genital	tract	(Hafner	et	al.,	2008;	Vasilevsky	et	al.,	2014),	and	CD4+	T	cells	have	been	shown	to	play	a	central	role	in	controlling	infection	through	IFN-γ	secretion	(Nagarajan	et	al.,	2005;	Nelson	et	al.,	2005;	Nogueira	et	al.,	2017).	Chlamydia	has	been	 suggested	 to	 increase	 the	 risk	 of	 acquiring	 HIV-1	 by	 increasing	 pro-inflammatory	cytokines	and	disrupting	genital	epithelial	cells	(Ficarra	et	al.,	2008;	Schust	 et	 al.,	 2012;	 Buckner	 et	 al.,	 2016).	 Moreover,	 chlamydia	 positive	 women	were	 reported	 to	 have	 a	 dramatic	 increase	 in	 the	 number	 of	 CXCR4	 and	 CCR5	chemokine	 receptors	 on	 their	 CD4+	 T	 cells	 in	 the	 endocervix	 compared	 to	chlamydia	negative	women,	suggesting	that	they	may	be	highly	susceptible	to	HIV-1	 infection	 (Schust	 et	 al.,	 2012).	 In	mice,	 it	 has	 been	 shown	 that	 chlamydia	 also	elicits	 Th1	 and	 Th17	 immune	 responses	 that	 may	 promote	 both	 pathogen	clearance	and	genital	tract	damage	(Vicetti	Miguel	et	al.,	2016).	
	
M.	 genitalium	 is	 also	 often	 asymptomatic,	 and	 studies	 have	 found	 that	 these	infections	can	persist	 for	almost	 two	years	 (Jensen,	2006;	Cohen	et	al.,	2007).	M.	
genitalium	has	been	associated	with	PID,	cervicitis	and	other	adverse	reproductive	health	consequences.	In	a	systematic	review	and	meta-analysis,	M.	genitalium	was	associated	with	increased	risk	of	HIV	acquisition,	and	this	association	was	stronger	in	SSA	where	the	burden	of	HIV	is	greatest	(Mavedzenge	and	Weiss,	2009).	Several	studies	 have	 reported	 that	M.	genitalium	 infection	 in	 women	 is	 associated	 with	inflammatory	 responses,	 triggering	 the	 production	 of	 cytokines	 and	 the	recruitment	 of	 activated	HIV	 target	 cells	 (Zhang	 and	Wear,	 2000;	 Starnbach	 and	Roan,	2008;	Wu	et	al.,	2008;	Masson	et	al.,	2014).		
N.	gonorrhoeae	infection	has	also	been	associated	with	increased	HIV	susceptibility	in	 women,	 that	 may	 be	 mediated	 by	 recruitment	 of	 activated	 immune	 cells	 or	micro-ulceration	associated	with	 infection	(Levine	et	al.,	1998).	N.	gonorrhoeae	 is	also	 a	major	 cause	 of	 PID,	 and	 this	 can	 in	 turn	 facilitate	 with	 HIV	 transmission	(Jarvis	and	Chang,	2012).	In	a	murine	model,	Th17	cells	were	shown	to	be	critical	for	the	clearance	of	N.	gonorrhoeae	(Feinen	et	al.,	2010).		
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Of	the	protozoal	STIs,	T.	vaginalis	is	the	most	common	non-viral	and	non-bacterial	STI	worldwide	and	recently	 there	has	been	an	alarming	rise	 in	 the	prevalence	of	this	 STI	 in	 adolescents	 (Fichorova	 et	 al.,	 2015).	 T.	 vaginalis	 is	 a	 flagellated	unicellular	 organism,	 which	 adheres	 to	 vaginal	 epithelial	 cells	 and	 causes	disruption	 of	 the	 epithelial	 layer,	 partially	 due	 to	 flagellation	 (Schwebke	 and	Burgess,	 2004;	 Midlej	 and	 Benchimol,	 2010).	 Trichomonas	 has	 also	 been	associated	 with	 increased	 susceptibility	 to	 HIV,	 as	 well	 as	 HSV-2	 (Hirt	 and	Sherrard,	2015).			HSV-2	 is	a	prevalent	viral	STI	 that	accounts	 for	approximately	30%	of	all	STIs	 in	SSA	 (Looker	 et	 al.,	 2015).	 A	 recent	meta-analysis	 reported	HIV	 acquisition	 to	 be	almost	tripled	in	the	presence	of	HSV-2	infection	in	both	women	and	men	(Looker	et	al.,	2017).	In	adolescent	girls	between	the	ages	of	16-18	years,	a	study	in	rural	KwaZulu-Natal	 showed	 a	 prevalence	 of	 10%	 (Karim	 et	 al.,	 2014).	 Following	primary	 infection,	HSV-2	 remains	 latent	 in	 the	 sacral	 ganglia	of	 infected	persons	and	reactivates	periodically,	causing	genital	ulceration	and	viral	shedding	(Croen	et	al.,	1991).	Studies	have	also	shown	that	women	may	shed	HSV-2	in	their	genital	secretions	 without	 any	 clinical	 symptoms	 (Cherpes	 et	 al.,	 2005).	 However,	ulceration	caused	by	HSV-2	has	been	associated	with	increased	activated	CD4+	T	cells,	 providing	more	 target	 cells	 for	HIV	 (Rebbapragada	 et	 al.,	 2007),	 and	 these	CD4+	 T	 cells	 expressing	 CCR5	 persist	 even	 in	 healed	 genital	 lesions	 (Zhu	 et	 al.,	2009).	 The	 high	 burden	 of	 HSV-2	 is	 thought	 to	 have	 contributed	 to	 the	 high	prevalence	of	HIV	in	SSA	(Wald	and	Link,	2002;	Freeman	et	al.,	2006).			
1.5.3 The	vaginal	microbiome	and	bacteria	vaginosis	(BV)	
The	vaginal	microbiota	(VMB)	is	a	collection	of	microorganisms	lying	superficial	to	the	 epithelial	 cells	 of	 the	 vagina	 (Ma	 et	 al.,	 2012),	 that	 consist	 of	 bacteria	 that	colonize	 the	 vagina,	 and	 can	 play	 a	 protective	 role	 against	 pathogens	 (when	healthy	Lactobacilli	 spp.	predominate)	 (Atashili	 et	 al.,	2008;	Linhares	et	al.,2011;	Witkins	et.,	2017).	These	healthy	commensal	microbial	communities	are	believed	to	constitute	the	first	line	of	defense	against	invading	pathogens	(Dethlefsen	et	al.,	
	
 
18	
2007).	Vaginal	Lactobacillus	spp,	metabolize	glycogen	to	produce	lactic	acid	(both	D-	 and	 L-isomers)	 that	 maintain	 the	 lower	 FRT	 pH	 <4.5	 (Huang	 et	 al.,	 2014;	Mirmonsef	et	al.,	2014).	While	the	lower	FRT	is	typically	colonized	by	Lactobacilli	spp.	during	health,	vaginal	hygiene	practices,	sexual	behaviours	and	even	diet	may	cause	disturbances	in	the	VMB	(Myer	et	al.,	2005;	Hutchinson	et	al.,	2007;	Thoma	et	al.,	2011;	Alcaide	et	al.,	2015).			Disturbances	 in	Lactobacilli	colonization	of	 the	vagina	 is	associated	with	a	highly	prevalent,	 recurrent	or	persistent	vaginal	dysbiosis	–	 called	BV	–	which	 typically	results	in	the	vaginal	pH	increasing	to	>4.5	(Ravel	et	al.,	2011;	Gajer	et	al.,	2012).	BV	is	further	characterized	by	an	overgrowth	of	endogenous	bacteria	communities	(thought	 to	 originate	 from	 the	 GI	 tract	 or	 male	 partners)	 and	 a	 relatively	 low	abundance	of	vaginal	Lactobacillus	spp	(Ma	et	al.,	2012).	Lactobacillus	crispatus	has	been	described	to	be	the	most	abundant	bacteria	in	the	healthy	vagina	specifically	in	women	of	European	ancestry	(Ravel	et	al.,	2011).	L.	crispatus	has	been	shown	in	
vitro	 to	 inhibit	 Candida	 albicans,	 and	 protect	 HeLa	 cells	 from	 infection	 by	chlamydia	(Rizzo	et	al.,	2013;	Petrova	et	al.,	2015;	Nardini	et	al.,	2016).			Although	 debate	 on	 the	 classification	 of	 VMB	 during	 health	 and	 BV	 states	 is	ongoing,	Ravel	et	al.	(2011)	initially	suggested	that	these	can	be	divided	into	five	community	 types	 (CTs):	 characterized	 by	 the	 predominant	 bacteria	 spp	 of	 L.	
crispatus	(CT	I),	L.	gasseri	(CT	II),	L.	iners	(CT	III),	L.	jensenii	(CT	IV),	and	a	diverse	VMB	 dominated	 by	 anaerobes	 (CT	 V).	 More	 recently,	 Anahtar	 et	 al.	 (2015)	suggested	 that	 this	 could	 be	 simplified	 into	 four	 CTs;	with	 CT	 I	 dominated	 by	L.	
crispatus,	 CT	 II	 dominated	 by	L.	iners,	 CT	 III	 dominated	 by	Gardnerella	vaginalis,	and	 CT	 IV	 lacking	 consistent	 dominant	 bacterial	 species.	 Anahtar	 et	 al.	 (2015)	further	 reported	 that	 only	 37%	 of	 healthy	 (asymptomatic)	 South	 African	 young	women	 had	 a	 Lactobacillus-dominated	 VMB.	 Researchers	 from	 our	 group	subsequently	 suggested	 an	 alternate	 VMB	 classification	 in	 predominantly	asymptomatic	AGYW	from	two	cohorts	in	South	Africa,	based	on	an	unsupervised	approach	 to	 the	 16S	 rRNA	 gene	 sequence	 data	 using	 Fuzzy	 clustering	 with	weighted	UniFrac	distances,	in	which	CTs	dominated	by	Gardnerella	vaginalis	and	
Prevotella-mixed	groups	would	be	grouped	together	(C1),	while	those	dominated	
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by	 L.	 crispatus	 (considered	 C2),	 and	 L.	 iners	 (considered	 C3)	 would	 be	 grouped	separately	(Figure	1.4;	Lennard	et	al.,	2017).			Irrespective	of	geographical	location,	women	with	BV	have	bacterial	communities	dominated	by	a	more	diverse	VMB	(composed	of	G.	vaginalis,	Atopobium	vaginae,	
Prevotella	bivia	and	other	facultative	anaerobic	gram-positive	or	negative	bacteria;		Ravel	et	al.,	2011;	Srinivasan	et	al.,	2012;	Anahtar	et	al.,	2015;	Petrova	et	al.,	2015;	Lennard	 et	 al.,	 2017).	 However,	 this	 classification	 of	 BV	 is	 not	 simple,	 as	 some	healthy	women	do	not	have	a	 lactobacilli-dominated	vagina	(Petrova	et	al.,	2017;	Bayigga	et	al.,	2018).				
	
Figure	1.4.	 Composition	of	 the	 vaginal	microbiota	 according	 the	 community	 types	
describe	 in	 young	 SA	 women	 by	 Lennard	 et	 al	 (2017).	 A	 healthy	 vagina	 has	 been	described	as	that	dominated	by	L.	crispatus.	Healthy	African	women	however	mostly	have	
L.	 iners	 and	 a	 diverse	 VMB	 with	 Gardnerella	 spp,	 Prevotella	 spp,	 and	 other	 facultative	anaerobes.	 BV	 is	 characterized	 by	 overgrowth	 of	 anaerobes.	 Figure	 drawn	 by	 Iyaloo	Konstantinus.			The	current	gold	standard	for	laboratory	diagnosis	of	BV	is	called	Nugent	scoring,	and	 is	based	on	evaluating	 the	morphology	and	gram	stain	 reactivity	of	bacteria	(Nugent	 et	 al.,	 1991).	 This	 method	 assesses	 the	 relative	 abundance	 of	 gram-positive	rods,	gram-variable	coccobacilli	and	gram-negative	curved	rods	(Nugent,	1991).	The	scoring	is	based	on	a	linear	scale	ranging	from	0	-	10;	a	score	between	0	-	 3	 is	 considered	 healthy,	 4	 -	 6	 is	 intermediate,	 and	 7	 -	 10	 is	 indicative	 of	 BV.	Alternatively,	Amsel	 criteria	 is	more	 frequently	used	clinically,	 and	assesses	 four	
L.	crispatus	dominated	 L.	iners	dominated	 Diverse	VMB	
Less	common	in	African	women	 More	common	in	African	women	
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characteristics:	 (i)	vaginal	pH	>4.5,	 (ii)	 the	presence	of	 clue	cells	on	a	 saline	wet	mount,	(iii)	a	homogenous	and	thin	vaginal	discharge,	and	(iv)	a	release	of	a	fishy	amine	odor	after	adding	potassium	hydroxide.	For	a	patient	 to	be	considered	BV	positive	 by	 Amsel	 criteria	 and	 receive	 antibiotic	 treatment,	 three	 of	 these	 four	clinical	characteristics	have	to	be	evident	(Amsel	et	al.,	1983).		BV	increases	HIV-1	risk	significantly	(Low	et	al.,	2011;	Cohen	et	al.,	2012;	Achilles	and	Hillier,	2013).	Women	with	BV	are	at	a	heightened	risk	of	HIV	acquisition,	and	HIV	positive	women	with	BV	are	three	times	more	 likely	to	transmit	 the	virus	to	their	male	partners	(Coleman	et	al.,	2007;	Cohen	et	al.,	2012).	Moreover,	BV	is	also	associated	with	an	up	to	1.9-fold	increased	incidence	of	bacterial	STIs	(Wiesenfeld	et	al.,	2003).	The	mechanism	by	which	BV	increases	HIV	risk	 in	women	has	been	attributed	 to	 several	 factors;	 including	 increased	 concentrations	 of	 pro-inflammatory	mediators,	such	as	IL-1α,	IL-1β	and	TNF-α,	in	BV	positive	compared	to	BV	negative	women	(Masson	et	al.,	2014;	Joag	et	al.,	2018).	The	increase	in	these	pro-inflammatory	 cytokines	 may	 facilitate	 HIV	 infection	 by	 disrupting	 the	epithelial	barrier	(Bruewer	et	al.,	2003),	and	by	activating	nuclear	factor-κB,	which	binds	to	the	HIV	long	terminal	repeat	and	promotes	HIV	replication	(Osborne	et	al.,	1989;	Stroud	et	al.,	2009).			
1.6 Endogenous	female	sex	hormones		
The	 hormones	 involved	 in	 the	 regulation	 of	 the	 female	 reproductive	 system	include	 follicle-stimulating	 hormone	 (FSH),	 Gonadotropin-releasing	 hormone	(GnRH),	luteinizing	hormone	(LH),	estrogen	(E2)	and	progesterone	(P4;	Wira	et	al.,	2015).	The	menstrual	cycle	occurs	as	a	 result	of	 changes	 in	 these	hormones	 that	are	 in	 turn	 regulated	 by	 the	 hypothalamic-pituitary	 axis.	 During	 the	 follicular	phase	of	the	menstrual	cycle,	FSH	and	LH	released	from	the	hypothalamus	travel	in	the	 blood	 to	 the	 ovaries	 to	 stimulate	 growth	 of	 about	 15-20	 eggs	 and	 the	production	of	estrogen.	An	increase	in	E2	inhibits	the	production	of	FSH	to	allow	the	body	to	limit	the	number	of	follicles	that	mature	(Pessina	et	al.,	2006).	This	is	followed	 by	 the	 production	 of	 LH	 needed	 for	 the	 eggs	 to	 be	 released	 from	 the	ovaries,	also	known	as	ovulation.	Ovulation	requires	the	follicle	to	rupture	so	that	
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the	ovum	can	be	released	into	the	fallopian	tube.	The	ruptured	follicle	becomes	the	corpus	 luteum,	 which	 produces	 both	 E2	 and	 P4	 needed	 to	 maintain	 optimum	conditions	 for	 fertilization	 and	 implantation	 during	 this	 luteal	 phase.	 In	 the	absence	 of	 pregnancy,	 the	 corpus	 luteum	 shrinks	 and	 levels	 of	 E2	 and	 P4	 start	decreasing.	 P4	 plays	 a	 role	 in	 maintaining	 pregnancy,	 whereby	 increased	 levels	lead	 to	 inhibition	 of	 ovulation	 during	 pregnancy,	 while	 decreased	 levels	 lead	 to	menstruation	and	endometrial	repair	(Challis	et	al.,	2009).		
1.6.1 Effect	of	endogenous	hormones	on	FRT	microenvironment	
Endogenous	 hormones	 play	 an	 important	 role	 in	 regulating	 immunity	 and	 the	microenvironment	of	the	FRT	(Tan	et	al.,	2015;	Wira	et	al.,	2015).	Susceptibility	to	pathogens	 can	 vary	 depending	 on	 the	 menstrual	 cycle	 due	 to	 hormonal	fluctuations.	E2	and	P4	regulate	various	aspects	of	the	immune	system	in	the	FRT,	both	 directly	 or	 indirectly,	 including	 mucosal	 cellular	 composition,	 chemokines	and	 cytokines,	 homing	 of	 immune	 cells,	 epithelial	 cell	 receptor	 expression	 and	epithelial	barrier	 integrity	 (Wira	et	al.,	 2005b;	Heldring	et	al.,	2007;	Fahey	et	al.,	2008).	 Although	 not	 yet	 fully	 characterized,	 P4	 receptors	 are	 found	 on	plasmacytoid	 DCs,	 macrophages,	 CD4+	 and	 CD8+	 T	 cells	 (Wira	 et	 al.,	 2015;	Hapgood	 et	 al.,	 2018).	 E2	 receptors	 are	 also	 expressed	 by	 many	 immune	 cells,	including	 neutrophils,	 T	 cells,	 B	 cells	 and	 NK	 cells	 (Fish,	 2008).	 E2	 modulates	signaling	 pathways	 of	 pro-inflammatory	 receptors	 and	 PRRs	 (Jorgenson	 et	 al.,	2005;	 Aflatoonian	 et	 al.,	 2007;	 Lin	 et	 al.,	 2009).	 P4	 also	 regulates	 some	immunological	pathways,	including	modulating	cytokine	production,	up-regulating	HIV-1	receptor	CCR5	expression,	and	increasing	expression	of	PRRs	by	fibroblasts	(Hirata	et	al.,	2007).			Antibodies	in	cervical	mucus	have	been	shown	to	decrease	during	ovulation,	or	are	diluted	out	by	increased	mucus	secretion,	but	increase	in	concentration	during	the	secretory	 and	 proliferative	 phases	 of	 the	 menstrual	 cycle	 (Wira	 et	 al.,	 2011).	Cytotoxic	T	lymphocytes	(CTL),	sampled	by	endometrial	biopsy,	were	found	to	be	less	 cytotoxic	 during	 the	 luteal	 phase,	 and	 more	 cytotoxic	 during	 the	 follicular	phase	of	the	menstrual	cycle	(White	et	al.,	1997a).	In	addition,	expression	of	CXCR4	
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(also	 an	 HIV	 co-receptor,	 that	 is	 the	 receptor	 for	 the	 chemokine	 stromal	 cell-derived	factor	1	[SDF-1])	on	human	epithelial	cells	lining	the	endometrium	in	the	FRT	increases	during	the	proliferative	phase	(Yeaman	et	al.,	2003).			The	 concentration	 of	 AMPs	 and	 cytokines	 also	 fluctuates	 during	 the	 menstrual	cycle.	For	example,	levels	of	human	beta-defensins	(HBD)-1,	-2	and	-3	peak	during	the	secretory	phase	of	the	menstrual	cycle	(King	et	al.,	2003).	In	vitro	studies	found	that	endogenous	P4	was	associated	with	lower	genital	pro-inflammatory	cytokines	production	 (including	 TNF-α,	 IFN-g	 and	 IL-12)	 and	 increased	 production	 of	 the	anti-inflammatory	cytokine	IL-10	(Butts	et	al.,	2007;	Kyurkchiev	et	al.,	2007;	Jones	et	 al.,	 2010;	 Grandi	 et	 al.,	 2016).	 These	 genital	 tract	 pro-inflammatory	 cytokines	attract	immune	cells,	including	HIV	targets	cells	CD4+	T	cells,	to	the	FRT	(Arnold	et	al.,	2016).		In	addition,	hormonal	changes	also	affect	the	integrity	of	the	FRT	epithelial	barrier.	Proteases	 involved	in	degradation	of	the	epithelial	barrier	have	been	found	to	be	elevated	during	the	luteal	phase	(Bradley	et	al.,	2018).	Conversely,	concentrations	of	 anti-proteases	 are	 elevated	 during	 ovulation	 and	 the	 follicular	 phase	 of	 the	menstrual	 cycle	 (Birse	 et	 al.,	 2015).	 Anti-proteases	 are	 important	 for	 reducing	inflammation	 and	 have	 been	 shown	 to	 inhibit	 binding	 and	 replication	 of	 HIV	(Aboud	et	 al.,	 2014).	Therefore,	 epithelial	barrier	 integrity	 likely	depends	on	 the	phase	 of	 menstrual	 cycle	 as	 endogenous	 E2	 promotes	 proliferation	 of	 epithelial	cells,	 while	 P4	 has	 been	 associated	 with	 thinning	 of	 the	 vaginal	 epithelium	 in	animal	models	(Marx	et	al.,	1996;	Patton	et	al.,	2000).	These	alterations	in	mucosal	barrier	 permeability	 during	 the	 menstrual	 cycle	 might	 lead	 to	 differences	 in	susceptibility	 to	 pathogens,	 including	 HIV.	 Figure	 1.5	 summarizes	 some	 of	 the	known	effects	of	the	menstrual	cycle	on	the	microenvironment	of	the	FRT.				
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Figure	1.5.	The	influence	of	endogenous	hormone	on	immunity	and	the	integrity	of	
the	epithelial	barrier	 in	 the	FRT.	 The	 follicular	phase	 is	 characterized	by	 increases	 in	anti-proteases,	 anti-inflammatory	 cytokines	 and	 an	 intact	 epithelial	 barrier.	 Similarly,	during	 ovulation	 there	 is	 a	 high	 level	 of	 anti-proteases	 in	 addition	 to	 AMPs.	 The	 luteal	phase	has	high	levels	of	pro-inflammatory	cytokines	causing	an	influx	of	highly	activated	CD4+	 T	 cells	 expressing	 CCR6	 and	 CCR5.	 Although	 the	mucus	 layer	 is	 thick	 during	 this	time,	the	epithelial	barrier	integrity	is	weakened.	Figure	drawn	by	Iyaloo	Konstantinus.		
1.7 Hormonal	contraceptives	
It	 is	 estimated	 that	 hormonal	 contraceptives	 are	 used	by	more	 than	140	million	women	worldwide	(UNDESA,	2015).	About	a	quarter	of	women	in	SSA	use	modern	contraceptive	methods	 (Chersich	et	al.,	2017).	A	wide	 range	of	HCs	are	available	for	women	to	choose	 from,	 including:	combined	oral	contraceptive	pills	 (COCPs),	contraceptive	 patches,	 levonorgestrel	 intrauterine	 devices	 (IUDs),	 levonorgestrel	(LNG)	 implants,	 combined	 contraceptive	 vaginal	 rings	 and	 long-acting	 injectable	contraceptives.	 In	 SSA,	 the	 long-acting	 injectable	 progestins	 [depot-medroxyprogesterone	 acetate	 (DMPA)	 and	 norethisterone	 enanthate	 (NET-EN)]	are	the	most	commonly	used	methods,	making	up	about	47%	of	all	contraceptive	choices	in	SA	(Figure	1.6;	UNDESA,	2015).	In	addition,	non-hormonal	methods	are	
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also	available,	including:	male	and	female	condoms,	male	and	female	sterilization,	copper	IUDs	(Cu-IUDs),	the	withdrawal	and	rhythm	methods.	A	study	conducted	in	SA	young	women	between	20	and	29	years	found	that	their	contraceptive	choices	were	largely	determined	by	partner’s	opinion,	although	availability	and	side	effects	of	contraceptives	were	also	important	(Oluwole	and	Skaal,	2016).			
	
Figure	 1.6.	 World	 map	 of	 the	 most	 popular	 contraceptive	 method	 by	 country.	Permanent	methods	such	as	male	 (deep	purple)	and	 female	sterilization	(turquoise)	are	common	in	North	America	and	Asia.	In	Europe,	women	mostly	use	the	pill	(green),	while	condoms	are	widely	used	in	Russia	(medium	blue).	The	southern	African	region	popular	method	is	 the	 injectable	contraceptives	(royal	purple).	 Image	taken	from	United	Nations	Department	 of	 Economic	 and	 Social	 Affairs	 Population	 Division,	 2015	 (Available	 at:	https://onlinedoctor.superdrug.com/birth-control-around-the-world/).		
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1.7.1 DMPA	and	NET-EN	
Injectable	 contraceptives	 are	 popular	 in	 developing	 countries	 because	 they	 are	affordable,	 long-acting	 and	 relatively	 private.	 DMPA	 and	 NET-EN	 are	 both	 long-acting	 reversible	 methods	 of	 contraception	 (Jacobstein	 and	 Polis,	 2014).	 DMPA,	first	 discovered	 in	 1951	 by	 the	 Upjohn	 Company,	 is	 administered	 as	 a	 150mg	intramuscular	 injection	 of	 the	 synthetic	 17-hydroxyprogesterone	 derivative	 of	progesterone	 as	 an	 aqueous	microcrystalline	 suspension,	 that	 is	 slowly	 released	into	 the	 blood	 stream;	 and	 administered	 every	 three	 months.	 Following	administration,	 DMPA	 plasma	 concentrations	 increase	 steadily	 to	 plasma	 levels	0.2ng/ml	within	24	hours	(Mishell,	1996).	In	contrast,	NET-EN,	first	used	in	1957	by	 the	 Schering	Company,	 is	 delivered	 as	 a	 200mg	 intramuscular	 injection	of	 an	oily	 solution	 of	 17C-alpha-ethinyl-17-beta-heptanoyloxy-4-esterene-3-one	progesterone	 derivative,	 administered	 every	 two	 months.	 Following	administration,	NET-EN	plasma	concentrations	reach	a	peak	of	5.5	to	11ng/ml	in	about	10	days.	Therefore,	with	both,	there	is	a	sharp	increase	in	progestogen	blood	concentration	in	the	first	two	days,	followed	by	a	decline	over	the	following	weeks.	Both	 injectable	 contraceptives	 bind	 to	 the	 progesterone	 receptor	 (PR)	 on	fibroblasts,	 smooth	 muscles	 and	 epithelial	 cells	 in	 the	 upper	 FRT	 (Kurita	 et	 al.,	2000;	 Rȩkawiecki	 et	 al.,	 2011;	 Kowalik	 et	 al.,	 2013).	 However,	 the	pharmacokinetics	 profiles	 of	 DMPA	 and	 NET-EN	 are	 different	 from	 those	 of	 the	endogenous	 P4.	 Both	 have	 higher	 binding	 affinities	 to	 the	 PR	 than	 endogenous	progesterone,	but	bind	more	weakly	to	the	androgen	receptor	than	P4	(Schindler	et	al.,	2003).	MPA	also	binds	with	high	affinity	to	the	glucocorticoid	receptor	(GR)	while	the	endogenous	progesterone	and	NET-EN	only	bind	weakly	to	this	receptor	(Sedgh	et	al.,	2016;	Hapgood	et	al.,	2018).	The	GR	receptor	has	immunomodulatory	effects,	whereby	binding	of	an	agonist	leads	to	transactivation,	whereas	binding	of	an	antagonist	results	in	transrepression	(Africander	et	al.,	2011).		
1.7.2 NuvaRing	
The	NuvaRing®	combined	contraceptive	vaginal	ring	(CCVR)	is	a	self-administered	HC	product	that	can	be	used	monthly,	which	was	first	marketed	in	2001	but	only	
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became	available	 in	the	private	health	sector	 in	South	Africa	 in	2013	(Figure	1.7;	Roumen,	2008).	It	is	made	of	the	inert	copolymer	evatane,	and	it	measures	54mm	in	diameter	and	4mm	in	thickness,	that	contains	a	combination	of	ethinylestradiol	(EE)	and	etonogestrel	(ENG)	which	are	equally	dispersed	inside	the	ring	(Mulders	and	Dieben,	2001).	NuvaRing®	slowly	 releases	a	 low	dose	of	progestin	ENG	and	estrogen	EE	over	three	weeks,	which	are	absorbed	through	the	vaginal	epithelium.	On	average,	 it	 is	 estimated	 that	120μg	of	ENG	and	15μg	of	EE	are	 released	daily	from	 the	 ring	 (Timmer	and	Mulders,	 2000;	Oddsson	et	 al.,	 2005).	The	maximum	concentration	 of	 EE	 (approximately	 35pg/ml)	 is	 attained	within	 2-3	 days,	while	the	maximum	concentration	of	ENG	(approximately	1700pg/ml)	is	attained	after	1	week	of	ring	 insertion.	The	manufacturers	recommend	that	 the	 three	continuous	weeks	of	use	be	 followed	by	a	ring	free	week,	during	which	withdrawal	bleeding	normally	 occurs.	 The	 main	 advantages	 of	 NuvaRing	 are	 the	 lower	 doses	 of	contraceptive	hormones	released	and	convenience	of	using	 it	 for	a	whole	month.	The	 daily	 controlled-release	 of	 hormones	 also	 avoids	 fluctuation	 in	 hormone	levels.	NuvaRing	has	also	be	shown	to	produce	superior	cycle	control	compared	to	COCPs	with	the	same	hormone	formulation	(Bjarnadóttir	et	al.,	2002).										
	
	
Figure	1.7.	Illustration	of	how	NuvaRing	is	placed	inside	the	vagina.	The	clear	plastic	ring	is	folded	and	pushed	into	the	vagina.	This	ring	stays	for	three	weeks	and	it	is	replaced	afterwards.	 Image	 taken	 from	https://www.obgynecologistnyc.com/procedures/nuvaring-birth-control-vaginal-ring/.			
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1.7.3 COCPs	
COCPs	 are	 taken	 orally	 each	 day	 to	 prevent	 pregnancy,	 being	 the	 third	 most	popular	HC	method	globally	(UNDESA,	2015).	Early	COCPs	regimens	consisted	of	a	28-day	pill	pack,	which	included	7	placebo	pills	taken	at	the	end	of	the	21	days	to	initiate	 withdrawal	 bleeding	 (Nappi	 et	 al.,	 2016).	 Other	 regimens	 with	 shorter	hormone	free	days	(2-4	days)	are	now	available	on	the	market,	as	they	have	lighter	and	shorter	withdrawal	bleeds	(Ahrendt	et	al.,	2009;	Mansour	et	al.,	2011).	Of	the	many	COCPs	available	on	the	market,	Nordette®	and	Trisaphil®	birth	control	pills	are	 commonly	 available	 in	 South	 Africa,	 and	 contain	 LNG	 and	 EE.	 Nordette®	COCPs	 contains	 0.15mg	 of	 LNG	 [d(-)-13	 betaethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one],	 and	0.03mg	of	EE,	 [19-nor-17α-pregna-1,3,5	 (10)-trien-20-yne-3,17-diol].	 In	 contrast,	 Trisaphil®	 has	 a	 triphasic	 hormonal	 regimen	 of	three	different	drugs:	phase	1	is	comprised	of	6	tablets	each	containing	0.05mg	of	LNG,	and	0.03mg	of	EE;	phase	2	is	comprised	of	5	tablets,	each	containing	0.075mg	LNG	 and	 0.04mg	 EE;	 and	 phase	 3	 is	 comprised	 of	 10	 tablets,	 each	 containing	0.125mg	 LNG	 and	 0.03mg	 EE.	 A	 major	 drawback	 of	 COCPs	 is	 that	 daily	 intake	makes	compliance	more	difficult,	 and	also	 the	occurrence	of	daily	 fluctuations	of	hormonal	plasma	levels.		
1.7.4 Public	health	perspective	on	HCs	and	HIV	acquisition		
HCs	 have	 had	 profound	 health	 benefits	 for	women	 and	 their	 infants	worldwide,	with	 significantly	 reduced	 mortality	 and	 morbidity	 (WHO,	 2017).	 Despite	 the	enormous	gains	of	HCs,	current	data	suggests	that	injectable	HCs	may	increase	HIV	risk	 in	women.	SSA	has	 the	highest	 injectable	contraceptives	use,	which	coincide	with	 the	 highest	 prevalence	 of	HIV	 in	 the	world	 (Butler	 et	 al.,	 2013).	 CCVRs	 are	currently	not	available	in	public	clinics	in	SSA	(Kestelyn	et	al.,	2018),	and	there	is	therefore	not	enough	data	on	the	CCVRs	and	risk	of	HIV	acquisition.	The	impact	of	NuvaRing	 on	 the	 vaginal	 microenvironment	 is	 of	 particular	 interest	 given	 the	interest	in	combining	hormonal	contraceptives	with	microbicides	or	ART	in	these	rings.			
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Several	 observational	 and	 recent	 meta-analyses	 have	 shown	 that	 DMPA	significantly	 increases	a	woman’s	risk	of	HIV-1	 infection	(Hild-Petito	et	al.,	1998;	Trunova	 et	 al.,	 2006;	 Morrison	 et	 al.,	 2015;	Wall	 et	 al.,	 2015;	 Polis	 et	 al.,	 2016;	Butler	 et	 al.,	 2016).	 In	 contrast,	 there	 is	 still	 no	 convincing	 evidence	on	HIV	 risk	from	 observational	 studies	 on	 NET-EN	 and	 COCPs,	 and	 insufficient	 studies	 on	NuvaRing,	 HC	 patches,	 or	HC	 implants	 (Polis	 et	 al.,	 2016).	 Because	 the	 available	epidemiological	 data	 vary	 in	quality,	 the	WHO	have	 resisted	 changing	 guidelines	on	use	of	the	injectable	DMPA	formulation.	There	is	a	risk	that	taking	DMPA	off	the	market	 may	 be	 more	 harmful	 to	 infant	 and	 maternal	 health,	 as	 women	 may	experience	 unintended	 pregnancies	 as	 a	 consequence.	 To	 improve	 confidence	 in	the	observational	risk	data,	a	randomized	controlled	trial	has	just	been	completed	–	called	the	“Evidence	for	Contraceptive	Options	and	HIV	Outcomes	(ECHO)”	study	-	a	multi-centre,	open-label,	 randomized	clinical	 trial	comparing	HIV	 incidence	 in	women	 using	 DMPA,	 LNG,	 and	 Cu-IUD,	 and	 the	 results	 will	 be	 communicated	during	2019	(http://echo-consortium.com).			
1.8 Biological	mechanisms	by	which	HCs	increase	risk	for	HIV	
infection	
Several	mechanisms	to	explain	the	relationship	between	certain	HCs	and	increased	HIV	 risk	 have	 been	 proposed	 (Blish	 and	 Baeten,	 2011;	Hickey	 et	 al.,	 2016).	 HCs	have	been	suggested	to	thin	the	vaginal	epithelium	in	animal	models	(Marx	et	al.,	1996;	 Butler	 et	 al.,	 2016).	 In	 addition,	 HCs	 cause	 extension	 of	 the	 endocervical	columnar	 epithelium	 into	 the	 ectocervix,	 also	 known	 as	 cervical	 ectopy	 (Hild-Petito	et	al.,	1998).	HCs	have	also	been	shown	to	alter	both	 the	composition	and	metabolism	of	the	VMB	(Achilles	and	Hillier,	2013).	HCs	might	initiate	changes	in	systemic	 or	 local	 immunity	 by	 modulating	 the	 levels	 of	 defense	 proteins	 and	soluble	mediators,	including	chemotactic	cytokines	(Morrison	et	al.,	2014,	Ngcapu	et	 al.,	 2015;	Deese	 et	 al.,	 2015),	which	 are	 likely	 to	 influence	 recruitment	 of	HIV	target	 cell	 and	 increased	 expression	 of	 chemokine	 receptors	 needed	 for	 HIV	 to	infect	cells.	Some	of	the	proposed	mechanisms	are	summarized	in	Figure	1.8.			
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Figure	 1.8.	 Summary	 of	 proposed	mechanisms	 by	 which	 HCs	 contribute	 to	 HIV-1	
transmission.	HCs	alter	immunity,	disrupt	vaginal	structures,	increase	genital	infections,	and	alter	the	VMB.	Figure	drawn	by	Iyaloo	Konstantinus.			
1.8.1 Impact	of	HCs	on	structural	features	of	the	FRT	
HCs	 have	 been	 suggested	 to	 affect	 the	 epithelial	 barrier	 of	 the	 FRT,	 although	published	 reports	 have	 been	 conflicting.	 Some	 studies	 have	 found	 a	 decrease	 in	thickness,	while	others	found	no	changes	(Bahamondes	et	al.,	2000;	Eschenbach	et	al.,	 2000;	 Mitchell	 et	 al.,	 2014).	 Thinning	 of	 the	 vaginal	 epithelium	 has	 been	observed	in	rhesus	macaques	treated	with	high	doses	of	DMPA	(Hild-Petito	et	al.,	1998).	A	study	comparing	a	progesterone-based	IUD	and	COCPs	found	that	women	on	both	HC	methods	had	comparable	epithelial	thickness,	but	thickness	was	lower	compared	to	women	not	using	any	HCs	(Tjernlund	et	al.,	2015).	Interestingly,	one	study	 found	 that	 HCs	 (DMPA,	 COCPs	 and	 LNG-implant)	 generally	 induced	hyperplasia	 of	 the	 vaginal	 epithelium	 in	 women	 (Ildgruben	 et	 al.,	 2003).	 Using	proteomics,	Chandra	et	al.	 (2013)	found	changes	 in	adherens	(protein	complexes	that	occur	at	cell–cell	 junctions	in	epithelial	tissues)	and	epithelial	tight	junctions	proteins	 in	 vaginal	 biopsies	 of	 women	 following	 12	 weeks	 of	 DMPA	 use.	Furthermore,	 DMPA	 was	 associated	 with	 a	 downregulation	 of	 many	 genes	involved	 in	 the	 maintenance	 of	 the	 mucosal	 barrier	 while	 COCPs	 were	 not	(Zalenskaya	et	al.,	2018).	Therefore,	HCs	might	affect	intraepithelial	tight	junctions	
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and	 compromise	 the	 integrity	 of	 the	 epithelial	 barrier.	 In	 a	 South	 African	 study,	women	with	clinically	signs	of	a	disrupted	genital	epithelium	and	abnormal	vaginal	discharge	were	at	the	highest	risk	for	HIV	acquisition	(Hazard	ratio:	4.30,	95%	CI:	2.55,	8.22;	Abbai	et	al.,	2016).			HCs	have	been	reported	 to	cause	cervical	ectopy	(Venkatesh	and	Cu-uvin,	2013),	with	 COCPs	 being	 associated	 with	 the	 largest	 areas	 of	 cervical	 ectopy,	 but	 not	DMPA	(Bright	et	al.,	2014).	Ectopy	in	turn	is	associated	with	a	heightened	HIV	risk	(Moss	et	al.,	1991).	Adolescents	are	more	likely	to	have	larger	areas	of	ectopy	due	to	metaplasia,	 which	 can	 occur	 during	 puberty	 (Moscicki	 et	 al.,	 1999).	 It	 is	 also	during	this	time	that	adolescents	seek	HCs.			
1.8.2 Impact	of	HCs	on	immunity	
Several	 studies	 have	 reported	 that	 DMPA	 impacts	 production	 of	 cytokines	 and	chemokines	in	the	FRT,	although	some	suggested	that	cytokines	were	suppressed	(Ngcapu	 et	 al.,	 2015),	 others	 showed	differential	 effects	 (Fichorova	 et	 al.,	 2015),	while	others	suggested	upregulation	in	these	(Deese	et	al.,	2015).			Cervical	 swabs	 from	 women	 on	 DMPA	 had	 higher	 levels	 of	 RANTES	 but	 pro-inflammatory	cytokines	including	IL-1β	and	IL-6	did	not	differ	from	women	not	on	contraceptives	(Fichorova	et	al.,	2015).	DMPA	users	were	further	reported	to	have	elevated	MIP-1α,	MIP-1β,	 IL-6,	 IL-8,	 IP-10	and	RANTES;	while	NET-EN	users	had	elevated	 IL-6,	 IL-8	 and	 RANTES	 concentrations	 (Deese	 et	 al.,	 2015).	 In	 a	 recent	study,	DMPA	users	were	found	to	have	elevated	RANTES	and	lower	concentrations	of	 biodefensin-2	 (BD-2;	 Morrison	 et	 al.,	 2018).	 Thus,	 cytokines	 associated	 with	DMPA	 use	 in	 observational	 studies	 include	 those	 that	 have	 been	 found	 to	 be	associated	with	 increased	HIV	 acquisition	 risk,	MIP-1α,	MIP-1β,	 IL-6,	 IL-8,	 IP-10	and	 RANTES	 (Mlisana	 et	 al.,	 2012;	 Morrison	 et	 al.,	 2014;	 Masson	 et	 al.,	 2015a).	Inflammatory	 cytokines	 may	 cause	 activation	 of	 HIV	 target	 cells	 and	 their	recruitment	to	the	genital	mucosa.	In	agreement	with	this,	increased	frequencies	of	activated	cervical	CD4+	T	cells	were	observed	in	women	using	DMPA	(Byrne	et	al.,	
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2016;	Chandra	et	al.,	2013).	Use	of	COCPs	was	found	to	increase	expression	of	IFN-
g,	IL-12	and	IL-10	in	cervical	secretions	(Barousse	et	al.,	2007).			In	 contrast	 to	 these	 studies	 showing	 increased	 cytokine	 production	 associated	with	 HC	 use,	 an	 observational	 study	 conducted	 in	 South	 African	 women	 found	lower	cervicovaginal	concentrations	of	cytokines	IL-12	and	IL-15,	and	chemokines	MCP-1,	MDC,	 eotaxin	 and	 fractalkine	 in	 those	using	DMPA	 (Ngcapu	 et	 al.,	 2015).	The	 current	 understanding	 of	 the	 impact	 of	 HCs	 on	 cytokine	 production	 in	 the	genital	mucosa	 thus	 remains	 limited,	 as	most	 studies	 are	 observational	 and	 few	included	data	collected	during	randomized	trials.			Use	of	DMPA	may	facilitate	HIV-1	infectivity	by	causing	an	increase	in	HIV	target	cells	and	through	the	regulation	of	their	co-receptors	(Baeten	et	al.,	2001;	Ghanem	et	 al.,	 2005;	 Chandra	 et	 al.,	 2013).	 Epithelial	 tissue	 biopsies	 from	women	 using	DMPA	showed	an	increase	in	macrophages	and	T	cells	expressing	CCR5	(Chandra	et	 al.,	 2013).	 Another	 study	 in	 South	 Africa	 found	 that	women	 using	 DMPA	 had	more	 cervical	 CCR5+	 CD4+	 T	 cells	 compared	 to	 women	 not	 using	 long-term	contraceptives	 (Byrne	 et	 al.,	 2016).	 Interestingly,	 Byrne	 et	 al.	 (2016)	 found	 that	women	in	the	same	study	who	were	in	the	luteal	phase	of	menstruation	also	had	higher	 CCR5	 expression	 compared	 to	women	 in	 the	 follicular	 phase.	Women	 on	COCPs	were	 also	 found	 to	have	 elevated	CCR5	expression	on	 their	T	 cells	 in	 the	cervical	epithelium	(Prakash	et	al.,	2002).	In	contrast,	women	using	the	progestin	based	IUD	had	reduced	expression	of	CCR5	on	their	cervical	T	cells	(Achilles	et	al.,	2014).			In	contrast	 to	 the	other	HC	products,	 there	have	been	comparatively	 few	studies	assessing	the	effect	of	NuvaRing	use	on	immunity	in	the	FRT.	Michel	et	al.	(2015)	reported	 that	 NuvaRing	 use	was	 associated	with	 decreased	 CD207+	 Langerhans	cells	in	the	vaginal	epithelium	compared	to	DMPA	users.		
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1.8.3 Impact	of	HCs	on	STIs	
A	 number	 of	 studies	 have	 identified	 associations	 between	 the	 use	 of	 HCs	 and	acquisition	of	STIs	(other	than	HIV).	COCP	use	has	been	reported	to	increase	risk	for	chlamydia,	and	HPV	infection	(Cottingham	and	Hunter,	1992;	Borgdorff	et	al.,	2015).	 DMPA,	 similarly,	 was	 shown	 to	 increase	 susceptibility	 to	 HSV-2	 and	decrease	 immune	 responses	 to	HSV-2	 in	mice	 (Gillgrass	 et	 al.,	 2003).	 In	women,	DMPA	use	was	found	to	be	at	double	the	risk	of	acquiring	HSV-2	compared	to	those	not	 using	 HCs	 (Grabowski	 et	 al.,	 2015).	 Baeten	 et	 al.	 (2001)	 reported	 that	 both	injectable	 HCs	 and	 COCPs	 were	 associated	 with	 increased	 risk	 of	 chlamydia	infection.	However,	no	association	was	observed	between	DMPA	use	and	risk	 for	syphilis	and	gonorrhoea	infection	(Baeten	et	al.,	2001;	Harris	et	al.,	2009;	Marks	et	al.,	2011;	Noguchi	et	al.,	2014).			
1.8.4 Influence	of	HCs	on	the	VMB	
Studies	 investigating	 the	 impact	 of	 HCs	 on	 the	 composition	 and	 stability	 of	 the	VMB	have	 yielded	 conflicting	 results.	 A	 recent	meta-analysis	 that	 included	more	than	 50	 studies	 found	 that	 women	 using	 different	 HCs	 were	 at	 up	 to	 25%	decreased	risk	 for	both	prevalence	and	 incidence	of	BV	compared	 to	women	not	using	 HCs	 (Vodstrcil	 et	 al.,	 2017).	 The	 use	 of	 HCs	 has	 been	 found	 to	 alter	 the	normal	microbiota	 in	women	 according	 to	 age,	 favoring	Lactobacillus	fermentum	and	E.	coli	in	women	between	the	age	of	20	–	30	years,	and	L.	fermentum,	Candida	and	E.	coli	in	women	between	the	age	of	31	–	40	years	(Kazi	et	al.,	2012).			A	 study	 on	 CCVRs	 (NuvaRing)	 in	 Rwandan	 women	 reported	 an	 association	between	 vaginal	 dysbiosis	 and	 increase	 in	 the	 biomass	 associated	with	 the	 used	ring,	 which	 was	 predominantly	 colonized	 by	 Lactobacillus	 and	 several	 BV-associated	 bacteria	 (Crucitti	 et	 al.,	 2018).	 Another	 study	 comparing	 the	levonorgestrel-releasing	IUD	(Mirena®)	with	COCPs	observed	a	trend	towards	an	increased	abundance	of	BV-associated	bacteria	in	women	using	the	former,	and	an	increase	in	Lactobacillus	in	women	using	the	latter	(Brooks	et	al.,	2017).			
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DMPA	use	has	been	associated	with	decreased	concentrations	of	H2O2-producing	lactobacilli,	 but	 also	 decreased	 concentrations	 of	 G.	 vaginalis	and	 total	 bacterial	load	(Mitchell	et	al.,	2014;	Roxby	et	al.,	2016).	The	hypo-estrogenic	effect	of	DMPA	(and	the	effects	this	lack	of	estrogen	has	on	important	nutrients	needed	to	sustain	protective	 lactobacilli	 in	 the	vagina)	has	been	proposed	 to	be	 the	mechanism	by	which	this	HC	method	alters	the	VMB	(Wessels	et	al.,	2018).			
1.9 Study	aims	and	objectives	
The	 overall	 aim	 of	 this	 dissertation	 is	 to	 investigate	 the	 impact	 of	 several	 HC	methods	on	the	immune	microenvironment	of	the	FRT	of	South	African	adolescent	girls	(15-19	years)	at	risk	for	HIV	acquisition,	in	a	randomized	crossover	study.		
Rationale	for	this	study	Young	women	in	South	Africa	are	extremely	vulnerable	to	both	HIV	infection	and	unintended	 pregnancies	 (Cowan	 and	 Pettifor,	 2009;	 UNAIDS,	 2017).	Epidemiological	data	suggests	that	some	forms	of	HCs	used	to	prevent	pregnancy	may	 increase	 HIV	 risk,	 although	 reports	 have	 been	 conflicting.	 Given	 that	adolescence	is	the	time	when	most	young	women	seek	access	to	HCs,	during	early	time	points	in	their	sexual	maturity,	it	is	important	to	evaluate	how	HCs	modulate	the	 immune	 microenvironment	 of	 the	 vagina.	 Despite	 the	 possible	 association	between	 long-acting	 injectable	 HCs	 and	 increased	 risk	 of	 HIV	 acquisition	 from	observational	 studies,	 the	 WHO	 concluded	 in	 2016	 that	 they	 still	 do	 not	 have	sufficient	evidence	 to	change	 the	current	guidelines	 that	 indicate	 “no	restriction”	for	 use	 of	 progestin-only	 injectable	 contraceptives,	 until	more	 randomized	 trials	provide	quality	data	 for	all	available	 forms	of	contraception.	To	address	this	gap,	this	 randomized	 crossover	 trial	 evaluating	 the	 use	 of	 NuvaRing,	 NET-EN	 and	COCPs	on	the	 immune	microenvironment	of	 the	vagina	 in	adolescent	girls	at	risk	for	 HIV	 acquisition	 was	 conducted	 in	 Cape	 Town,	 South	 Africa	 –	 called	 the	uCHOOSE	study.			
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Objective	 1:	 To	 characterize	 cervical	 CD4+	 T	 cells,	 Th17	 cells	 and	 Th7-related	cytokines	in	the	female	reproductive	tract	of	young	adolescents	and	to	investigate	the	 impact	of	 genital	 infections	 and	STIs	on	 these	 cervical	HIV-susceptible	T	 cell	subsets.		
Objective	2:	To	investigate	whether	BV	and	the	vaginal	microbiota	alter	Th17	cell	abundance	and	activation	and	related	cytokines	in	the	genital	tracts	of	AGYW.		
Objective	3:	To	investigate	the	impact	of	NuvaRing,	NET-EN	and	COCPs	on	immune	cells	including	CD4+	T	cells,	Th17	cells,	Th17-related	cytokines,	and	CD8+	T	cells.																			
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2.1 Abstract	Since	the	FRT	is	the	first	site	for	HIV	transmission	during	heterosexual	intercourse,	studies	 characterizing	 immune	 cells	 and	HIV	 target	 cells	 at	 this	mucosal	 site	 are	critical.	CD4+CCR5+	T	cells	are	the	primary	HIV	target	cells	that	become	infected	following	sexual	exposure.	Of	this	subset,	Th17	cells	have	recently	been	suggested	to	 be	 the	 most	 susceptible	 to	 infection.	 Although	 described	 to	 make	 up	 a	 large	proportion	of	the	CD4+	T	cells	in	the	FRT,	little	is	known	about	their	presence	and	their	 characteristics	 in	 adolescent	 girls.	 The	 aim	of	 this	 part	 of	 the	 study	was	 to	characterize	the	immune	microenvironment	in	the	FRT,	focusing	on	CD4+	T	cells,	with	particular	 focus	on	Th17	 cells,	 and	Th17-related	 cytokines	 in	 South	African	adolescents.	 Cervical	 Th17	 cells,	 defined	 by	 expression	 of	 CCR6	 and	 CCR10	 by	FACS	analysis,	were	identified	to	be	a	major	CD4+	T	cell	subset	(making	up	54%	of	total	CD4+	T	 cells)	 in	 cervical	 cytobrushes	 collected	 from	a	 cohort	of	151	AGYW	(15-19	 years),	 assessed	 cross-sectionally	 into	 the	 uCHOOSE	 study.	 In	 addition,	higher	frequencies	of	Th17	cells	than	CCR6-CCR10-	CD4+	T	cells	expressed	CCR5	similarly	 to	 what	 has	 been	 shown	 by	 previous	 studies	 (68%	 versus	 56%,	respectively).	 The	 concentrations	 of	 Th17-related	 cytokines	 were	 measured	 by	Luminex.	 Of	 these,	 the	 Th17	 regulatory	 cytokine	 IL-31	 had	 the	 highest	 median	concentration	(32	pg/ml)	while	the	inflammatory	cytokine	IL-1β	(associated	with	the	 differentiation	 of	 Th17	 cells)	 was	 detected	 at	 the	 highest	 maximum	concentration	 (8040	pg/ml).	Adolescents	with	yeast	 infection	had	 lower	 cervical	Th17	cell	frequencies	compared	to	those	without	yeast,	although	genital	cytokine	concentrations	were	similar.	On	the	contrary,	asymptomatic	bacterial	STIs	did	not	appear	 to	 influence	 the	 frequency	 and	 activation	 status	 of	 cervical	 Th17	 cells,	although	 concentrations	 of	 IL-1β	 and	 IL-17A	 were	 elevated.	 Only	 4.8%	 of	adolescent	 girls	 were	 contraceptive	 naïve	 at	 baseline	 in	 this	 cohort.	 However,	previous	contraceptive	use	did	not	seem	to	affect	cervical	Th17	cell	frequencies	or	Th17-related	cytokines	compared	to	the	HC	naïve	group.							
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2.2 Introduction	The	 FRT	 has	 evolved	 to	 meet	 the	 unique	 requirements	 of	 balancing	 immune	protection	against	harmful	pathogens,	while	tolerating	allogeneic	spermatozoa,	the	developing	 semi-allogenic	 fetus	 and	 commensal	 VMB	 (Wira	 et	 al.,	 2005a).	 Only	recently	have	we	started	 to	understand	 the	complexity	of	 the	 immune	system	 in	the	 FRT	 and	 how	 it	 interacts	 with	 pathogens.	 The	 mucosal	 microenvironment,	including	 immune	 cells	 in	 the	 FRT	 is	 regulated	 by	 sex	 hormones	 including	endogenous	estradiol	and	progesterone	(Wira	et	al.,	2010).		Mucosal	 CD3	 T	 lymphocyte	 cells	 are	 distributed	 in	 the	 upper	 and	 lower	reproductive	tract	of	the	FRT	(White	et	al.,	1997b;	Lee	et	al.,	2015a).	CD4+	T	cells	in	the	reproductive	tract	are	the	primary	targets	for	sexual	transmission	of	HIV	to	women	 (Saba	 et	 al.,	 2010;	 Shen	 et	 al.,	 2012;	 Stieh	 et	 al.,	 2014).	 These	 cells	may	express	CCR5,	a	chemokine	receptor	that	is	needed	for	HIV	infection.	Although	HIV	can	infect	resting	memory	CD4+	T	cells,	the	efficiency	of	infection	is	much	higher	in	activated	CD4+	T	cells,	which	have	been	defined	by	expression	of	CD38	and	HLA-DR	 (Zhang	et	 al.,	 1999;	Meditz	 et	 al.,	 2011;	 Joag	 et	 al.,	 2016).	 CD4+	T	 cells	 are	 a	heterogeneous	 T	 cell	 subset	 and	 are	 defined	 by	 their	 chemokine	 receptor	expression	patterns	and	the	cytokines	they	produce.	Different	T	cells	subsets	differ	in	 their	 susceptibility	 to	 HIV	 infection	 (Cicala	 et	 al.,	 2009;	 Gosselin	 et	 al.,	 2010;	Buzon	 et	 al.,	 2014),	 and	 Th17	 cells	 have	 recently	 been	 suggested	 to	 be	 more	susceptible	to	HIV	infection	than	other	subsets	(including	Th1,	Th2	and	Treg	cells;	Monteiro	 et	 al.,	 2011;	McKinnon	et	 al.,	 2015;	 Stieh	 et	 al.,	 2016).	Moreover,	Th17	cells	 were	 found	 to	 be	 selectively	 depleted	 in	 the	 gut	 mucosa	 of	 HIV-infected	individuals	(Prendergast	et	al.,	2010).		There	is	now	accumulating	evidence	that	the	inflammatory	cytokines	IL-1β,	IL-33	(related	 to	 IL-1),	 IL-23	 (related	 to	 IL-12),	 IL-6,	 and	 TNF-α	 are	 involved	 in	differentiation	of	naïve	CD4+	T	cells	to	Th17	cells	(Stockinger	and	Veldhoen,	2007;	Korn	et	al.,	2009).	In	turn,	Th17	cells	produce	IL-17A,	IL-17F,	IL-21	and	IL-22,	and	are	 critical	 for	 immune	 defense	 against	 both	 fungal	 and	 bacterial	 infections,	particularly	 at	 mucosal	 surfaces	 (Ghilardi	 and	 Ouyang,	 2007;	 Aujla	 et	 al.,	 2007;	
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Awasthi	and	Kuchroo,	2009;	Sugimoto	et.,	2008;	Guglani	and	Khader,	2010).	A	key	role	for	Th17	cells	is	to	recruit	neutrophils	to	the	site	of	infection	through	the	co-production	 of	 IFN-γ	 and	 TNF-α	 (Pelletier	 et	 al.,	 2014).	 Since	 Th17	 cells	 are	inflammatory,	they	are	closely	regulated	by	the	anti-inflammatory	and	regulatory	cytokines	IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ	and	sCD40L	(Li	et	al.,	2018;	Sandquist	and	Kolls,	2018).			Th17	 cells	 selectively	 express	 the	 transcription	 factor	 RORγt	 and	 receptors	including	CCR6,	IL-23R,	CD161,	and	CCR4	(Annunziato	et	al.,	2007;	Prendergast	et	al.,	2010).	CCR6	is	a	homing	receptor	to	mucosal	surfaces	and	has	been	established	as	 a	 robust	marker	 for	 human	Th17	 cells	 (Singh	 et	 al.,	 2008;	Wang	 et	 al.,	 2009;	Stieh	 et	 al.,	 2016;	 Lee	 and	Körner,	 2017).	 CCR6,	 together	with	 its	 ligand	MIP-3a	(CCL20),	are	both	important	in	the	pathogenesis	of	and	immunity	to	HIV	infection	(Lee	 and	 Körner,	 2017).	 Furthermore,	 MIP-3a	 has	 also	 been	 shown	 in	 vitro	 to	facilitate	 efficient	 HIV-1	 integration	 in	 resting	 CD4+	 T	 cells,	 by	 binding	 to	 CCR6	together	with	other	cytokines	(Cameron	et	al.,	2010).		The	presence	of	Th17	cells	at	the	genital	mucosa	has	previously	been	described	in	adult	women	 (Rodriguez-Garcia	 et	 al.,	 2014),	 although	 little	 is	 known	 about	 the	frequency	 of	 these	 highly	HIV	 susceptible	 CD4+	 T	 cells	 at	 the	 genital	mucosa	 of	adolescents	at	high	risk	for	HIV	infection.	Development	of	a	better	understanding	of	the	factors	that	influence	recruitment	and	activation	of	these	highly	susceptible	HIV	 target	 cells	 at	 the	 genital	 mucosa	 is	 important	 for	 the	 development	 of	 HIV	prevention	 strategies.	 The	 aim	 of	 this	 Chapter	 was	 therefore	 to	 evaluate	characteristics	of	CD4+	T	cells	and	Th17	cells	and	profile	Th17-related	cytokines	in	AGYW,	in	relation	to	reproductive	health	and	in	response	to	infection	with	STIs.								
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2.3 Materials	and	Methods	
2.3.1 Study	participants	
The	uCHOOSE	study	was	a	randomized	crossover	HC	trial	to	compare	acceptability	of	 the	 CCVR	 NuvaRing	 compared	 to	 NET-EN	 and	 COCPs	 (Triphasil	 or	 Nordette)	that	 screened	 a	 total	 of	 156	 healthy,	 HIV-negative	 sexually	 active	 adolescents	between	the	ages	of	15-19	years,	who	were	seeking	family	planning	services	at	the	Desmond	Tutu	HIV	Foundation	Youth	Centre	Sexual	Reproductive	Health	clinic	in	Masiphumelele,	 Cape	 Town	 (Table	 2.2).	 Eligibility	 criteria	 included	 being	contraceptive	 naïve	 or	 wanting	 a	 method	 change,	 residing	 in	 Masiphumelele,	having	had	no	symptomatic	STI	within	the	prior	40	days,	negative	urine	pregnancy	test	 and	 no	 intent	 to	 become	pregnant	 in	 the	 next	 8	months,	 normal	 pap	 smear	within	 the	 last	 12	 months,	 no	 contra-indications	 to	 any	 of	 the	 study	 products,	willing	to	refrain	from	inserting	any	non-study	vaginal	products	or	objects	into	the	vagina	throughout	the	duration	of	study	participation,	and	willing	to	use	condoms	for	anal	and	vaginal	sex.	From	these	156	AGYW	that	were	screened,	151	met	the	eligibility	criteria,	and	from	these,	a	total	of	130	adolescents	were	enrolled.	Assent	was	obtained	from	the	adolescents	<18	years	of	age,	while	consent	was	obtained	from	 their	 legal	 guardians.	AGYW	³18	years	provided	written	 informed	 consent.	Demographic,	sexual	risk	behaviours	and	clinical	data	were	collected	at	enrolment	and	 follow	 up	 visits	 using	 structured	 questionnaires	 administered	 by	 a	 trained	counselor	at	 the	Youth	Centre.	This	study	was	approved	by	the	Faculty	of	Health	Sciences	Research	 Ethics	 Committee	 of	 the	University	 of	 Cape	Town	 (HREC	REF	801/2014).	In	addition,	UCT	HREC	approved	this	study	as	a	part	of	this	PhD	(REC	818/2016;	 Konstantinus).	 Results	 in	 this	 chapter	will	 focus	 on	 adolescents	 from	the	screening	visit	only	who	met	the	eligibility	criteria	(n=151),	and	will	be	cross-sectional.	More	details	on	the	randomized	trial	and	follow-up	visits	are	provided	in	Chapter	4,	section	4.4.1.					
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2.3.2 Sample	collection	
The	following	genital	tract	samples	were	collected	in	the	following	order:	1. Menstrual	cup	(MC):	Cervicovaginal	secretions	were	collected	by	inserting	a	menstrual	 cup	 (Softcup®)	 for	 30	 minutes.	 These	 were	 used	 to	 analyse	Th17-related	cytokines	by	Luminex	(section	2.3.8	and	2.3.9).	2. STI	 testing:	A	 vulvovaginal	 swab	was	 collected	 for	 STI	 testing	using	 an	 in	house	 validated	 multiplex	 PCR	 assay,	 which	 was	 performed	 at	 the	 STI	Reference	 Laboratory	 at	 the	 NICD,	 Sandringham	 as	 previously	 described	(Lewis	et	al.,	2012;	section	2.3.4).	3. BV	Nugent	scoring:	Posterior	fornix	and	lateral	wall	swabs	were	collected	to	prepare	a	wet	mount	slide	for	BV	Nugent	scoring	by	Gram	staining,	and	for	detection	 of	 yeast	 hyphae	 and	 spores	 (section	 2.3.4).	 Nugent	 scoring	was	performed	 at	 the	 STI	 Reference	 Laboratory	 at	 the	 NICD,	 Sandringham,	Johannesburg.	4. Vaginal	microbiome:	A	lateral	vaginal	wall	swab	was	collected	for	16S	rRNA	and	shotgun	metagenomic	sequencing,	performed	by	Christina	Balle	(Dept	Immunology,	 UCT).	 The	 microbiome	 data	 will	 not	 be	 included	 in	 this	dissertation	as	it	formed	part	of	Christina	Balle’s	PhD	dissertation,	which	is	currently	being	examined.	5. Flow	 cytometry:	 An	 endocervical	 cytobrush	 (Digene®	 Corporation,	 MD,	USA)	 was	 collected	 for	 cervical	 mononuclear	 cells	 (CMCs),	 which	 were	analysed	using	flow	cytometry	(section	2.3.6).		
2.3.3 Blood	specimens	
Blood	 specimens	 were	 collected	 using	 a	 Serum	 Separator	 Tube	 (SST)	 for	 the	measurement	of	endogenous	hormones:	estradiol	(E2),	 luteinizing	hormone	(LH)	and	follicle	stimulating	hormone	(FSH).	These	measurements	were	performed	by	the	 Bioanalytical	 Research	 Corporation	 laboratories	 (BARC;	 Cape	 Town,	 South	Africa).	HSV-2	serology	was	performed	on	serum	by	the	BARC	laboratory,	directed	against	antibodies	to	HSV-2	glycoproteins	G-1	and	G-2.	
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2.3.4 Reproductive	tract	infections	and	vaginal	pH		
Cervical	 swabs	were	sent	 to	 the	National	 Institute	of	Communicable	Diseases	 for	screening	 for	 STIs,	 yeast	 (hyphae	 on	 Gram	 stain	 slide)	 and	 BV	 (Nugent	 scoring;	NICD,	 Johannesburg,	 South	 Africa).	 For	 BV	 diagnosis,	 FLOQSwabsÔ	 (Copan	Diagnostics,	 CA,	 USA)	were	 collected	 from	 the	 lateral	 vaginal	wall	 and	 posterior	fornix,	smeared	onto	a	glass	slide	and	Gram	stained	for	Nugent	scoring.	According	to	Nugent	scores,	women	were	categorized	as	being	BV-negative	(Nugent	scores	0–3),	 having	 intermediate	 microbiota	 (Nugent	 scores	 4–6),	 or	 being	 BV-positive	(Nugent	score	7–10).	For	STI	testing,	a	vulvovaginal	swabs	(DryswabsÔ,	Medical	Wire	 and	 Equipment,	 England)	 were	 collected	 and	 screened	 for	 Neisseria	
gonorrhoeae,	 Mycoplasma	 genitalium,	 Chlamydia	 trachomatis	 and	 Trichomonas	
vaginalis	 by	 multiplex	 PCR	 at	 the	 National	 Health	 Laboratory	 Services	 STI	Surveillance	 laboratory	 in	 Sandringham,	 Johannesburg,	 as	 previously	 described	(Lewis	 et	 al.,	 2012).	 For	measurement	 of	 vaginal	 pH,	 swabs	were	 collected	 from	the	 posterior	 fornix	 and	 lateral	 vaginal	 wall	 and	 then	 rolled	 onto	 pH	 indicator	strips	 and	 compared	 with	 colour	 zones	 representing	 different	 pH	 values	 (pH	range:	3.6-8.2;	Düren,	Germany).		
	
2.3.5 	Processing	of	cervical	cytobrushes		
Cervical	 mononuclear	 cells	 were	 collected	 using	 a	 Digene®	 cervical	 sampler	[Digene	Corporation,	MD,	USA;	(Gumbi	et	al.,	2008)].	Briefly,	the	cervical	cytobrush	was	 inserted	 into	 the	 endocervical	 os	 under	 speculum	 examination,	 rotated	through	 360°	 and	 immediately	 placed	 into	 a	 15ml	 tube	 containing	 3ml	 of	 cold	transport	medium	[RPMI	1640	(Life	Technologies	Corporation,	CA,	USA)	medium	supplemented	with	5mM	glutamine,	 fungazone,	penicillin,	streptomycin	and	10%	fetal	 calf	 serum	 (FCS)].	 The	 cervical	 cytobrushes	 were	 transferred	 to	 4°C	 in	 a	Nalgene	bench-top	cooler	(Rochester,	NY,	USA)	and	transported	to	the	laboratory	within	4	hours	of	collection.		Cervical	cytobrushes	were	processed	by	gently	rotating	them	against	the	sides	of	the	15ml	tubes	to	dislodge	cells.	The	transport	medium	was	then	flushed	through	
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the	cytobrush	30	times	using	a	sterile	Pasteur	pipette.	The	cytobrush	was	removed	and	discarded.	 The	 cell	 suspension	was	 centrifuged	 at	 320g	 for	 10	minutes.	 The	supernatant	was	collected	and	then	stored	at	-80°C	for	other	assays.	The	pelleted	cells	were	dislodged,	 resuspended	 in	100µl	 phosphate	buffered	 saline	 (PBS)	and	immediately	prepared	for	flow	cytometry.		
2.3.6 	Flow	cytometry	
As	part	of	this	study,	a	9-colour	flow	cytometry	panel	was	designed	and	optimized	to	measure	 CCR6+	 CCR10-	 Th17	 cell	 subsets	 in	 cervical	 cytobrush	 preparations	from	 the	 uCHOOSE	AGYW	 (Table	 2.1).	 Cervical	 cells	were	 transferred	 to	 a	 96	 v-bottom	 well	 plate	 (Corning®	 Incorporated,	 Kennebunk,	 USA).	 The	 cells	 were	phenotyped	 using	 monoclonal	 antibodies	 to	 detect	 the	 following	 markers:	 CD3,	CCR6,	 CCR5	 (BD	 Biosciences,	 Plymouth,	 UK);	 CD4,	 CD19,	 CD14	 (Invitrogen,	Carlsbad,	USA);	CD38	(eBioscience,	CA,	USA);	and	CD8,	CCR10,	HLA-DR	(Biolegend,	CA,	 USA).	 All	 antibodies	 were	 titrated	 to	 optimize	 the	 noise/signal	 ratio.	 Viable	cells	 were	 identified	 using	 a	 LIVE/DEAD®	 ViVid	 stain	 (Life	 Technologies).	Fluorescence	 minus	 one	 (FMO)	 controls	 were	 used	 to	 set	 the	 gates.	 Data	 were	acquired	 on	 a	 BD	 FORTESSAÔ	 cytometer	 and	 analyzed	 with	 FlowJo	 Software	(version	 9.9.5;	 Tree	 Star,	 Ashland,	 OR,	 USA).	 Rainbow	 beads	were	 used	 daily	 to	calibrate	 the	 FORTESSA	 to	 ensure	 that	 the	 fluorescence	 measurements	 were	comparable	in	all	the	experiments.		For	 staining,	 the	 CMCs	 resuspended	 in	 100µl	 of	 PBS	were	 transferred	 from	 the	15ml	 tubes	 to	 a	 96-well	 plate	 (Corning,	MA,	USA).	 The	 cells	were	 centrifuged	 at	1215g	 at	 4°C	 for	 5	 minutes,	 the	 supernatant	 discarded	 and	 the	 cell	 pellet	 was	resuspended	in	50µl	of	ViVid	and	incubated	in	the	dark	at	room	temperature	(RT)	for	 20	 minutes.	 The	 cells	 were	 washed	 twice	 with	 PBS	 (100µl	 and	 150µl,	respectively)	 for	 5	 minutes	 at	 1215g	 at	 4°C,	 and	 stained	 with	 chemokine	antibodies	 (CCR6,	CCR10	and	CCR5)	at	37°C	 for	30	minutes.	The	cells	were	 then	washed	twice	in	PBS	(100µl	and	150µl,	respectively)	for	5	minutes	at	1215g	at	4°C,	and	thereafter	stained	with	a	cocktail	of	antibodies	(CD14,	CD19,	CD3,	CD4,	CD8,	
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CD38,	HLA-DR)	by	 incubating	 them	 in	 the	dark	at	RT	 for	30	minutes.	Cells	were	washed	as	previous,	 resuspended	 in	150µl	Cellfix	and	 transferred	 to	a	5ml	FACS	tube	 and	 acquired	 within	 24	 hours	 using	 the	 BD	 FORTESSAÔ	 cytometer.	Compensation	tubes	were	prepared	with	every	acquisition.	
	
	
Table	2.1	Summary	of	antibodies	included	in	the	optimized	9-colour	panel	
			
2.3.7 Gating	strategy	
A	summary	of	the	gating	strategy	used	to	identify	T	cell	populations	and	activation	of	these	cells	is	shown	in	Figure	2.1.	A	time	gate	was	set	to	establish	a	stable	flow	stream	and	exclude	any	 inconsistency,	 followed	by	a	singlet	gate	 to	exclude	cells	clumped	together.	A	dump	channel	was	set	to	exclude	CD14	(monocytes),	CD19	(B	cells)	and	dead	cells.	Live	CD3	were	gated	on	to	exclude	other	cells,	and	CD4+	and	CD8+	cells	were	gated	on	from	the	CD3	population.		
Marker	 Fluorochrome	 Laser	 Function	CD14	CD19	ViVid	 Paci-ic	blue	 Violet	 Dump	channel	CD3	 APC-H7	 Red	 T	lymphocytes	cell	marker	CD4	 PE-Cy5.5	 Green	 CD4	T	cell	marker	CD8	 BV711	 Violet	 CD8	T	cell	marker	CD38	 PE-Cy7	 Green	 Activation	marker	HLA-DR	 Alexa	-luor	700	 Red	 Activation	marker	CCR5	 APC	 Red	 Co-receptor	CCR6	 BV605	 Violet	 Homing	marker	CCR10	 PE	 Green	 Memory	like	skin-resident	T	cells	
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Figure	2.1.	Gating	strategy	for	T	cell	phenotyping	from	cervical	cytobrush-derived	T	
cells.	A	 time	gate	was	 set	 followed	by	a	 singlet	 gate	 to	 exclude	doublets.	Next,	 live	CD3	cells	were	gated	by	excluding	dead	lymphocytes	(Pacblue	positive),	on	followed	by	CD4+	and	 CD8+	 T	 cell	 gates.	 Chemokine	 receptors	 CCR6	 and	 CCR10	were	 stained	 to	 identify	different	CD4+	T	cell	 subsets	 including	Th17	cells.	Activated	cells	were	defined	as	 those	expressing	CD38	or/and	HLA-DR.	The	CCR5	chemokine	receptor	needed	for	HIV-1	entry	was	also	stained.			The	median	numbers	of	CD3+	cells	 that	were	recovered	per	cytobrush	 from	151	samples	was	769	(range	10	–	19695).	Furthermore,	21/151	cytobrushes	had	<100	CD3	counts	per	cytobrush	and	were	therefore	not	included	in	final	FACS	analysis	as	 they	 were	 considered	 not	 to	 have	 adequate	 CD3+	 cell	 numbers	 for	 Boolean	gating	(Liebenberg	et	al.,	2011a).			
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2.3.8 Menstrual	cup	processing	
Cervicovaginal	 secretions	were	 collected	 by	 inserting	 a	 Softcup®	menstrual	 cup	[(MC),	Evofem	Inc,	CA,	USA]	 for	30	minutes.	The	MC	containing	genital	 fluid	was	placed	 into	 a	 labelled	 sterile	 50ml	 polypropylene	 tube	 (Greiner	 Bio	 One,	Frickenhausen,	 Germany),	 transferred	 to	 4°C	 in	 a	 Nalgene	 (Rochester,	 NY,	 USA)	bench-top	cooler	and	transported	to	the	laboratory	for	further	processing	within	4	hours	of	collection.	In	the	laboratory,	the	MC	was	weighed	and	the	volume	of	the	secreted	 fluid	was	calculated	by	subtracting	the	average	weight	of	 the	50ml	tube	containing	an	unused	MC	(Jaumdally	et	al.,	2017).	The	MC	plastic	membranes	were	pushed	 inside	 out	 using	 a	 sterile	 pipette	 tip	 to	 allow	 the	 collected	 secretions	 to	flow	 out	 of	 the	 MCs	 into	 the	 tubes.	 The	 tubes	 were	 centrifuged	 at	 453g	 for	 10	minutes	 at	 4°C	with	 brakes	 off.	 The	MCs	were	 removed	 after	 centrifugation	 and	discarded.	 The	 MC	 secretions	 were	 diluted	 five-fold	 with	 PBS	 according	 to	 the	calculated	 weight	 of	 the	 collected	 secretions,	 and	 stored	 at	 -80°C	 to	 measure	cytokines	using	Luminex	assays.		
2.3.9 Measurement	of	Th17-related	cytokines	by	Luminex	
The	concentrations	of	IL-17A,	IL-22,	IL-21,	IL-1β,	IL-4,	IL-6,	IL-10,	IL-17F,	IL-23,	IL-25,	 IL-31,	 IL-33,	 IFN-γ,	 sCD40L	 and	 TNF-α	 were	 measured	 using	 Bio-Plex	 Pro™	Human	Th17	 cytokine	Luminex	kits	 (Bio-Rad	Laboratories	 Inc,	CA,	USA).	Briefly,	diluted	 MC	 secretions	 were	 thawed	 overnight	 at	 4°C.	 To	 separate	 the	 mucous	pellets	 from	 the	 fluid	 supernatants,	 the	 secretions	 were	 transferred	 to	 a	 Spin-X	0.2µm	filter	tubes	(Corning®	 Incorporated),	centrifuged	at	1950g	for	10	minutes	and	 the	 supernatants	 removed.	 After	 filtering	 the	 supernatants,	 samples	 were	transferred	 to	 the	Luminex	plates.	 Luminex	assays	were	performed	according	 to	the	manufacturer	Bio-Plex	Pro™	Human	Th17	cytokine	assays	instruction	manual.	Data	 was	 collected	 using	 a	 Bio-Plex™	 Suspension	 Array	 Reader	 (Bio-Rad	Laboratories	 Inc),	 and	 a	 5-parameter	 logistic	 regression	 formula	 was	 used	 to	calculate	 sample	 concentrations	 from	 the	 standard	 curves.	 To	 assess	 inter-plate	variability,	specimens	from	six	participants	were	run	across	all	plates	and	a	total	of	six	plates	were	run.	Cytokine	concentrations	that	were	below	the	detection	limit	of	
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the	 assay	 were	 reported	 as	 the	 mid-point	 between	 the	 lowest	 concentrations	measured	for	each	cytokine	and	zero.	Overall,	detection	of	IL-4	and	IL-10	was	low,	with	 only	 37%	 and	 42%	 of	 samples	 having	 detectable	 levels,	 respectively;	 see	Appendix	Table	A1.			
2.3.10 	Statistical	analyses	
Statistical	 analysis	 was	 performed	 using	 Prism	 version	 6.0	 (GraphPad	 Software,	CA,	 USA),	 STATA™	 version	 12	 (StataCorp,	 TX,	 USA)	 and	 R	 Studio.	 Baseline	demographic,	 clinical	 and	 behavioral	 characteristics	 were	 summarized	 with	descriptive	 statistics	 including	 frequencies,	 medians	 with	 interquartile	 ranges	(IQR).	 For	 categorical	 variables,	 the	 Fisher’s	 exact	 test	 was	 used	 to	 compare	groups.	Non-parametric	Mann-Whitney	U	test	and	Wilcoxon	Signed	Rank	test	were	used	 for	 unmatched	 and	 paired	 samples,	 respectively.	 For	 comparison	 between	more	than	two	groups,	the	Kruskal-Wallis	one-way	analysis	of	variance	was	used.	Correlations	 were	 performed	 using	 the	 Spearman	 Rank	 test.	 A	 p-value	 of	 ≤0.05	was	considered	to	be	statistically	significant.																			
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2.4 Results	A	 total	of	156	adolescent	girls	were	 screened,	 and	151	HIV	negative	adolescents	who	met	the	eligibility	criteria	(see	section	2.3.1)	were	included	in	this	study.	Five	girls	were	not	included	because	of	medical	conditions	[anemic	(n=1),	being	treated	with	 antibiotics	 for	 tuberculosis	 (n=1),	 being	 hypertensive	 (n=1),	 having	 raised	liver	 function	 (n=1)]	 or	 because	 they	 were	 below	 the	 target	 age	 for	 this	 study	(n=1).	 The	median	 age	 of	 adolescents	 at	 enrolment	was	 17	 years	 (range	 15-19)	(Table	2.2),	with	a	median	BMI	of	25kg/m2,	which	falls	just	above	a	weight	that	is	considered	 normal	 (18.5-24.9;	 https://www.nhlbi.nih.gov/health/educational).	The	prevalence	of	STIs	at	the	screening	visit	was	56.2%	(85/151),	with	infections	with	C.	trachomatis	being	the	most	prevalent	(33.1%;	50/151).	Despite	expecting	high	rates	of	asymptomatic	infections,	it	was	unexpected	that	all	of	the	STIs	in	this	adolescent	 cohort,	 diagnosed	 using	 laboratory	 testing,	 were	 asymptomatic.	 The	prevalence	of	BV	(Nugent	score	7-10)	was	43.0%	(65/151),	while	14.6%	(22/151)	AGYW	had	evidence	of	 yeast	 infections.	The	 age	of	 sexual	debut	 in	 this	 group	of	young	 women	 was	 15	 (14-16),	 and	 9.3%	 of	 the	 AGYW	 reported	 to	 have	 had	multiple	sexual	partners.	The	majority	of	the	adolescents	had	been	on	some	form	of	HC	prior	to	enrolment.			
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Table	2.2	Characteristics	of	South	African	AGYW	included	in	the	study	
Characteristic Median (IQR) or %(n/N) 
 N 151 
Age [median years (range)] 17 (15–19) 
Sexual debut [median years (range)] 15 (14-16) 
Multiple partners [% (n/N)] 9.3% (12/128*) 
Vaginal cleansing [% (n/N)] 12.8% (19/148*) 
BMI (kg/m2) [median (range)] 25.0 (21.8 - 28.9) 
Serum hormone conc. [median (range)]  
E2 (pmol/l)  100.0 (74.7 - 141.8) 
S-FSH (U/L)  4.9 (3.6 - 6.0) 
LH (IU/L)  4.2 (2.0 - 6.0) 
Prior contraceptive method [% (n/N)] 
    None  4.8% (7/144*) 
    DMPA  19.4% (28/144*) 
    NET-EN  65.3% (94/144*) 
    COCPs 8.3% (12/144*) 
    Implanon  2.1% (3/144*) 
Genital infections [% (n/N)]                                 
    No STI or BV  19.2% (29/151) 
    N. gonorrhoeae  12.0% (18/151) 
    T. vaginalis 8.6% (13/151) 
    C. trachomatis 33.1% (50/151) 
    M. genitalium 2.7% (4/151) 
    HSV-2 seropositive 27.1% (41/151) 
    Presence of yeast hyphae 14.6% (22/151) 
BV Nugent scoring [% (n/N)] 
    BV negative (Nugent 0-3) 45.7% (69/151)  
    Intermediate (Nugent 4-6) 11.3% (17/151) 
    BV positive (Nugent 7-10) 43.0% (65/151) 
*Missing values for those n ≠ 151 due to data not provided by some participants 
BV, bacterial vaginosis; BMI, body mass index; E2, estradiol; S-FSH, follicle stimulating hormone; 
LH, luitenizing hormone 		
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2.4.1 Characteristics	of	cervical	T	cells	in	adolescents	
Of	the	CD3+	T	cells	found	in	cervical	cytobrushes	of	adolescents,	44.9%	were	CD4+	while	22.8%	were	CD8+	(Figure	2.2A).	A	greater	proportion	of	CD8+	than	CD4+	T	cells	 expressed	 the	 activation	 markers	 CD38	 (p=0.0005)	 and	 CD38/HLA-DR	(p=0.03;	 Figure	 2.2B).	 Higher	 frequencies	 of	 CD8+	 than	 CD4+	 T	 cells	 expressed	CCR5	 (p=0.01,	 Figure	 2.2C),	 although	 there	 was	 a	 strong	 positive	 correlation	between	frequencies	of	CD4+	and	CD8+	T	cells	expressing	CCR5	(r=0.76,	p<0.0001;	Figure	 2.2D).	 In	 contrast,	 significantly	 higher	 frequencies	 of	 CD4+	 T	 cells	 than	CD8+	 T	 cells	 expressed	 CCR6	 (p<0.0001).	 There	 was	 also	 a	 positive	 correlation	between	CD4+	and	CD8+	T	cells	expressing	CCR6	(r=0.31,	p=0.0006;	Figure	2.2D).				
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Figure	2.2.	Characterization	of	phenotype	and	activation	status	of	cervical	T	cell	in	
adolescents.	(A)	Proportion	of	CD4+	(peach)	and	CD8+	(yellow)	T	cells.	(B)	Proportion	of	CD4+	and	CD8+	cells	expressing	activation	markers	CD38	and	HLA-DR.	(C)	Frequency	of	CD4+	 and	 CD8+	T	 cells	 expressing	 chemokine	 receptors	 (CCR5	 [left	 panel],	 CCR6	 [right	panel]).	 (D)	Correlation	plots	between	CD4+	and	CD8+	expressing	CCR5	(top	panel)	and	CCR6	(bottom	panel).	Box	and	whisker	plots	represent	the	median,	IQR	and	range.	Mann-Whitney	U	 test	was	used	 to	compare	CD4+	and	CD8+	T	cell	 frequencies.	Spearman	rank	test	was	used	to	test	correlations.	P≤0.05	were	considered	significant.			
CD4+ CD8+
0
20
40
60
80
100
%
CD
3⁺
	 T
	c
el
ls
CD4+ CD8+
0
20
40
60
80
100
%
CD
3⁺
	 T
	c
el
ls
CD38+ HLA-DR+
p=0.0005 p=0.325
CD38+
HLA-DR+
p=0.030
0
20
40
60
80
100
%
CD
3⁺
	 T
	c
el
ls
CCR5+ CCR6+
p=0.010 p	<0.0001
0 20 40 60 80 100
0
20
40
60
80
100
																												%	CD4	CCR5+
				
				
				
				
			%
CD
8	
	 C
CR
5+
r	=	0.76p	<	0.0001
0 20 40 60 80 100
0
20
40
60
80
100
%
CD
8	
	 C
CR
6+
%CD4		CCR6+
r	=	0.31p	=	0.0006
D	C	
A	 B	
	
 
51	
2.4.2 Phenotype	and	activation	of	cervical	Th17	cells		
Th17	cells	have	previously	been	reported	 to	be	a	major	T	cell	 subset	 in	 the	FRT,	using	CCR6	expression	by	CD4+	T	cells	to	define	this	helper	cell	subset	(Rodriguez-Garcia	 et	 al.,	 2014).	 Although	 several	 studies	 have	 shown	 that	 Th17	 cells	 can	express	a	number	of	different	chemokine	receptors	(including	CCR4),	the	majority	have	been	shown	to	express	CCR6,	which	mediates	mucosal	homing	in	response	to	MIP-3a	(Acosta-Rodriguez	et	al.,	2007;	Singh	et	al.,	2008).	For	this	study,	Th17-like	cells	 were	 considered	 to	 be	 CD4+	 T	 cells	 that	 express	 CCR6.	 Furthermore,	 the	chemokine	receptor	CCR10	was	used	to	differentiate	Th17	from	Th22	cells	known	to	 express	 higher	 levels	 of	 this	 chemokine	 (Ye	 et	 al.,	 2012).	 Although	 IL-17	production	directly	by	these	cells	was	not	measured,	these	cells	have	been	referred	to	as	Th17	cells	throughout	this	study.			More	 than	 half	 of	 cervical	 CD4+	 T	 cells	 were	 considered	 Th17-like	 (54.4%;	CCR6+CCR10-),	 and	 CCR6-CCR10-	 CD4+	 T	 cells	 (representing	 Th1	 and	 Th2	 cells	[Zhong	et	al.,	2017])	were	 the	next	most	abundant	subset;	42.2%)	(Figure	2.3A).	Cervical	Th17	cells	were	similar	across	all	age	groups,	and	frequencies	in	younger	adolescents	 (15-17	years;	median	50.0%)	were	 the	 same	as	 in	older	adolescents	(18-19	years;	median	56.0%).			As	HIV	preferentially	infects	activated	CD4+	T	cells	and	CCR5	is	the	preferred	co-receptor	 for	 viral	 entry	 (Joag	 et	 al.,	 2016;	 Stieh	 et	 al.,	 2016),	 expression	 of	activation	 markers	 HLA-DR/CD38	 and	 co-receptor	 CCR5	 were	 evaluated	 on	adolescent	cervical	Th17	cells	(Figure	2.3).	More	Th17	cells	expressed	CD38	than	HLA-DR	 (Figure	 2.3B).	 The	 frequency	 of	 CCR5	 expressing	 Th17	 cells	 was	significantly	higher	 than	CCR6-CCR10-	CD4+	T	 cells	 (p<0.0001;	Figure	2.3C).	 Co-expressions	 of	 CCR5/CD38	were	 also	more	 frequent	 for	 Th17	 cells	 compared	 to	CCR6-CCR10-	CD4+	T	cells	(p=0.0008).	These	data	suggest	that	cervical	Th17	cells	in	 adolescents	 were	 highly	 activated,	 and	 expressed	 higher	 levels	 of	 CCR5	 than	Th1-	and	Th2-like	cells	in	the	FRT.				
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Figure	 2.3.	 Cervical	 CD4+	 T	 cells	 in	 young	 adolescents.	 (A)	 Proportions	 of	 different	subsets	 of	 CD4+	 T	 cells	 defined	 by	 CCR6	 and	 CCR10	 chemokine	 receptors.	 Th17	 cells	(CCR6+CCR10-)	are	represented	by	the	blue	dots,	CCR6-CCR10+	CD4+	T	cells	are	shown	in	clear	squares,	CCR6+CCR10+	CD4+	T	cells	are	shown	in	clear	triangles,	and	CCR6-CCR10-	CD4+	T	 cells	 are	 shown	 in	black	 inverted	 triangles.	 (B)	Frequencies	of	CD38+	and	HLA-DR+	Th17	cells	 (CCR6+CCR10-;	blue	bars)	 and	Th1/2-like	T	 cells	 (CCR6-CCR10-;	black).	(C)	Expression	of	CCR5	alone	and	in	combination	with	CD38	and/or	HLA-DR	by	Th17	cells	(CCR6+CCR10-;	blue	bars)	and	Th1/2-like	T	cells	(CCR6-CCR10-;	black).	Mann-Whitney	U	tests	 were	 applied	 to	 compare	 the	 markers	 between	 the	 groups,	 and	 p≤0.05	 were	considered	significant.		
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2.4.3 Evaluating	genital	Th17-related	cytokines	
Fifteen	Th17-related	cytokines	were	measured	in	softcup	secretions,	including	two	family	members	of	IL-17	produced	by	Th17	cells:	IL-17A	and	IL-17F	(Figure	2.4).	For	 analysis,	 the	 cytokines	were	 divided	 into	 those	 produced	 by	 Th17	 cells	 (IL-17A,	IL-17F,	IL-21,	IL-22),	those	involved	in	the	differentiation	of	Th17	cells	(IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α),	and	those	involved	in	the	regulation	of	Th17	cells	(IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ,	sCD40L)	(Martinez	et	al.,	2008;	Maeda,	2013;	Patel	and	Kuchroo,	2015).	Although	they	are	considered	the	defining	cytokines	produced	by	Th17	cells,	both	IL-17A	and	IL-17F	were	detected	at	low	concentrations	in	cervical	secretions	 from	 these	 adolescents	 (median	 concentration	 of	 1.3	 pg/ml	 and	 3.5	pg/ml,	respectively),	which	was	close	to	the	detection	limit	of	the	assay	(1.2	pg/ml	and	 3.0	 pg/ml,	 respectively).	 Concentrations	 of	 IL-17A	 and	 IL-17F	 positively	correlated	 (r=0.77,	 p<0.0001;	 Figure	 2.5A).	 Of	 the	 cytokines	 produced	 by	 Th17	cells,	 IL-22	 was	 present	 at	 the	 highest	 median	 concentration	 of	 6.4	 pg/ml,	 and	correlated	 positively	 with	 IL-17A	 (r=0.67,	 p<0.0001),	 IL-17F	 (r=0.75,	 p<0.0001;	Figure	2.5A),	and	IL-21	concentrations	(r=0.58,	p<0.0001).			IL-1β,	 IL-6,	 TNF-α,	 IL-23,	 and	 IL-33	 all	 tended	 to	 be	 co-regulated	 and	 positively	correlated	 with	 one	 another	 (Figure	 2.5B).	 Furthermore,	 these	 inflammatory	cytokines	 also	 correlated	 positively	with	 production	 of	 IL-17A	 and	 IL-17F	 (data	not	 shown).	 Similarly,	 IL-25,	 IL-4,	 IL-10,	 IFN-γ	 and	 sCD40L	 also	 correlated	with	one	another	(Figure	2.5C)	as	well	as	with	IL-17A	and	IL-17F	concentrations	(data	not	shown).	Cervical	concentrations	of	Th17-related	cytokines	did	not	differ	by	age	group	(data	not	shown).	
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Figure	 2.4.	 Abundance	 of	 Th17-related	 cytokines	 in	 the	 lower	 reproductive	 tract	
(LRT)	of	adolescent	girls.	Cytokines	were	grouped	into	three	groups	according	to	their	primary	Th17-related	functions;	 including	those	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21,	IL-22),	those	involved	in	Th17	differentiation	(IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α),	and	those	 involved	 in	 regulating	 Th17	 cells	 (IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ,	 sCD40L).	 The	median	(middle	lines)	and	IQR	(error	bars)	are	plotted	on	the	graph.			
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Figure	 2.5.	 Correlation	 between	 Th17-related	 cytokines	 in	 genital	 secretions	 of	
adolescent	girls.	 Cytokines	were	 grouped	 into	 three	 groups	 according	 to	 their	primary	Th17-related	functions;	including	those	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21,	IL-22),	 those	 involved	 in	 Th17	 differentiation	 (IL-6,	 IL-1β,	 IL-23,	 IL-33,	 TNF-α),	 and	 those	involved	in	regulating	Th17	cells	(IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ,	sCD40L).	Only	significant	correlation	 coefficients	 (Rho	 scores)	 are	 displayed	 in	 blue	 (representing	 positive	correlations).	
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2.4.4 Relationship	 between	 Th17	 cell	 frequencies	 and	 Th17-
related	cytokines		
The	relationship	between	Th17	cells	and	Th17-related	cytokines	was	investigated.	Frequencies	of	cervical	Th17	cells	in	cytobrushes	did	not	appear	to	correlate	with	concentrations	 of	 the	 Th17-related	 cytokines	 (data	 not	 shown).	 However,	 the	extent	 of	 Th17	 activation	 (CD38+)	 tended	 to	 correlate	 positively	 with	 genital	concentrations	 of	 IL-17A	 (r=0.22,	 p=0.01),	 IL-17F	 (r=0.17,	 p=0.05),	 IL-6	 (r=0.21,	p=0.02),	 IL-10	 (r=0.25,	 p=0.004),	 and	 sCD40L	 (r=0.19,	 p=0.04;	 Figure	 2.6),	although	 none	 of	 these	 associations	 remained	 significant	 after	 adjusting	 for	multiple	 comparisons.	 Interestingly,	 there	 was	 a	 weak	 negative	 correlation	between	the	frequency	of	Th17	cells	expressing	CCR5	and	IL-17A	(p=0.02,	r=-0.20)	(data	not	shown).		
	
Figure	2.6.	Correlation	between	the	frequencies	of	activated	(CD38+)	Th17	cells	and	
Th17-related	cytokines	(IL-17A,	IL-17F,	IL-6,	IL-10	and	sCD40L).	Spearman	Rank	test	was	applied	to	test	the	relationships	between	cervical	Th17	cells	(R6+R10-	CD4+)	T	cells	and	 Th17-related	 cytokines	 in	 the	 lower	 reproductive	 tract.	 P≤0.05	 were	 considered	significant,	and	only	significant	relationships	are	shown.		
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2.4.5 Endogenous	hormones	and	Th17	cells	
The	 relationship	 between	 endogenous	 hormone	 levels	 and	 cervical	 Th17	 cell	frequencies	 and	 state	 of	 activation	 was	 next	 investigated.	 While	 FSH	 did	 not	appear	 to	 change	 activation	 or	 frequency	 of	 cervical	 Th17	 cells,	 E2	 correlated	negatively	with	 frequencies	 of	 activated	 Th17	 cells	 expressing	HLA-DR	 (r=-0.23,	p=0.01;	Table	2.3)	and	those	co-expressing	CD38/HLA-DR	(r=-0.22,	p=0.01).	There	were	also	weak	negative	correlations	between	LH	and	Th17	cells	expressing	CD38	(r=-0.22,	p=0.01),	CD38/HLA-DR	(r=-0.20,	p=0.02),	CCR5/CD38	(r=-0.19,	p=0.03),	CCR5/HLA-DR	 (r=-0.19,	 p=0.04)	 and	CCR5/CD38/HLA-DR	 (r=-0.19,	 p=0.03).	The	relationship	 between	 Th17-related	 cytokines	 and	 endogenous	 serum	 hormones	was	also	investigated,	however	there	were	no	statistically	significant	correlations	(data	not	shown).			
Table	2.3	Relationship	between	endogenous	hormone	concentrations	and	cervical	Th17	cell	activation	
		
		 E2	 FSH	 LH	
		 Spearman	correlation	p-value	(rho)	%Th17	 0.842	(-0.018)	 0.030	(0.748)	 0.333	(0.090)	CCR5+	 0.069	(0.169)	 0.279	(-0.101)	 0.545	(-0.056)	CD38+	 0.057	(-0.177)	 0.197	(-0.121)	 0.015	(-0.225)	HLA-DR+	 0.010	(-0.237)	 0.102	(-0.153)	 0.089	(-0.159)	CD38+HLA-DR+	 0.013	(-0.229)	 0.160	(-0.132)	 0.025	(-0.208)	CCR5+CD38+	 0.394	(-0.080)	 0.317	(-0.094)	 0.035	(-0.196)	CCR5+HLA-DR+	 0.105	(-0.152)	 0.055	(-0.178)	 0.041	(-0.190)	CCR5+CD38+HLA-DR+	 0.088	(-0.159)	 0.241	(-0.110)	 0.038	(-0.193)	
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2.4.6 Impact	 of	 yeast	 infection	 on	 cervical	 Th17	 cells	 and	
cytokines		
Th17	 cells	 have	been	 reported	 to	play	 a	pivotal	 role	 in	defense	 against	 infection	with	 Candida	 albicans	 (Hernandez-Santos	 et	 al.,	 2013;	 Levitz,	 2009).	 Here,	 the	effect	 of	 yeast	 infection,	 indicated	 by	 the	 present	 of	 fungal	 hyphae	 or	 spores	 on	Gram	 stained	 slides,	 on	 the	 frequency	 and	 activation	 status	 of	 Th17	 cells	 was	investigated.	For	 this	analysis,	only	23/151	adolescents	with	no	STIs	(chlamydia,	gonorrhoeae,	 mycoplasma,	 or	 trichomonas)	 also	 excluding	 co-infections	 were	included.	 Adolescents	 who	 had	 evident	 yeast	 infections	 (n=16)	 had	 a	 lower	frequency	 of	 Th17	 cells	 compared	 to	 those	 without	 yeast	 (n=7;	 p=0.02;	 Figure	2.7A).	On	the	contrary,	the	proportion	of	CCR6-CCR10-	CD4+	T	cells	(Th1	and	Th2	cells)	 was	 higher	 in	 yeast+	 adolescents	 (p<0.001,	 Figure	 2.7C).	 Although	 both	yeast+	 and	 yeast-	 adolescents	 had	 similar	 frequencies	 of	 Th17	 cells	 that	 were	activated	 or	 expressed	 CCR5,	 there	 was	 a	 trend	 towards	 a	 decrease	 in	 these	markers	 in	 yeast+	 adolescents	 (Figure	 2.7B).	 Similarly,	 CCR5,	HLA-DR	 and	CD38	(p<0.0001)	 on	 CCR6-CCR10-	 CD4+	 T	 cells	 tended	 to	 be	 lower	 in	 yeast+	 girls	(Figure	 2.7D).	 In	 contrast,	 Th17-related	 cytokines	 did	 not	 appear	 to	 differ	significantly	 in	 adolescents	 with	 or	 without	 genital	 yeast	 being	 evident	 (Figure	2.8).			
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Figure	2.7.	 Impact	of	yeast	 infection	on	 frequency	and	activation	status	of	cervical	
Th17	cells	in	adolescents.	 (A)	Frequency	of	Th17	cells	 in	yeast-	(clear	box)	and	yeast+	(green	 box)	 adolescents.	 (B)	 Expression	 of	 CD38,	 HLA-DR	 and	 CCR5	 on	 Th17	 cells,	stratified	by	yeast	 infection	status.	(C)	Frequency	of	CCR6-CCR10-	CD4+	T	cells	between	yeast-	 and	 yeast+	 adolescents.	 (D)	 Expression	 of	 CD38,	 HLA-DR	 and	 CCR5	 on	 CCR6-CCR10-	CD4+	T	cells	stratified	by	yeast	 infection	status.	Box	and	whisker	plots	show	the	median	(middle	line),	IQR	(box)	and	range	(whiskers).	Mann-Whitney	U	tests	were	used	to	compare	the	groups	and	P≤0.05	were	considered	significant.			
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Figure	 2.8.	 Impact	 of	 yeast	 infection	 on	 genital	 tract	 Th17-related	 cytokine	
concentrations.	Adolescents	without	yeast	infections	are	shown	as	clear	bars,	while	those	with	 a	 yeast	 infection	 are	 shown	 as	 green	 bars.	Mann-Whitney	 U	 tests	 were	 used	 to	compare	the	groups,	and	p≤0.05	were	considered	significant.			
2.4.7 Impact	of	STIs	on	Th17	cells	and	cytokines	
Th17	 cells	 are	 thought	 to	 play	 an	 important	 role	 in	 regulating	 immunity	 against	pathogens	 in	 the	 FRT	 (Feinen	 et	 al.,	 2010;	 Wazen	 et	 al.,	 2013).	 To	 ascertain	whether	 the	 frequency	 and/or	 activation	 status	 of	 Th17	 cells	was	 influenced	 by	STIs,	like	C.	trachomatis,	N.	gonorrhoeae,	M.	genitalium	and	T.	vaginalis,	these	cells	were	 compared	 between	 STI-	 (n=22)	 and	 STI+	 (n=31)	 adolescents	 who	 did	 not	have	 a	 yeast	 infection	 or	 BV	 (Nugent	 7-10).	 Median	 Th17	 event	 counts	 (per	cytobrush)	 in	 STI-	 and	 STI+	 adolescents	 did	 not	 differ	 significantly	 (246	 vs	 283	respectively,	Figure	2.9A	left	panel),	and	the	frequency	of	cervical	Th17	cells	and	their	activation	status	(CD38	and	HLA-DR)	did	not	differ	by	STI	status	(Figure	2.9A	right	panel	and	2.9B,	respectively).	Although	not	significant,	higher	frequencies	of	activated	 (CD38+)	 cervical	 Th17	 cells	 expressed	 CCR5	 in	 STI+	 compared	 to	 STI-	adolescents	(p=0.09;	Figure	2.9C).			
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Figure	 2.9.	 Impact	 of	 STIs	 (including	 chlamydia,	 gonorrhoeae,	 mycoplasma	 and	
trichomonas)	 on	Th17	 cell	 frequencies	 and	 activation	 status.	 (A)	 Th17	 counts	 (left	panel)	 and	 frequencies	 (right	 panel)	 in	 STI-BV-	 (black	 dots)	 and	 STI+BV-	 (red	 dots)	adolescents.	Bars	 indicated	median	values,	and	error	bars	 indicate	IQR.	(B)	Activation	of	Th17	cells	as	measured	by	markers	CD38	and	HLA-DR	(STI-BV-	[black	dots]	and	STI+BV-	[red	dots];	bars	indicated	median	values,	and	error	bars	indicate	IQR).	(C)	Frequencies	of	CCR5	 expression,	 alone	 (left	 panel)	 or	 in	 combination	 with	 activation	 markers	 (CD38,	middle	panel;	and	HLA-DR,	right	panel).	Box	and	whisker	plots	show	the	median	(middle	
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line),	 IQR	 (box)	and	range	 (whiskers).	Mann-Whitney	U-tests	were	used	 to	compare	 the	groups,	and	P≤0.05	were	considered	significant.			Research	from	our	group	and	others	have	shown	that	certain	STIs	are	associated	with	 the	 induction	 of	 several	 cytokines,	 including	 IL-1β	 and	 IL-17	 which	 were	measured	in	this	study	(Crowley-Nowick	et	al.,	2000;	Mlisana	et	al.,	2010;	Masson	et	al.,	2014;	Deesa	et	al.,	2015;	Masson	et	al.,	2015b).	In	this	adolescent	cohort,	IL-17A	(p=0.001)	and	IL-1β	(p=0.02)	were	significantly	elevated	in	adolescents	who	had	 an	 STI	 compared	 to	 those	 with	 no	 STI	 (Figure	 2.10).	 IL-1β	 remained	significant,	after	adjusting	for	multiple	comparisons.			
Figure	2.10.	 Impact	of	STIs	on	genital	concentrations	of	Th17-related	cytokines,	 in	
adolescents	 with	 (red	 box)	 and	 without	 STIs	 (clear	 boxes).	Box	 and	 whisker	 plots	show	 the	median	 (middle	 line),	 IQR	 (box)	 and	 range	 (whiskers).	Mann	Whitney	U-tests	were	used	to	compare	the	groups.	*p<0.05;	**p<0.01.			
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Since	chlamydia	infection	was	highly	prevalent	in	this	cohort	(33%,	Table	2.2),	its	effect	 alone	 on	 cervical	 Th17	 cells	 and	 Th17-related	 cytokines	 was	 also	investigated.	For	this	analysis,	13	adolescents	with	asymptomatic	chlamydia	only	(BV+C-)	 were	 compared	 to	 22	 adolescents	 without	 an	 STI	 or	 BV	 (BV-C-).	Chlamydia	did	not	alter	the	frequencies	and	activation	status	of	Th17	cells	(Figure	2.11A).	 On	 the	 contrary,	 IL-17A	 was	 significantly	 elevated	 in	 adolescents	 with	chlamydia	compared	to	those	without	(p=0.004,	Figure	2.11B).			
	
Figure	2.11.	Impact	of	asymptomatic	chlamydia	on	Th17	cell	frequencies,	activation	
status	 and	 concentrations	 of	 Th17-related	 cytokines,	 in	 adolescents	 with	 (black	
box)	 and	 without	 chlamydia	 (purple	 boxes).	 (A)	 Th17	 frequencies	 (left	 panel)	 and	expression	 of	 CCR5,	 CD38	 and	 HLA-DR	 on	 Th17	 cells	 (right	 panel).	 Concentrations	 of	Th17-related	cytokines	in	adolescents	with	and	without	chlamydia.	Box	and	whisker	plots	show	 the	median	 (middle	 line),	 IQR	 (box)	 and	 range	 (whiskers).	Mann-Whitney	U-tests	were	used	to	compare	the	groups,	and	P≤0.05	were	considered	significant.	**p<0.01.	
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2.4.8 Impact	of	previous	HC	use	on	Th17	cells	and	cytokines	
Since	 only	 4.8%	 of	 adolescents	were	 contraceptive	 naïve	 at	 baseline,	 Th17	 cells	between	contraceptive	naïve	versus	contraceptive	users	were	compared.	For	this	analysis,	 samples	 were	 available	 from	 112	 adolescents	 (naïve=6,	 NET-EN=75,	COCPs=10	 and	 DMPA=21).	 Frequencies	 of	 Th17	 cells	 were	 not	 significantly	different	between	contraceptive	naïve	adolescents	and	those	who	had	previously	used	 NET-EN,	 COCPs,	 or	 DMPA	 (Figure	 2.12).	 The	 proportion	 of	 Th17	 cells	expressing	 CCR5	 did	 not	 differ	 significantly	 between	 contraceptive	 naïve	 and	adolescents	using	any	contraceptives.	However,	adolescents	who	had	used	NET-EN	had	 significantly	 lower	 proportions	 of	 Th17	 cells	 expressing	 CCR5	 compared	 to	those	 using	 DMPA	 or	 COCPs	 (p=0.04	 and	 p=0.001,	 respectively).	 In	 addition,	adolescents	 who	 previously	 used	 COCPs	 had	 significantly	 higher	 frequencies	 of	CCR5+	 Th17	 cells	 compared	 to	 those	 using	 DMPA	 (p=0.01).	 Expression	 of	activation	markers	by	Th17	cells	did	not	differ	significantly	between	contraceptive	naïve	 and	 contraceptive	 users.	 However,	 a	 greater	 proportion	 of	 cervical	 Th17	cells	 from	AGYW	using	NET-EN	expressed	HLA-DR	and	HLA-DR/CD38	compared	to	those	using	COCPs	or	DMPA.			In	 contrast	 to	 Th17	 cell	 frequencies	 or	 activation	 status,	 Th17-related	 cytokines	did	not	differ	significantly	between	adolescents	who	had	previously	used	different	forms	 of	 hormonal	 contraception	 compared	 to	 those	 who	were	 naïve	 to	 HCs	 at	enrolment	(Figure	2.13).				
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Figure	 2.12.	 Effect	 of	 previous	 contraceptive	 use	 on	 cervical	 Th17	 cell	 activation	
status	 and	 CCR5	 expression.	 Frequencies	 of	 activated	 Th17	 cells	 were	 compared	between	groups	of	naïve	 (n=6),	DMPA	(n=21),	NET-EN	(n=75)	and	COCPs	users	 (n=10).	Box	 and	whisker	plots	 show	 the	median	 (middle	 line),	 IQR	 (box)	 and	 range	 (whiskers).	P≤0.05	was	considered	significant.		
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Figure	2.13.	Th17-related	genital	tract	cytokines	stratified	by	previous	use	of	hormonal	contraceptives.	(A)	Cytokines	produced	by	Th17	cells.	(B)	Cytokines	involved	in	the	differentiation	of	Th17	cells.	(C)	Cytokines	involved	in	the	regulation	of	Th17	cells.	Kruskal-Wallis	and	Mann-Whitney	U	tests	were	used	to	compare	cytokine	concentrations	according	to	HC	group,	and	P≤0.05	were	considered	significant.	
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2.5 Discussion	Characterization	of	HIV	 target	 cells	 in	 the	FRT	of	AGYW	remains	an	 important	 gap	 in	our	understanding	of	mucosal	predictors	of	HIV	risk.	The	purpose	of	this	chapter	was	to	characterize	 the	 immune	microenvironment	 in	 adolescent	 girls,	with	 a	 focus	on	Th17	cells	and	Th17-related	cytokines.	As	previously	described	in	adult	women	(Nkwanyana	et	al.,	2009),	cervical	CD4+	T	cells	were	more	abundant	 in	cervical	cytobrush	samples	than	CD8+	T	cells.	While	more	CD8+	T	cells	expressed	CCR5	(the	major	HIV	co-receptor	for	heterosexual	 transmission	as	well	as	 the	cognate	receptor	 for	MIP-1a,	MIP-1b	and	RANTES;	 Zang	 et	 al.,	 2001),	 more	 CD4+	 T	 cells	 expressed	 CCR6	 (mucosal	 homing	receptor,	the	cognate	receptor	for	MIP-3a,	and	marker	for	Th17	cells;	Lee	et	al.,	2017).			In	this	study,	cervical	Th17	cells	were	characterized	by	expression	of	CCR6	of	CD4+	T	cells,	 but	 lack	 of	 CCR10	 expression	 (Acosta-Rodriguez	 et	 al.,	 2007;	 McKinnon	 et	 al.,	2015;	 Stieh	 et	 al.,	 2016).	 Using	 this	 chemokine	 receptor	 definition	 of	 Th17	 cells	(CCR6+CCR10-),	Th17	cells	were	found	to	be	the	major	CD4+	T	cell	subset	in	the	FRT	of	adolescent	girls	 (median	 frequency	of	54.4%),	 followed	by	CCR6-CCR10-	CD4+	T	cells	(Th1/Th2;	Zhong	et	al.,	2017).	Rodriguez-Garcia	et	al.	(2014)	previously	reported	that	genital	tract	Th17	frequencies	ranged	between	11.3%	-	23.7%	depending	on	anatomical	site,	 including	 the	 cervix.	 This	 current	 study	 included	 adolescents	 for	 the	 first	 time,	although	 age	 did	 not	 appear	 to	 influence	 the	 frequency	 of	 Th17	 cells	 (comparing	cervical	 Th17	 frequencies	 in	 younger	 [15-17	 years]	 versus	 older	 [18-19	 years]).	 A	previous	 study	 from	 our	 group	 characterized	 IL-17	 producing	 cervical	 cytobrush-derived	 CD4+	 T	 cells	 (by	 intracellular	 staining	 for	 IL-17	 following	 stimulation	 with	PMA/ionomycin)	 in	 adult	 South	 African	women	 (+18	 years),	 which	were	 detected	 at	more	than	half	the	frequencies	of	those	reported	in	this	study	(Masson	et	al.,	2015b).	In	women	from	Kenya,	another	study	reported	that	higher	frequencies	of	IL-17-producing	Th17	cells	were	detected	in	cervical	cytobrushes	compared	to	blood,	where	Th17	cells	were	 also	 defined	 by	 intracellular	 staining	 of	 IL-17	 following	 PMA/ionomycin	stimulation	 (McKinnon	 et	 al.,	 2011).	 While	 PMA/ionomycin	 stimulation	 and	intracellular	 IL-17	 staining	 are	 likely	 to	 underestimate	 Th17	 cell	 numbers,	 it	 is	 also	possible	 that	 defining	 this	 functional	 subset	 using	 chemokine	 receptor	 expression	
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(CCR6+CCR10-)	 may	 overestimate	 this	 subset.	 Furthermore,	 it	 is	 possible	 that	expression	 of	 CCR6	 on	 immune	 cells	 is	 not	 static,	 as	 it	 is	 stored	 intracellularly,	 or	 is	continually	recycled	between	the	cytoplasmic	and	cell	surface	compartments	(Ebert	et	al.,	2002).	Ebert	and	colleagues	(2002)	found	that	~50%	of	the	CD4+	T	cells	stained	for	CCR6	 once	 permeabilized,	 suggesting	 that	 a	 subpopulation	 of	 cells	 constitutively	express	CCR6	intracellularly	in	the	absence	of	surface	expression.	Following	activation,	however,	 some	 (but	 not	 all)	 of	 these	 cells	 begin	 expressing	 CCR6	 on	 their	 surfaces	(Ebert	et	al.,	2002).		Susceptibility	of	Th17	cells	to	HIV	infection	has	been	documented	by	a	number	of	recent	studies,	with	some	attributing	this	to	higher	expression	of	the	HIV	CCR5	co-receptor	by	this	subset	compared	to	other	CD4+	T	cells	(El	Hed	et	al.,	2010;	McKinnon	et	al.,	2011;	Rodriguez-Garcia	et	al.,	2014;	McKinnon	et	al.,	2015;	Stieh	et	al.,	2016).	In	adolescents,	this	study	did	find	that	higher	frequencies	of	CCR6+CCR10-	Th17	cells	expressed	CCR5	compared	to	CCR6-CCR10-	CD4+	T	cells.	While	frequencies	of	highly	activated	Th17	and	CCR6-CCR10-	 CD4+	 T	 cells	 were	 similar,	 significantly	 higher	 frequencies	 of	 highly	activated	 Th17	 cells	 expressed	 CCR5	 than	 CCR6-CCR10-	 CD4+	 subset.	 Since	 it	 is	well	established	 that	 HIV	 preferably	 infects	 highly	 activated	 CD4+	 T	 cells	 (Bégaud	 et	 al.,	2006;	 Koning	 et	 al.,	 2005;	Meditz	 et	 al.,	 2011;	 Joag	 et	 al.,	 2016),	 it	 is	 likely	 that	 this	finding	 would	 contribute	 to	 HIV	 risk	 in	 these	 adolescents.	 Moreover,	 expressing	 the	chemokine	receptor	CCR6	by	Th17	cells	draws	them	to	mucosal	surfaces	like	the	genital	tract	 as	 this	 chemokine	 receptor	 mediates	 mucosal	 homeostatic	 and	 inflammatory	responses	(Schutyser	et	al.,	2003).		For	 naïve	 CD4+	 T	 cells	 to	 differentiate	 into	 Th17	 cells,	 different	 combinations	 of	cytokines	 and	 chemokines	 are	 involved	 (Martinez	 et	 al.,	 2008;	 Spolski	 and	 Leonard,	2009;	Monteleone	et	al.,	2011;	Jin	and	Dong,	2013;	Brockmann	et	al.,	2017).	The	15-plex	Th17	panel	 that	was	used	 to	measure	cytokines	 in	 this	 study	 included	 IL-17A	and	 IL-17F,	which	are	both	produced	by	Th17	cells,	in	addition	to	IL-21	and	IL-22.	Of	these,	IL-22	was	 detected	 at	 the	 highest	 concentrations	 in	 genital	 secretions,	 and	 is	 known	 to	induce	expression	of	AMPs	 (Liang	et	 al.,	 2006).	Of	 the	 two	 IL-17	 isomers,	 IL-17F	was	detected	at	higher	 concentrations	 than	 IL-17A.	Most	 studies	 to	date	measured	 IL-17A	(also	known	as	IL-17)	in	the	FRT,	but	not	IL-17F	(McKinnon	et	al.,	2011;	Masson	et	al.,	
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2015b;	 Boily-Larouche	 et	 al.,	 2017).	 Since	 these	 two	 subtypes	 differ	 in	 some	 aspects	including	less	potency	of	IL-17F	to	induce	cytokines,	understanding	their	inflammatory	roles	 and	 that	 of	 other	 IL-17	 subtypes	 not	 measured	 in	 this	 study	 in	 the	 FRT	 is	important.	IL-6,	IL-1β,	IL-21,	IL-23,	IL-33	and	TNF-α	play	a	role	in	the	differentiation	of	Th17	cells	(Hebel	et	al.,	2011;	Lasigliè	et	al.,	2011;	Patel	and	Kuchroo,	2015).	Of	these,	IL-1β	thought	to	amplify	the	differentiation	of	Th17	cells	was	measured	at	the	highest	concentrations.	Of	the	cytokines	that	are	involved	in	regulating	Th17	cells	(including	IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ	 and	 sCD40L),	 IL-31	 was	 detected	 at	 the	 highest	concentrations.	 IL-31	 belongs	 to	 the	 IL-6	 cytokine	 family,	 and	 it	 can	 positively	 and	negatively	affect	Th17	differentiation	(Zhang	et	al.,	2008).	Furthermore,	genital	IL-31	in	these	adolescents	strongly	correlated	positively	with	sCD40L,	a	cytokine	that	provides	an	optimal	cytokine	environment	for	the	differentiation	of	Th17	cells	(Iezzi	et	al.,	2009).	A	similar	positive	correlation	between	 IL-31	and	sCD40L	was	 found	 in	healthy	serum	(de	J.	Guerrero-García	et	al.,	2018).	IL-10,	a	major	regulatory	cytokine	produced	by	Treg	cells,	 was	 found	 to	 correlate,	 albeit	 relatively	 weakly,	 with	 about	 half	 of	 the	 Th17-related	cytokines	(including	IL-21,	IL-23,	IL-33,	TNF-α,	IL-4,	IL-25	and	IFN-γ).	In	mice,	IL-10	has	been	shown	to	negatively	regulate	RORγt	(expressed	by	Th17	cells)	and	Th17-related	cytokine	production	by	macrophages	and	T	cells	(Gu	et	al.,	2008).	While	genital	tract	concentrations	of	IL-17A	and	IL-17F	correlated	positively	with	higher	frequencies	of	activated	(CD38+)	cervical	Th17	cells,	 IL-17A	appeared	to	correlate	negatively	with	frequencies	of	CCR5+	Th17	cells.	While	none	of	the	chemokines	that	bind	to	CCR5	were	measured	 as	 part	 of	 this	 study	 (such	 as	 MIP-1a,	 MIP-1b	 and	 RANTES),	 these	 CCR5-binding	chemokines	do	correlate	positively	with	inflammatory	cytokines	like	IL-1β	and	IL-6	that	were	measured	(Masson	et	al.,	2014).	Since	others	from	our	group	have	found	that	CCR5	expression	by	cervical	CD4+	T	cells	in	adult	women	are	negatively	associated	with	 genital	 concentrations	 of	 CCR5-binding	 chemokines	 (such	 as	 RANTES),	 and	 that	higher	 concentrations	 of	 RANTES	 in	 the	 FRT	 is	 associated	 with	 CCR5	 receptor	internalization	 (Liebenberg	et	 al.,	 2011),	 it	 is	 also	possible	 therefore	 that	 some	of	 the	CCR5+	 frequency	 loss	 that	was	 noted	 in	 this	 study	 of	 adolescent	 reproductive	 health	was	related	to	high	levels	of	inflammation	and	CCR5-binding	chemokines.			Endogenous	hormones	such	as	E2	and	P4	play	an	important	role	in	host	immunity	such	as	 regulating	 induction	 of	 cytokines	 and	 chemokines	 (Polese	 et	 al.,	 2014;	 Khan	 and	
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Ansar	 Ahmed,	 2016).	 Adolescence	 is	 a	 time	 of	 dramatic	 hormonal	 changes,	 and	therefore	the	impact	of	E2,	FSH	and	LH	on	Th17	cells	and	Th17-related	cytokines	was	evaluated.	Endogenous	E2	and	LH	levels	were	negatively	associated	with	the	frequency	of	 highly	 activated	 (CD38+HLA-DR+)	 Th17	 cells,	 suggesting	 that	 these	 endogenous	female	hormones	may	modulate	cellular	activation.	However,	no	association	was	found	between	 genital	 concentrations	 of	 any	 of	 the	 Th17-related	 cytokines	 and	 serum	hormone	 levels.	 Although	 the	 direct	 effects	 of	 E2	 and	 LH	 on	 Th17	 cells	 or	 IL-17	secretion	 were	 not	 addressed	 in	 this	 study	 and	 are	 not	 known,	 studies	 in	postmenopausal	women	showed	an	inverse	correlation	between	E2	deficiency	and	IL-17A	serum	levels	(Molnar	et	al.,	2014).			The	 involvement	of	 genital	 tract	Th17	 cells	 to	 controlling	vaginal	 yeast	 infections	has	not	 been	 elucidated,	 although	 both	 Th1	 and	 Th17	 responses	 are	 thought	 to	 be	important	 in	 immune	 defense	 against	 C.	 albicans	 infections	 (Kagami	 et	 al.,	 2014;	Pietrella	 et	 al.,	 2011).	 Candida	 albicans	 is	 the	 most	 commonly	 fungal	 pathogen	 of	humans	 and	 is	 frequently	 found	 on	 the	 mucosal	 surfaces	 of	 the	 body,	 including	 the	lower	FRT	 (Richardson	and	Moyes,	2015).	 In	 this	 study,	 adolescents	who	had	vaginal	yeast	hyphae	evident	on	their	wet	mounts	had	lower	frequencies	of	cervical	Th17	cells	than	yeast	negative	adolescents.	Furthermore,	IL-17A,	IL-17F	and	IL-22	are	also	thought	to	be	critically	 important	 for	 immune	protection	against	C.	albicans	infection	 (Conti	et	al.,	2015).	However,	Th17-related	genital	tract	cytokines	appeared	to	be	similar	in	yeast	positive	and	yeast	negative	AGYW.	Masson	et	al.	(2015b)	previously	reported	that	adult	women	who	had	evidence	of	vaginal	candidal	pseudohyphea	had	lower	concentrations	of	 genital	 IL-17	 compared	 to	women	who	did	not	have	detectable	 yeast	 infections.	 In	addition,	 in	vitro	 stimulation	 of	 human	 PBMCs	with	C.	albicans	 down-regulated	 IL-17	production	(Cheng	et	al.,	2010).		While	vaginal	yeast	appeared	to	be	associated	with	lower	frequencies	of	Th17	cells,	the	presence	of	STIs	did	not	appear	 to	similarly	 influence	Th17	 frequencies	 	or	activation	status.	However,	concentrations	of	both	IL-17A	and	IL-1β	were	elevated	in	adolescents	with	an	STI,	and	this	is	similar	to	what	has	been	described	in	adult	women	(Masson	et	al.,	2015b).	It	is	possible	that	cells	other	than	CD4+	T	cells	are	producing	IL-17A,	such	as	γδ	T	cells	(Price	et	al.,	2012),	which	are	also	abundant	at	mucosal	surfaces	such	as	the	
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FRT	 (Alcaide	 et	 al.,	 2016;	 Strbo	 et	 al.,	 2016).	 Alternatively,	 it	 is	 also	 possible	 that	elevated	 inflammatory	 cytokines	 like	 IL-1β	 may	 influence	 CCR6	 internalization	 and	cycling,	 by	 predicting	 increased	 production	 of	 MIP-3a	 (the	 cognate	 chemokine	 for	CCR6).	 MIP-3a,	 which	 was	 not	 measured	 in	 this	 study,	 can	 be	 induced	 following	treatment	of	immune	cells	with	IL-1β	(Li	et	al.,	2013).	However,	the	small	sample	size	of	the	adolescents	in	this	study	who	had	single	infections	are	likely	to	have	influenced	this	outcome	as	previous	studies	have	suggested	that	genital	tract	Th17	cells	are	increased	in	women	with	laboratory-diagnosed	STIs.	For	example,	gonorrhoea	had	been	reported	to	 initiate	 Th17	 responses	 associated	 with	 recruitment	 of	 neutrophils	 and	 a	 pro-inflammatory	milieu	(Feinen	et	al.,	2010;	Feinen	and	Russell,	2012).			High	 BMI	 has	 previously	 been	 shown	 to	 increase	 frequencies	 of	 blood	 Th17	 cells	 in	children	(Schindler	et	al.,	2017).	Similarly,	high	BMI	in	adults	has	been	linked	to	higher	concentrations	 of	 IL-17	 in	 genital	 secretions,	 as	 well	 as	 IL-6,	 IL-12,	 and	 IL-1RA	(Ventolini	 et	 al.,	 2017).	 However,	 BMI	 did	 not	 appear	 to	 influence	 cervical	 Th17	frequencies	or	 IL-17	concentrations	 in	adolescents	 in	 this	 study,	 although	 the	median	BMI	 for	 the	 cohort	 was	 >25,	 which	 would	 be	 considered	 high	 by	 international	standards.		Most	 of	 the	 adolescents	 recruited	 into	 the	 study	 were	 not	 contraceptive	 naïve	 at	enrolment,	although	information	collected	on	how	long	they	had	been	using	HCs	prior	to	enrolment	was	 limited.	Therefore,	 the	relationship	between	previous	contraceptive	use	 and	 Th17	 cells	 was	 important	 to	 evaluate.	 Despite	 this	 limitation,	 contraceptive	naïve	adolescents	had	 similar	 cervical	Th17	 frequencies	 and	 level	of	 activation	as	 the	adolescents	 who	 were	 using	 HCs.	 However,	 differences	 were	 observed	 when	 the	different	HC	products	were	compared	at	enrolment.	In	adolescents	that	had	been	using	in	NET-EN	prior	to	enrolment,	expression	of	CCR5	on	Th17	cells	was	significantly	lower	compared	to	those	reporting	DMPA	and	COCPs	use.	In	contrast,	expression	of	HLA-DR	and	 HLA-DR	with	 CD38	was	 lower	 in	 adolescents	 reporting	 to	 previously	 have	 used	COCPs	 compared	 to	 NET-EN	 and	 DMPA	 users.	 Th17-related	 cytokines	 in	 genital	secretions	 did	 not	 appear	 to	 differ	 significantly	 between	 adolescents	 who	 had	 never	used	HCs	compared	to	those	who	had.			
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Less	 than	 20%	 of	 the	 adolescents	 in	 this	 study	 had	 no	 BV	 or	 STI	 (chlamydia,	gonorrhoeae,	 mycoplasma	 and	 trichomonas).	 STIs	 were	 associated	 with	 significantly	increased	 concentrations	 of	 IL-17A	 and	 IL-1β	 in	 genital	 secretions,	 as	 has	 previously	been	 described	 (Masson	 et	 al.,	 2014).	 In	 contrast,	 cytokines	 like	 IL-10	 and	 IL-4	 that	negatively	regulate	Th17	cells	were	only	detected	at	low	levels	in	the	genital	tract.	This	finding	 fits	 with	 previous	 observations	 that	 inflammatory	 responses	 suppress	 anti-inflammatory	responses	and	vice	versa	(Zhang	et	al.,	2007).		The	analyses	in	this	Chapter	have	some	limitations	that	should	be	acknowledged.	Th17	cells	were	not	measured	 in	blood	so	 it	was	not	possible	 to	determine	the	relationship	between	 blood	 and	 genital	 tract	 Th17-related	 cytokines.	 Furthermore,	 there	were	 no	older	 women	 in	 this	 cohort	 to	 compare	 Th17	 cells	 and	 Th17-related	 cytokines	 in	younger	 versus	 older	 women.	 However,	 the	 distribution	 of	 these	 cells	 remained	comparable	between	the	participants	when	stratified	by	age.			In	 conclusion,	 highly	 activated	 Th17	 cells	 were	 found	 to	 be	 abundant	 in	 the	 FRT	 of	adolescents,	which	expressed	high	levels	of	CCR5.	Th17-related	cytokines,	known	to	be	involved	 in	 different	 Th17	 pathways,	 were	 detected	 in	 the	 FRT,	 and	 appeared	 to	 be	induced	 by	 several	 factors	 like	 STIs.	 The	 presence	 of	 Th17	 cells	 and	 Th17-related	cytokines	in	adolescents	could	indicate	protective	immune	responses	in	the	lower	FRT	that	 are	 important	 for	 maintaining	 immunological	 homeostasis.	 However,	 these	increased	Th17	frequencies	could	also	render	adolescents	more	susceptible	to	HIV.		
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3.1	Abstract	BV	is	a	common	vaginal	dysbiosis	among	reproductive-aged	women,	caused	by	changes	 in	 vaginal	 microbial	 communities,	 which	 results	 in	 inflammatory	changes	 in	 the	 lower	 FRT.	 Th17	 cells	 are	 known	 to	 be	 important	 for	 defense	against	 bacterial	 infections,	 although	 their	 interaction	 with	 the	 vaginal	microbiota	and	BV	is	not	yet	understood.	Adolescence	is	a	time	of	increased	risk	for	BV	and	Th17	cells	are	abundant	in	the	genital	tracts	of	these	young	women.	The	 aim	 of	 this	 study	was	 to	 evaluate	whether	 BV	 and	 the	 vaginal	microbiota	were	 associated	 with	 changes	 in	 cervicovaginal	 Th17	 cell	 populations	 and	activation	status	 in	AGYW,	as	well	as	with	the	genital	 tract	cytokines	related	to	these	cells.	For	this	study,	BV	was	characterized	by	Nugent	score	(Nugent	7-10	were	 considered	 BV+),	 vaginal	 pH	 was	 measured	 using	 Macherey-Nagel	 pH	strips	 (pH>4.5	 considered	 high),	 and	 16S	 rRNA	 gene	 sequencing	 of	 cervical	swabs	was	 used	 to	 define	 community	 types	 using	 unsupervised	 clustering:	 C1	being	more	 diverse;	 C2	 predominantly	made	 of	Lactobacillus	crispatus;	 and	 C3	predominantly	 made	 up	 of	 Lactobacillus	 iners.	 While	 frequencies	 and	 the	activation	status	of	CCR6+CCR10-	Th17	cells	were	similar	in	BV+	and	BV-	AGYW	(by	 Nugent	 scoring)	 and	 by	 vaginal	 community	 types	 (C1,	 C2	 and	 C3),	 Th17-related	 cytokines	 were	 significantly	 elevated	 in	 BV+	 compared	 to	 BV-	adolescents,	and	in	C1	versus	C2	and	C3	adolescents.	These	findings	suggest	that	microbial	changes	in	the	lower	FRT	of	adolescents	and	BV-associated	changes	do	influence	the	profile	of	Th17-related	cytokines	although	not	Th17	cells.								
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3.2 Introduction	
BV	is	a	highly	prevalent,	recurrent	and	complex	vaginal	dysbiosis	characterized	by	 a	 shift	 in	 the	 vaginal	microbiota	 from	 one	 dominated	 by	 Lactobacillus	 spp.	(including	L.	crispatus,	L.	jensenii,	L.	gasseri,	L.	johnsonii,	and	L.	mucosae)	to	more	diverse	 non-Lactobacillus	 anaerobic	 bacterial	 communities	 dominated	 by	various	species,	including	Prevotella,	Gardnerella,	Atopobium,	and	Sneathia	(Vitali	et	 al.,	 2007;	 Brotman	 et	 al.,	 2010;	 Xia	 et	 al.,	 2016).	 A	 recent	 review	 has	highlighted	 some	 of	 the	 challenges	 that	 the	 international	 scientific	 community	has	faced	in	developing	a	universally	relevant	definition	for	BV	(McKinnon	et	al.,	2019).	McKinnon	et	al.	 (2019)	summarize	some	of	 the	major	reasons	 for	 these	challenges	 being	 that	 “normal”	 bacterial	 profiles	may	 differ	markedly	 between	women,	particularly	women	of	different	ethnicities	(Ravel	et	al.,	2011);	that	the	methodologies	 for	 diagnosing	 BV	 have	 differed	 quite	 widely	 between	 studies;	and	 there	 is	 still	 no	 consensus	 on	 what	 constitutes	 a	 “pathogenic”	 versus	“pathobiont”	 bacterial	 community	 with	 regards	 to	 BV.	 Currently,	 BV	 may	 be	defined	clinically	as	symptomatic	BV	(Klebanoff	et	al.,	2004),	by	high	vaginal	pH	levels	(pH>4.5),	as	“Amsel-BV”	(Amsel	et	al.,	1983),	“Nugent-BV”	(Nugent	et	al.,	1991)	or	“molecular-BV”	(McKinnon	et	al.,	2019),	each	of	which	depends	on	the	method	used	for	diagnosis.			Symptomatic	 BV	 is	 non-specifically	 diagnosed	 if	 women	 present	 with	 vaginal	discharge,	 a	 fishy	 odor	 and	 vaginal	 itching	 or	 burning	 (Amsel	 et	 al.,	 1983).	However,	most	women	with	BV	are	 asymptomatic	 (Mlisana	et	 al.,	 2011).	BV	 is	often	 diagnosed	 in	 the	 clinical	 setting	 using	 Amsel’s	 criteria	 according	 to	 the	release	of	a	fishy	amine	odor	(on	addition	of	potassium	hydroxide),	presence	of	squamous	cells	coated	with	bacteria	(known	as	clue	cells),	and	high	vaginal	pH	levels	(Amsel	et	al.,	1983;	White	et	al.,	2011;	Nelson	et	al.,	2015).	The	sensitivity	and	 specificity	 of	 Amsel’s	 criteria	 have	 ranged	 from	 37%	 to	 70%	 and	 94%	 to	99%,	 respectively,	 compared	 to	 Nugent	 scoring	 (Coleman	 and	 Gaydos,	 2018).	The	current	international	gold	standard	for	diagnosing	BV	is	the	Nugent	scoring	system	 (Nugent,	 1991).	 However,	 this	 method	 is	 not	 used	 frequently	 in	 the	clinical	 setting	 as	 experienced	 laboratory	 staff	 and	 relatively	 specialized	
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equipment	(microscopes	and	gram	stains)	are	needed.	“Molecular-BV”	describes	dysbiosis	identified	using	any	molecular	technique.	Due	to	the	complexity	of	BV,	bacterial	 community	 types	 (CT)	have	become	useful	 for	 the	characterization	of	vaginal	dysbiosis	(Ravel	et	al.,	2011;	Ma	et	al.,	2012).	Vaginal	CTs	characterizes	the	 microbiota	 based	 on	 the	 dominant	 microbial	 species,	 although	 several	groups	 have	 suggested	 different	 classifications	 within	 each	 CT:	 Ravel	 et	 al.	(2011)	 first	 recommended	 five	 CTs	 in	 a	 large	 study	 of	 more	 than	 300	asymptomatic	North	American	women	(including	African,	Caucasian,	Asian	and	Hispanic	American	women);	Anahtar	et	al.	(2015)	subsequently	suggested	that	a	four	 CT	 system	 was	 best	 to	 describe	 vaginal	 bacterial	 communities	 in	 146	asymptomatic	 South	 African	 women	 aged	 18-23	 years;	 and	 authors	 from	 our	group	later	argued	for	a	three	CT	system	with	Cluster	1	(C1)	being	most	diverse,	Cluster	 2	 (C2)	 being	 dominated	 by	 L.	 crispatus,	 and	 Cluster	 3	 (C3)	 being	dominated	by	L.	iners	(Lennard	et	al.,	2017).			Vaginal	 microbiome	 studies	 have	 found	 a	 strong	 correlation	 between	 high-diversity	microbial	 communities	 and	BV	diagnosed	 by	Nugent	 scoring	 (Van	de	Wijgert	 et	 al.,	 2014).	 Despite	 differences	 in	 how	 the	 vaginal	 bacterial	communities	 in	health	and	disease	should	be	clustered,	all	 studies	have	agreed	that	L.	crispatus	and	L.	iners	tend	to	be	the	most	prevalent	vaginal	lactobacilli	in	healthy	women	 (Ravel	 et	 al.,	 2011;	Anahtar	 et	 al.,	 2015;	Gosmann	et	 al.,	 2017;	Lennard	 et	 al.,	 2017;	McClelland	 et	 al,	 2018),	 although	molecular	 studies	 have	shown	 L.	 crispatus	 to	 be	 associated	 with	 better	 health	 outcomes	 than	 L.	 iners	(Ravel	et	al.,	2011;	Gosmann	et	al.,	2017).			Nugent-BV	 has	 been	 associated	with	 a	 1.5–3.0-fold	 increased	 risk	 of	 acquiring	STIs,	 including	HIV	(McClelland	et	al.,	2018;	Low	et	al.,	2011),	HPV	(Gillet	et	al.,	2011),	C.	trachomatis	 and	N.	gonorrhoeae	 (Brotman	et	 al.,	 2010;	Bautista	 et	 al.,	2017),	as	well	as	a	3-fold	increased	risk	of	HIV-1	transmission	to	a	male	partner	(Cohen	et	al.,	2012;	Klatt	et	al.,	2017).	This	is	particularly	concerning	in	young	SA	women,	as	HIV	is	exceptionally	prevalent	in	this	group	and	recent	data	estimates	the	prevalence	of	BV	 in	 these	women	to	be	around	42%	(Kharsany	and	Karim,	2016;	Torrone	et	al.,	2018).	The	association	between	BV	and	HIV	acquisition	 is	
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possibly	attributable	to	mucosal	inflammation,	which	increases	the	abundance	of	HIV	 target	 cells,	 and	 reduces	 epithelial	 barrier	 integrity	 (Spear	 et	 al.,	 2007;	Dandekar	 et	 al.,	 2010;	 Arnold	 et	 al.,	 2016;	 Klatt	 et	 al.,	 2017).	 Previous	 studies	have	shown	that	endogenous	microbiota	play	a	major	role	in	the	differentiation	of	 Th17	 cells	 in	 the	 small	 intestine,	 and	 that	 antibiotic	 treatment	 reduces	 the	number	 of	 Th17	 cells	 in	 the	 gut	 (Ivanov	 et	 al.,	 2008).	 Different	microbes	may	induce	the	production	of	cytokines	involved	in	the	differentiation	of	Th17	cells,	including	IL-6,	IL-1β,	IL-23,	IL-33	and	TNF-α	(Guglani	and	Khader,	2010).	Th17	cells,	in	turn,	produce	inflammatory	cytokines,	such	as	IL-17A,	IL-17F	and	IL-22,	which	may	 contribute	 to	 the	 inflammatory	 cascade	 and	promote	HIV	 infection	(Elhed	and	Unutmaz,	2010).			The	role	of	Th17	cells	and	related	cytokines	in	promoting	immunity	against	or	in	response	to	vaginal	dysbiosis	is	unknown.	Although	Th17	cells	are	critical	for	the	clearance	of	bacterial	pathogens,	their	susceptibility	to	HIV	is	of	major	concern.	Therefore,	 the	aim	of	this	chapter	was	to	evaluate	the	relationship	between	BV	(and	related	vaginal	dysbiosis)	with	the	presence	and	activation	status	of	Th17	cells	and	Th17-related	cytokines	in	the	lower	FRT	of	adolescents.												
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3.3 Materials	and	Methods	
 Study	participants	
As	described	in	Chapter	2,	a	total	of	151	HIV-negative	adolescent	girls	screened	at	 baseline	 were	 included	 in	 this	 cross-sectional	 analysis	 of	 the	 relationship	between	 BV	 and	 Th17	 cell	 frequencies	 (and/or	 their	 activation	 status;	 see	Chapter	 2,	 section	 2.3.1).	 Demographic,	 behavioral	 and	 clinical	 data	 was	collected	 as	 described	 in	 Chapter	 2	 and	 the	 same	AGYW	were	 included	 in	 this	analysis.		
 BV	diagnosis	
A	lateral	vaginal	wall/posterior	fornix	swab	was	collected	from	each	adolescent	for	Gram	staining	and	Nugent	scoring	(for	Nugent	scoring),	which	was	scored	at	the	 National	 Institute	 of	 Communicable	 Diseases	 (NICD,	 Sandringham,	Johannesburg).	 According	 to	Nugent	 score	 criteria,	 AGYW	were	 categorized	 as	being	BV	negative	(Nugent	scores	0–3),	having	intermediate	microbiota	(Nugent	scores	 4–6),	 or	 being	 BV	 positive	 (Nugent	 scores	 7–10).	 Vaginal	 pH	 was	measured	using	colour-fixed	indicator	strips	(Macherey-Nagel,	Duren,	Germany),	and	normal	vaginal	pH	was	considered	pH≤4.5	(Money	et	al.,	2005).	
	
 	Processing	of	cervical	cytobrushes	and	flow	cytometry	
Cervical	 cytobrushes	 were	 collected	 as	 described	 in	 Chapter	 2	 (section	 2.3.5),	and	processed	within	4	hours.	The	 freshly	 collected	cervical	 cells	were	stained	using	 a	 flow	 cytometry	 panel	 as	 described	 in	 Chapter	 2	 (section	 2.3.6),	 which	was	optimized	for	this	study.		
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 Measurement	of	Th17-related	cytokines	
The	concentrations	of	Th17-related	cytokines	(IL-17A,	IL-17F,	IL-21,	IL-22,	IL-6,	IL-1β,	 IL-23,	 IL-33,	 TNF-α,	 IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ	 and	 sCD40L)	 were	measured	by	Luminex,	as	described	in	Chapter	2	(section	2.3.9).		
 Vaginal	 16S	 rRNA	 gene	 amplification	 and	 Illumina	miSeq	
sequencing		
Vaginal	lateral	wall	swabs	were	collected	for	microbiome	analysis	by	16S	rRNA	amplicon	 sequencing,	 by	 Christina	 Balle	 as	 part	 of	 the	 larger	 uChOOSE	 study	(Christina	 Balle	 PhD	 thesis),	 and	 the	 method	 had	 been	 described	 elsewhere	(Lennard	 et	 al.,	 2017).	 Briefly,	 available	 swabs	 from	 150	 participants	 were	thawed	 and	 treated	 with	 an	 enzyme	 cocktail	 consisting	 of	 mutanolysin	(25kU/ml,	 Sigma	 Aldrich,	 Modderfontein,	 SA),	 lysozyme	 (450kU/ml,	 Sigma	Aldrich),	 and	 lysostaphin	 (4kU/ml,	 Sigma	 Aldrich)	 for	 1	 hour	 at	 37°C.	 The	microbial	DNA	was	extracted	using	Quick-DNATM	Fungal/Bacterial	Miniprep	kits	(Zymo	Research)	and	prepared	 for	sequencing.	The	V4	hypervariable	region	of	the	 bacterial	 16S	 rRNA	 genes	 was	 amplified	 by	 PCR	 using	 modified	 universal	primers	 (Pearce	 et	 al.,	 2014;	 Lennard	 et	 al.,	 2017).	 Samples	with	 ≥5000	 reads	were	selected	 for	downstream	analyses.	The	operational	 taxonomic	unit	 (OTU)	table	was	normalized	and	filtered	such	that	each	OTU	had	at	least	10	counts	in	at	least	20%	of	samples	or	a	relative	abundance	of	at	 least	0.001%	(as	previously	described;	Lennard	et	al.,	2017).		
 Statistical	analyses	
Baseline	 characteristics	were	 summarized	 using	 descriptive	measures,	 such	 as	median,	 frequencies	 and	 IQR.	 For	 categorical	 variables,	 the	 Fisher’s	 Exact	 test	was	 used	 to	 compare	 groups.	 Non-parametric	 Mann-Whitney	 U	 test	 and	Wilcoxon	 Signed	 Rank	 test	 were	 used	 for	 unmatched	 and	 paired	 samples	respectively.	For	comparison	between	more	than	two	groups,	the	Kruskal-Wallis	one-way	analysis	of	variance	was	used.	Correlations	were	performed	using	 the	
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Spearman	 Rank	 test.	 Multivariate	 logistic	 regression	 was	 used	 to	 assess	associations	 between	 BV	 and	 log10-transformed	 cytokine	 concentrations	 after	adjusting	 for	 possible	 confounders.	 Microbiota	 community	 clusters	 were	established	 by	 Fuzzy	 clustering	 using	 the	 R	 package	 ‘cluster’	 (Maechler	 et	 al.,	2017)	with	optimal	k,	a	membership	exponent	of	1.25	and	weighted	UniFrac	as	the	dissimilarity	measure.	Statistical	analysis	was	performed	using	Prism	version	6.0	(GraphPad	Software,	CA,	USA),	R	Studio	and	STATA™	version	12	(StataCorp,	TX,	USA).	 A	 p-value	 of	 ≤0.05	was	 considered	 to	 be	 statistically	 significant.	 The	Benjamini-Hochberg	 method	 was	 used	 to	 adjust	 for	 multiple	 comparisons	(Benjamini	and	Hochberg,	1995).																					
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3.4 Results	
Of	the	151	adolescents	screened	for	the	uCHOOSE	study	(Table	2.2,	Chapter	2),	46%	(69/151)	were	BV	negative	(Nugent	0-3),	11%	(17/151)	had	intermediate	vaginal	microbiota	(Nugent	4-7),	and	43%	(65/151)	were	BV	positive	(Nugent	7-10;	 Table	 3.1).	 Adolescents	 with	 BV	 (Nugent	 scores	 7-10)	 did	 not	 differ	 from	those	without	BV	(Nugent	scores	0-3)	 in	serum	hormone	 levels	of	FSH	and	LH,	although	 E2	 serum	 levels	 tended	 to	 be	 higher	 in	 those	 with	 BV	 (p=0.03)	 or	intermediate	Nugent	 scores	 (p=0.07).	Behavioural	 characteristics	 and	previous	contraception	 use	were	 similar	 between	 the	 groups	 (Table	 3.1).	 Prevalence	 of	STIs	 was	 high	 overall	 (Table	 2.2,	 Chapter	 2),	 but	 did	 not	 differ	 significantly	according	 to	BV	 status	 (Table	3.1).	However,	 the	prevalence	of	 evident	vaginal	yeast	 infections	 was	 significantly	 higher	 in	 BV-	 adolescents	 than	 BV+	 or	intermediate	 AGYW	 (p=0.02),	 while	 reported	 condom	 use	 was	 higher	 in	 BV-	versus	BV+	or	 intermediate	groups	(p=0.03).	As	has	previously	been	described	(Money	et	al.,	2005;	Hemalatha	et	al.,	2013),	vaginal	pH	was	significantly	higher	in	BV+	compared	to	BV-	adolescents	(pH5.0	[4.7	-	5.3]	versus	pH4.7	[4.4	-	5.0],	respectively,	p<0.0001),	and	those	with	intermediate	microbiota	had	pHs	similar	to	BV+	adolescents	(pH=5.3	[4.8	-	5.6]).				
Table	3.1	Participant	characteristics	according	to	Nugent-BV	status	
	 BV	negative	n=69	 Intermediate	n=17	 BV	positive	n=65	 		
n/N	(%),	Median	(IQR)			 	 	 	 p-value	
Median	age		 17	(16	-	18)	 17	(16	-	19)	 17	(16	-	18)	 0.355	
BMI	(kg/m2)	 25.1	(22.2	-	28.6)	 23.9	(21.4	-	25.3)	 25.8	(21.7	-	30.4)	 0.164	
Serum	hormone	levels	 	 	 	 				E2	(pmol/l)	 93.0	(74.0	-	137.5)	87.0	(57.5	-	129.5)	 107.5	(82.3	-	157.8)	 0.053				S-FSH	(U/L)	 5.0	(3.3	-	6.0)	 5.3	(2.9	-	5.9)	 4.8	(3.6	-	6.1)	 0.973				LH	(IU/L)	 4.0	(2.0	-	5.1)	 4.8	(2.3	-	6.5)	 4.9	(2.0	-	6.7)	 0.111	
Vaginal	pH	 4.7	(4.4	-	5.0)	 5.3	(4.8	-	5.6)	 5.0	(4.7	-	5.3)	 <0.0001	
Genital	infections	 	 	 	 				No	STI	 29/69	(42.0%)	 10/17	(58.8%)	 26/65	(40.0%)	 0.367	
			N.	gonorrhoeae	 8/69	(11.6%)	 1/17	(5.8%)	 9/65	(13.8%)	 0.990	
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3.4.1 Vaginal	microbiota	according	to	Nugent-BV	status	
To	evaluate	the	vaginal	microbial	composition	in	AGYW	at	baseline,	the	variable	region	4	(V4)	of	the	bacterial	16S	rRNA	gene	was	sequenced	to	assess	bacterial	relative	abundance	(Anahtar	et	al.,	2015).	Others	from	our	group	have	previously	reported	 that	 observed	 bacterial	 communities	 in	 vaginal	 samples	 from	adolescents	in	the	same	community	clustered	into	three	distinct	CTs	(C1,	C2,	C3)	by	Fuzzy	clustering,	with	weighted	UniFrac	distances	(Lennard	et	al.,	2017).	This	characterization	 of	 vaginal	 communities	was	 adopted	 in	 this	 chapter,	whereby	C1	 represents	 a	 more	 diverse	 microbiota	 with	 low	 Lactobacillus	 abundance,	while	 C2	 and	 C3	 were	 made	 up	 of	 predominantly	 L.	 crispatus	 and	 L.	 iners,	respectively	(Figure	3.1B).	This	analysis	was	conducted	by	Christina	Balle	as	part	of	 her	 PhD	 (submitted).	 Of	 the	 151	 baseline	 samples	 collected,	 141/151	 (BV	negative	 n=64,	 intermediate	 n=14,	 BV	 positive	 n=63)	 had	 sequence	 of	 high	enough	quality	to	analyze	(Balle,	Jaspan	et	al.,	personal	communication).		At	baseline,	52%	(73/141)	of	the	participants	had	a	non-Lactobacillus	dominated	microbiota,	while	 48%	 (68/141)	 had	 a	Lactobacillus-dominated	microbiota.	 Of	
			T.	vaginalis	 5/69	(7.2%)	 4/17	(23.5%)	 5/65	(7.7%)	 0.165	
			C.	trachomatis	 22/69	(31.9%)	 5/17	(29.4%)	 23/65	(35.3%)	 0.999	
			M.	genitalium	 2/69	(2.9%)	 0/17	(0%)	 2/65	(3.1%)	 0.601				HSV-2	serology	 16/69	(23.2%)	 2/17	(11.8%)	 19/65	(29.2%)	 0.440				Presence	of	yeast	hyphae	 16/69	(23.2%)	 2/17	(11.8%)	 5/65	(7.7%)	 0.020	
Behavioural	
characteristics	 	 	 	 				Age	of	sexual	debut	 15	(14	-	16)	 15	(14	-	16)	 15	(14	-	16)	 0.938				Condom	use	always	 43/61	(70.5%)	 9/12	(76.9%)	 26/54	(47.2%)	 0.030				Ever	washed	vagina	 3/69	(4.3%)	 2/18	(11.1%)	 8/65	(12.3%)	 0.217	
Previous	contraceptive	
use	 	 	 	 				None	 3/69	(4.3%)	 1/17	(5.8%)	 3/61	(4.9%)	 0.981				DMPA	 13/69	(18.8%)	 2/17	(11.7%)	 13/61	(21.3%)	 0.608				NET-EN	 45/69	(65.2%)	 12/17	(70.6%)	 37/61	(60.6%)	 0.531				COCP	 5/69	(7.2%)	 1/17	(5.8%)	 6/61	(9.8%)	 0.799				Implanon	 0/69	(0%)	 1/17	(5.8%)	 2/61	(3.2%)	 0.234	BV,	 bacterial	 vaginosis;	 BMI,	 body	 mass	 index;	 E2,	 estradiol;	 S-FSH,	 follicle	 stimulating	 hormone;	 LH,	luitenizing	hormone	
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those	with	a	Lactobacillus-dominant	microbiota,	21%	(30/141)	had	primarily	L.	
crispatus	 and	 27%	 had	 L.	 iners	(38/141).	 When	 these	 clusters	 were	 stratified	according	to	Nugent	criteria	(Figure	3.1A),	97%	of	BV+	adolescents	grouped	into	the	C1	CT	(61/63),	with	the	most	abundant	bacterial	species	being	G.	vaginalis,	
BVAB1,	Megasphaera	spp.,	L.	iners	and	Prevotella	spp.	Of	those	with	intermediate	Nugent	 scores,	 71%	 were	 classified	 into	 C1	 (10/14).	 Of	 those	 who	 were	considered	BV	 negative,	 44%	had	L.	crispatus-dominant	 CTs	 (28/64)	 and	 53%	had	L.	iners-dominant	CTs	(34/64).				
	
	Figure	 3.1.	 Vaginal	 microbial	 composition	 in	 adolescents	 at	 baseline.	 (A)	 Table	showing	 community	 types	 stratified	 according	 to	 BV	 status.	 (B)	 Unsupervised	hierarchical	 clustering	of	bacterial	 taxa	 in	vaginal	 lateral	wall	 swabs	 identified	by	16S	rRNA	 sequencing.	 Adolescents	 are	 labeled	 according	 to	 BV	 status	 and	 community	cluster.	Community	types	were	identified	using	fuzzy	clustering	based	on	the	dominant	bacterial	 species:	 C1	 (more	 diverse	 anaerobic	 bacteria),	 C2	 (L.	 crispatus)	 and	 C3	 (L.	
iners)	(according	to	the	method	described	by	Lennard	et	al.,	2017).	The	dendrogram	on	
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BV	status	
Community	cluster	 Negative	Intermediate	Positive	
BV	status	
C1	C2	C3	No	cluster	
Community	cluster	
A
B %	abundance	
		 	BV	negative	 Intermediate	 BV	positive	 	
																															n/N	(%)	
Community	types	 	 	 	 				C1	 2/64	(3.1%)	 10/14	(71.4%)	 61/63(96.8%)	 <0.0001				C2	 28/64(43.8%)	 2/14	(14.3%)	 0/63	(0%)	 <0.0001				C3	 34/64	(53.1%)	 2/14	(14.3%)	 2/63	(3.2%)	 <0.0001	
	 84	
the	 left	 of	 the	 figure	 shows	 the	 relatedness	 of	 different	 bacterial	 taxa.	 Figure	 3.1B	provided	by	Christina	Balle.			
3.4.2 Relationship	between	BV	status	and	Th17	cell	frequencies	
Since	 several	 studies	 have	 shown	 that	 Th17	 cells	 are	 important	 in	 protection	against	bacterial	and	fungal	pathogens	(Pietrella	et	al.,	2011;	Cooper,	2014),	the	relationship	 between	 BV	 status	 and	 cervical	 Th17	 cell	 frequencies	 and/or	activation	status	was	assessed.	Both	the	median	frequencies	of	Th17	cells,	their	relative	 counts,	 and	 the	proportion	expressing	CCR5	or	 activation	markers	did	not	differ	by	BV	status	(Figure	3.2),	irrespective	of	whether	STIs	were	excluded	from	 this	 analysis	 (data	 not	 shown).	 In	 addition,	 no	 significant	 differences	according	to	BV	status	in	overall	CD4+	T	cell	frequencies	or	activation	status	was	observed	(data	not	shown).			
Figure	 3.2.	 Proportion	 and	 phenotype	 of	 Th17	 cells	 stratified	 according	 to	 BV	
status	 (by	 Nugent	 scoring).	 (Top	 panel)	 Box	 and	 whisker	 plots	 (median,	 IQR	 and	range)	showing	Th17	counts	(first	graph),	Th17	frequencies	(second	graph)	and	CCR5	expression	 on	 Th17	 cells	 (third	 graph)	 according	 to	 BV	 status.	 (Bottom	 panel)	Expression	 of	 activation	markers	 CD38	 and	HLA-DR,	 and	 co-expression	 of	 CCR5	with	
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activation	markers	on	Th17	cells.	Mann-Whitney	and	Kruskal-Wallis	tests	were	used	to	compare	groups.	P<0.05	were	considered	significant.	ns=not	significant.			
3.4.3 Relationship	 between	 Th17	 cell	 frequencies,	 activation	
status	and	vaginal	community	types		
BV-associated	 microbial	 diversity	 in	 the	 vagina	 has	 been	 reported	 to	 be	associated	 with	 increased	 activated	 CD4+	 T	 cell	 frequencies	 in	 some	 cohorts	(Gosmann	 et	 al.,	 2017),	 but	 not	 others	 (Lennard	 et	 al.,	 2017).	 Th17	 cell	frequencies	and	activation	were	thus	compared	between	AGYW	according	to	CTs	to	 determine	 whether	 vaginal	 CTs	 in	 adolescents	 influence	 mucosal	 T	 cell	frequencies	or	function.	The	frequencies	and	counts	of	Th17	cells	were	found	to	be	evenly	distributed	across	the	three	CTs	(Figure	3.3).	Similarly,	expression	of	CCR5,	CD38	and	HLA-DR	on	Th17	cells	was	not	 significantly	different	between	the	groups.	In	addition,	overall	changes	in	CD4+	T	cell	frequencies	and	activation	did	not	significantly	differ	by	vaginal	CT	category	(data	not	shown).			
Figure	 3.3.	 Proportion	 and	 phenotype	 of	 Th17	 cells	 stratified	 according	 to	
community	 types	 (C1:	 diverse	 microbiome,	 C2:	 L.	 crispatus,	 C3:	 L.	 iners)	
determined	using	16S	rRNA	sequencing.	(Top	panel)	Box	and	whisker	plots	(median,	
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IQR	and	range)	of	Th17	counts	(first	graph),	Th17	frequencies	(second	graph)	and	CCR5	expression	on	Th17	cells	(third	graph).	(Bottom	panel)	Expression	of	activation	markers	CD38	 and	HLA-DR	 on	Th17	 cells,	 and	 co-expression	 of	 CCR5	 together	with	 activation	markers	on	Th17	cells.	Mann-Whitney	and	Kruskal-Wallis	 tests	were	used	to	compare	groups.	P<0.05	were	considered	significant.	ns=not	significant.			
3.4.4 Relationship	 between	 L.	 crispatus	 (C2)	 and	 L.	 iners	 (C3)	
CTs	and	Th17	cell	frequencies/activation	status		
Although	both	Lactobacillus	spp.	are	commonly	found	colonizing	the	lower	FRT	in	 healthy	 women,	 L.	 crispatus	 colonization	 has	 been	 reported	 to	 be	 more	beneficial	 than	L.	iners	(Verstraelen	 et	 al.,	 2009).	 Therefore,	 the	 frequency	 and	phenotype	of	Th17	 cells	were	 compared	 in	 a	 subset	of	 the	non-C1	adolescents	(focusing	on	those	who	did	not	have	any	STIs;	n=31).	Of	these,	42%	(13/31)	had	an	L.	crispatus-dominated	VMB	(C2),	and	58%	(18/31)	had	an	L.	iners-dominated	(C3)	 VMB.	 Adolescents	with	 C2	 and	 C3-type	 VMBs	 had	 similar	 relative	 counts	and	 frequencies	of	cervical	Th17	cells	 (Figure	3.4).	Although	there	was	a	 trend	towards	reduced	activation	of	Th17	cells	(co-expression	of	CD38	and	HLA-DR)	in	adolescents	who	had	an	L.	iners-dominated	CT	(C3)	compared	to	those	with	an	L.	
crispatus	dominated	 CT	 (C2).	 Overall	 frequencies	 of	 activated	 cells	 and	 those	expressing	CCR5	did	not	differ	significantly	between	the	two	groups.	
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	Figure	3.4.	Comparison	of	cervical	Th17	frequencies,	activation	status	and	CCR5	
expression	 in	 adolescents	with	L.	 crispatus-	 (C2;	 orange	 circles)	 versus	L.	 iners-
dominated	microbiota	(C3;	pink	circles).	(Top	panel)	Th17	counts,	Th17	frequencies,	and	 CCR5	 expression	 on	 Th17	 cells.	 (Bottom	panel)	 Expression	 of	 activation	markers	CD38	 and	HLA-DR	 on	Th17	 cells,	 and	 co-expression	 of	 CCR5	 together	with	 activation	markers	on	Th17	cells.	The	bar	represent	the	median,	the	error	bars	represent	the	IQR.	Mann-Whitney	U	test	was	used	to	compare	groups.	P<0.05	were	considered	significant.	ns=not	significant.			
3.4.5 Impact	 of	 BV	 status	 and	 vaginal	 CT	 clustering	 on	 genital	
cytokine	profiles		
Th17-related	cytokines,	including	IL-17A	and	IL-17F,	have	been	described	to	be	important	in	anti-bacterial	immunity	(Cooper,	2014).	Therefore,	the	relationship	between	 Th17-related	 cytokines	 and	 BV	 status	 and	 bacterial	 CTs	 was	investigated.	While	BV	status	and	CT	clustering	did	not	appear	to	influence	Th17	cell	 frequencies	 or	 activation	 profiles,	 all	 15	 of	 the	 Th17-related	 cytokines	differed	significantly	according	to	both	BV	status	(Figure	3.5)	and	CT	clustering	(Figure	3.6).	BV+	and	 intermediate	 adolescents	had	 significantly	higher	 genital	concentrations	of	Th17-related	 cytokines	 compared	 to	BV-	 adolescents	 (Figure	3.5).	Interestingly,	IL-17A	(p=0.01,	p.	adj=0.01),	IL-17F	(p=0.04,	p.	adj=0.06)	and	
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IL-10	 (p=0.03,	 p.	 adj=0.04)	 concentrations	 were	 significantly	 higher	 in	adolescents	with	an	intermediate	Nugent	score	compared	to	BV+	adolescents.		Similarly,	 adolescents	 with	 C2	 (L.	 crispatus)	 and	 C3	 microbiota	 (L.	 iners)	 had	significantly	 lower	 Th17-related	 cytokine	 concentrations	 compared	 to	 those	with	a	C1	microbiota	(more	diverse;	Figure	3.6).	Interestingly,	the	concentration	of	IL-1β	was	three	times	higher	in	adolescents	with	L.	iners-	(C3)	compared	to	L.	
crispatus-dominated	 VMB	 (C2)	 (1.67	 pg/ml	 vs	 0.43	 pg/ml,	 respectively,	p=0.001).	Genital	tract	IL-1β	concentrations	also	tended	to	be	six	times	higher	in	adolescents	with	 intermediate	Nugent	 scores	 compared	 to	 those	with	BV	 (217	pg/ml	vs	35	pg/ml;	Figure	3.5),	although	this	was	not	significant.	
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Figure	3.5.	Th17-related	cytokines	according	to	BV	status.	Cytokines	have	been	grouped	into	those	produced	by	Th17	cells	(first	row),	and	those	involved	in	their	differentiation	(second	row)	and	regulation	(third	row).	The	middle	line	represents	the	median,	and	the	error	bars	represent	the	IQR.	 Mann-Whitney	 U	 test	 was	 applied	 for	 comparisons	 between	 groups.	 *p<0.05;	 **p<0.01;	 ***p<0.001;	 ****p<0.0001,	 and	 those	 in	 blue	 (*)	remained	 significant	 after	 adjusting	 for	 multiple	 comparisons.
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Figure	3.6.	Th17-related	cytokines	according	to	the	vaginal	microbiome	community	type.	Cytokines	have	been	grouped	into	those	produced	by	Th17	cells	(first	row),	and	those	involved	in	their	differentiation	(second	row)	and	regulation	(third	row).	The	middle	line	shows	the	median,	and	the	error	bars	represent	the	IQR.	Mann-Whitney	U	test	was	applied	for	comparisons	between	groups.	*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001,	and	those	in	blue	(*)	remained	significant	after	adjusting	for	multiple	comparisons.	
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Because	condom	use	and	the	presence	of	vaginal	yeast	differed	according	to	BV	status	(see	 Table	 3.1),	 the	 associations	 between	 Th17-related	 cytokines	 and	 BV	 were	evaluated	using	a	multivariate	logistic	regression	in	order	to	adjust	for	these	potential	confounders	 (Figure	 3.7).	 After	 adjusting	 for	 STIs,	 IL-17A	 (I	 [intermediate]:	 β=2.52,	CI=1.38-3.67;	BV+:	β=0.90,	CI=0.15-1.65),	IL-17F	(I:	β=1.67,	CI=0.90-2.44;	BV+:	β=1.16,	CI=0.64-1.68),	 IL-6	 (I:	 β=1.70,	 CI=0.95-2.45;	 BV+:	 β=1.21,	 CI=0.69-1.74),	 IL-1β	 (I:	β=2.22,	CI=1.45-2.98;	BV+:	β=1.80,	CI=1.21-2.39),	 IL-23	 (I:	β=1.05,	CI=0.45-1.66;	BV+:	β=0.75,	CI=0.36-1.14),	IL-33	(I:	β=1.14,	CI=0.25-2.02;	BV+:	β=1.15,	CI=0.58-1.72),	TNF-α	(I:	β=1.97,	CI=1.19-2.74;	BV+:	β=1.65,	CI=0.15-1.65),	IL-4	(I:	β=1.14,	CI=0.45-1.83;	BV+:	β=1.06,	CI=0.54-1.58),	IL-25	(I:	β=1.08,	CI=0.43-1.74;	I:	BV+:	β=1.08,	CI=0.65-1.51)	and	IFN-γ	 (I:	 β=1.17,	 CI=0.06-2.27;	 BV+:	 β=1.09,	 CI=0.39-1.79)	 cytokines	 remained	positively	 associated	 with	 both	 having	 intermediate	 Nugent	 scores	 and	 being	 BV+.	Further	 adjusting	 condom	 use	 and	 yeast	 infections,	 IL-17A	 (I:	 β=3.67,	 CI=0.90-2.44;	BV+:	β=1.32,	CI=0.40-2.23),	IL-17F	(I:	β=1.81,	CI=0.77-2.85;	BV+:	β=1.52,	CI=0.88-2.16),	IL-6	(I:	β=2.02,	CI=1.06-2.97;	BV+:	β=1.65,	CI=0.93-2.36),	IL-1β	(I:	β=2.10,	CI=1.23-2.98;	BV+:	β=1.93,	CI=1.26-2.61),	IL-23	(I:	β=0.96,	CI=0.27-1.65;	BV+:	β=0.85,	CI=0.41-1.30),	TNF-α	 (I:	 β=1.61,	 CI=0.77-2.45;	 BV+:	 β=1.80,	 CI=1.15-2.45),	 IL-4	 (I:	 β=1.05,	 CI=0.29-1.81;	BV+:	β=1.18,	CI=0.62-1.74),	IL-25	(I:	β=1.05,	CI=0.30-1.80;	BV+:	β=1.21,	CI=0.71-1.71)	 and	 sCD40L	 (I:	 β=0.83,	 CI=0.15-1.52;	 BV+:	 β=0.43,	 CI=0.04-0.83)	 remained	significant	for	both	BV	intermediate	and	positive.		
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Figure	3.7.	Multivariate	 logistic	 regression	analysis	of	 the	 relationships	between	Th17-
related	 cytokines	 in	 adolescents	 with	 intermediate	 Nugent	 scores	 (orange)	 and	 those	
who	were	BV+	(black)	adolescents	(compared	to	BV-	adolescents),	adjusting	for	potential	
confounders	 (STIs,	 yeast	 infections	 and	 reported	 condom	 use).	 Multivariate	 logistic	regression	 was	 used	 to	 determine	 associations	 between	 log10-transformed	 cytokine	concentrations	and	BV	status.	Th17-related	cytokines	in	BV	negative	adolescents	were	used	as	the	 reference	 group.	 (Left	 panel)	 Unadjusted;	 (middle	 panel)	 Adjusted	 for	 STIs;	 (right	 panel)	Adjusted	for	STIs,	yeast	and	condom	use.	Dots/blocks	indicate	β-coefficients,	and	the	error	bars	indicate	the	95%	confidence	intervals	(CI).	*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001.			IL-10	has	a	non-redundant	role	in	anti-inflammatory	responses	by	acting	on	variety	of	immune	 cells	 (Hedrich	 and	 Bream,	 2010;	 Lyer	 and	 Cheng,	 2012),	 which	 includes	negatively	 regulating	 Th17	 immune	 responses	 by	 inhibiting	 the	 synthesis	 of	 pro-inflammatory	 cytokines	 (Huber	 et	 al.,	 2011).	 Since	 IL-10,	 IL-17A	 and	 IL-17F	 were	significantly	 elevated	 in	 BV	 intermediate	 compared	 to	 BV	 positive	 adolescents	 (see	Figure	 3.5),	 the	 relationship	 between	 IL-10	 and	 IL-17A	 and	 F	 were	 investigated	according	 to	 BV	 status.	 IL-17F	 correlated	 weakly	 albeit	 positively	 with	 IL-10	 in	 BV	negative	 adolescents	 (r=0.26,	 p=0.03;	 Figure	 3.8,	 first	 row),	 while	 no	 significant	correlation	 in	 the	 intermediate	 group	was	 observed.	 In	 BV+	 adolescents,	 there	was	 a	significant	positive	correlation	of	IL-10	with	both	IL-17A	(r=0.39,	p=0.001)	and	IL-17F	(r=0.50,	 p<0.0001).	 The	 ratio	 of	 IL-17A:IL-10	 and	 IL-17F:IL-10	was	 also	 investigated	(Figure	 3.8,	 second	 row).	 The	 ratios	 did	 not	 differ	 significantly,	 although	 the	median	ratio	of	IL-17A:IL-10	in	the	intermediate	group	tended	to	be	lower,	suggesting	a	lower	concentration	of	IL-10	compared	to	IL-17A	in	this	group.										
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Figure	 3.8.	 Correlation	 between	 IL-10	 and	 IL-17A	 (blue	 dots)	 or	 IL-17F	 (black	 dots)	
concentrations	 (top	 panels)	 and	 IL-17:IL10	 ratios	 (bottom	 panels),	 measured	 in	 BV	
negative,	 intermediate	 and	BV	positive	 adolescents.	Box	 and	whisker	 plots	 represent	 the	median,	IQR	and	range.	Only	significant	p-values≤0.05	are	displayed	on	the	graphs,	in	blue	(IL-17A)	or	black	text	(IL-17F).		
	
	
3.4.6 Relationship	 between	 L.	 crispatus-(C2)	 and	 L.	 iners-dominated	
(C3)	vaginal	CTs	and	Th17-related	cytokines		
To	 compare	 the	 impact	 of	 Lactobacillus	 dominated	 microbiota	 on	 genital	 cytokine	concentrations,	Th17-related	cytokines	(in	adolescents	without	STIs)	were	analysed	by	CT	 status.	 In	 the	 38	 AGYW	 included	 in	 this	 analysis,	 Th17-related	 cytokine	concentrations	were	similar	 in	the	two	Lactobacillus-dominated	CTs	(Figure	3.9),	with	the	exception	of	IL-21	which	tended	to	be	higher	in	AGYW	with	L.	crispatus-dominated	microbiota	 (3.30	 pg/ml)	 than	 those	 with	 L.	 iners-dominated	microbiota	 (0.08	 pg/ml,	p=0.26;	Figure	3.9A).	Similarly,	there	was	a	trend	towards	decreased	concentrations	of	IL-1β	in	adolescents	with	L.	crispatus-dominated	vaginal	microbiota	(p=0.03,	p.	adj=0.4;	Figure	3.9B).			
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Figure	3.9.	Comparisons	of	Th17-related	cytokines	in	adolescents	with	either	L.	crispatus-
(orange	 bars)	or	 L.	 iners-dominated	microbiota	 (pink	 bars).	 (A)	 Cytokines	 produced	 by	Th17	cells.	(B)	Other	cytokines	involved	in	the	differentiation	and	regulation	of	Th17	cells.	Box	and	 whiskers	 represent	 the	 median,	 IQR	 and	 range.	 Only	 significant	 p-values	 of	 ≤0.05	 are	displayed.			
3.4.7 Relationship	between	Nugent-BV	 and	Th17	 cells	 and	 cytokines	
in	the	presence	of	chlamydia	infection	
Since	asymptomatic	chlamydia	infection	alone	increased	IL-17A	genital	concentrations	(Chapter	2,	Figure	2.11),	and	it	was	highly	prevalent	in	this	cohort	(33%),	the	impact	of	BV	on	Th17	cells	in	the	presence	or	absence	of	chlamydia	was	investigated.	BV	positive	adolescents	with	chlamydia	(in	the	absence	of	other	STIs;	BV+C+)	were	compared	to	BV	positive	 adolescents	without	 any	 STIs,	 including	 chlamydia	 (BV+C-),	 adolescents	who	had	no	BV	and	STIs	(BV-C-),	and	those	who	only	had	chlamydia	(BV-C+).	Frequencies	of	
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Th17	 cells	 tended	 to	 be	 lower	 in	 BV+C+	 girls	 compared	 to	 BV+C-,	 BV-C-	 and	 BV-C+	(47.4%	 vs	 61.3%,	 55.5%	 and	 49.4%,	 respectively),	 however	 this	 was	 not	 significant	(p=0.07,	 Figure	 3.10A).	 However,	 the	 frequencies	 of	 Th17	 cells	 expressing	 CCR5	 and	activation	markers	(CD38)	were	similar	across	groups	(Figure	3.10B).			Next,	 the	 concentrations	 of	 Th17-related	 cytokines	 were	 compared	 between	 groups.	Adolescents	who	had	both	BV+C+	had	a	significantly	higher	 IL-17A,	 IL-17F,	and	 IL-10	concentrations	 compared	 to	 BV+C-	 adolescents	 (p=0.02,	 p=0.03,	 and	 p=0.002,	respectively),	in	addition	to	TNF-α	(p=0.02,	Figure	3.10C),	suggesting	an	additive	effect	of	 co-infection	 on	 these	 Th17-related	 cytokines.	 However,	 only	 IL-10	 remained	significant	after	adjusting	for	multiple	comparisons	(adj.	p=0.03).	Furthermore,	BV+C+	adolescents	 had	 elevated	 IL-17F	 (p=0.001),	 IL-21	 (p=0.04),	 IL-22	 (p=0.005),	 IL-6	(p=0.007),	 IL-1β	 (p<0.0001),	 IL-33	 (p=0.002),	 TNF-α	 (p<0.0001),	 IL-4	 (p=0.03),	 IL-10	(p=0.006),	 IL-25	 (p=0.0007),	 IL-31	 (p=0.03)	 and	 IFN-γ	 (p=0.001)	 compared	 to	adolescents	who	only	had	chlamydia	and	no	BV	(C+BV-,	Figure	3.10C).		
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Figure	3.10.	Comparison	of	genital	Th17	cells	and	Th17-related	cytokines,	according	 to	
BV	status,	 in	the	presence	and	absence	of	chlamydia	co-infection.	(A)	Frequency	of	Th17	cells	 in	 BV-chlamydia-	 (BV-C-;	 clear	 boxes),	 BV+chlamydia-	 (BV+C-;	 dot	 filled	 boxes),	BV+chlamydia+	 (BV+C+;	 purple	 filled	 boxes)	 and	 BV-chlamydia+	 AGYW	 (BV-	 C+;	 purple	outlined	clear	boxes).	(B)	Activation	(CD38	and	HLA-DR)	and	expression	of	CCR5	on	Th17	cells	by	 BV	 and	 C	 group.	 (C)	 Th17-related	 cytokines	 by	 BV	 and	 C	 group.	 Box	 and	 whisker	 plot	represent	the	median,	IQR	and	range	for	each	parameter.	Significant	differences	in	Th17-related	cytokines	 between	 BV+C-	 and	 BV+C+	 adolescents	 are	 shaded	 in	 grey.	Mann-Whitney	 U	 tests	were	used	to	compare	groups	and	p<0.05	were	considered	significant.	*p<0.05;	**p<	0.01;	***p<	0.001;	****p<0.0001.	Only	significant	p-values	of	≤0.05	are	displayed.		
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3.5	Discussion	
The	 vaginal	 microbiome	 is	 likely	 to	 interact	 with	 local	 genital	 tract	 immunity	 and	epithelial	barrier	 function	 in	 the	FRT,	 and	alterations	 in	 this	microbiome,	 such	as	BV,	have	 been	 linked	 to	 increased	 HIV	 susceptibility	 to	 HIV	 infection	 (Low	 et	 al.,	 2011;	Cohen	et	al.,	2012;	Gosmann	et	al.,	2017;	McClelland	et	al.,	2018).	 In	 this	Chapter,	 the	impact	 of	BV	and	an	 altered	VBM	on	Th17	 cells,	 the	 cytokines	 they	produce	 and	 that	regulate	 them	were	explored	 in	AGYW,	at	risk	 for	HIV	acquisition.	BV+	adolescents	as	well	 as	 those	who	had	 intermediate	Nugent	 scores	 (4-6)	had	higher	vaginal	pHs	 than	BV-	adolescents,	in	addition	to	having	more	diverse	C1	CT,	defined	by	fewer	lactic	acid	producing	 lactobacilli	 (Lennard	 et	 al.,	 2017).	 BV+	 adolescents	 reported	 less	 regular	condom	use,	although	they	were	also	less	likely	to	have	yeast	infections	by	Gram	stain.	Hutchinson	 et	 al.	 (2007)	 similarly	 reported	 that	 more	 consistent	 condom	 use	 was	associated	with	decreased	incidence	of	BV	in	women	whom	they	followed	for	a	total	of	3	 years.	 	Moreover,	 van	de	Wijgert	 (2007)	 and	 colleagues	 reported	 a	 strong	negative	association	between	BV	and	vaginal	yeast.		Previous	 studies	 that	 characterized	 the	 VMB	 in	 African	 women	 (African	 American	women	from	the	US	and	women	currently	living	in	Africa)	showed	that	fewer	of	these	women	 tended	 to	 have	 Lactobacillus-dominated	 microbiota,	 but	 rather	 had	 more	diverse	 microbiota	 compared	 to	 women	 of	 North	 American	 and	 European	 women	(Ravel	et	al.,	2011;	Anahtar	et	al.,	2015;	Bayigga	et	al.,	2018;	Lennard	et	al.,	2017).	As	others	 from	our	group	have	previously	 reported	 in	AGYW	from	 the	same	community,	the	VMB	of	adolescents	in	this	study	clustered	into	three	CTs	(Lennard	et	al.,	2017):	just	over	 half	 had	C1-dominated	VMBs	 in	which	 vaginal	 swabs	were	 characterized	 by	 the	presence	 of	 Gardnerella	 and	 other	 anaerobic	 bacterial	 species;	 while	 the	 rest	 of	 the	AGYW	had	VMBs	classified	as	either	C2	(dominated	by	L.	crispatus)	or	C3	(dominated	by	
L.	 iners).	 Furthermore,	 adolescents	 who	 were	 BV+	 or	 who	 had	 intermediate	 Nugent	scores	had	a	predominantly	C1	VMB,	with	the	most	abundant	species	being	G.	vaginalis,	
BVAB1,	Megasphaera,	L.	iners	 and	Prevotella	spp.,	while	BV-	adolescents	primarily	had	either	L.	crispatus	(C2)	or	L.	iners	(C3)	dominated	microbiota.			
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Th17	cells	are	thought	to	play	a	critical	role	in	destroying	extracellular	bacteria	(Carey	et	 al.,	 2016;	 Cosorich	 et	 al.,	 2017),	 although	 they	 are	 also	 highly	 susceptible	 to	 HIV	infection	(McKinnon	et	al.,	2015;	Stieh	et	al.,	2016).	In	this	cohort,	neither	the	frequency	nor	activation	status	of	Th17	cells	(defined	by	being	CCR6+	and	CCR10-	CD4+	T	cells)	differed	 by	 BV	 status	 or	 VMB	 CT	 classification.	 This	 data	 suggests	 that	 vaginal	CCR6+CCR10-	 Th17	 cells	 were	 not	 altered	 by	 BV	 nor	 the	microbiome	 in	 this	 cohort.	Although	no	previous	studies	have	evaluated	the	interplay	between	the	VMB	and	genital	Th17	cells,	conflicting	results	have	emerged	on	the	impact	of	BV	on	genital	tract	CD4+	T	cell	 frequencies.	While	 some	 studies	 found	 that	 vaginal	 dysbiosis	was	 not	 associated	with	any	change	in	genital	CD4+	T	cell	frequencies	or	activation	status	(Lennard	et	al.,	2017),	others	have	reported	increased	frequencies	and	more	activated	CD4+	T	cells	in	women	with	BV	or	vaginal	dysbiosis	(Rebbapragada	et	al.,	2008;	Thurman	et	al.,	2015;	Gosmann	et	al.,	2017).	In	this	study,	the	overall	frequency	of	CD4+	T	cells	and	activation	of	these	cells	were	also	not	altered	in	adolescents	with	BV	or	dysbiosis.			Since	 several	 studies	 have	 reported	 that	 L.	 crispatus	 is	 more	 beneficial	 than	 L.	 iners	(Borgdorff	et	al.,	2015;	Gautam	et	al.,	2015;	Petrova	et	al.,	2017),	the	phenotype	of	Th17	cells	 in	 adolescents	 with	 an	 L.	 crispatus	 were	 compared	 to	 those	 with	 an	 L.	 iners-dominated	 VMB,	 in	 the	 absence	 of	 any	 confounding	 common	 STIs	 (including	 C.	
trachomatis,	 N.	 gonorrhoeae,	 M.	 genitalium,	 or	 T.	 vaginalis).	 The	 frequency	 and	activation	 status	 of	 cervical	 Th17	 cells	 did	 not	 differ	 significantly	 in	 AGYW	 with	 L.	
crispatus-	and	L.	iners-dominated	VMBs,	those	with	L.	iners-dominated	VMBs	tended	to	be	less	activated	than	those	with	L.	crispatus-dominated	VMBs.			It	was	 interesting	 to	note	 in	 this	study	 that	AGYW	with	L.	iners-dominated	microbiota	(C3)	 tended	 to	 have	 higher	 genital	 concentrations	 of	 IL-1β	 than	 adolescents	 with	 L.	
crispatus-dominated	 VMBs	 (C2).	 None	 of	 the	 other	 cytokines	 produced	 by	 Th17	 cells	(including	IL-17A,	IL-17F,	IL-21	and	IL-22),	or	others	involved	in	Th17	differentiation	or	regulation	appeared	to	differ	by	Lactobacilli	group.	IL-1β	is	also	thought	to	be	important	in	driving	the	differentiation	of	Th17	cells	(Lasigliè	et	al.,	2011),	although	adolescents	with	an	L.	iners-dominate	VMB	had	similar	frequencies	of	Th17	cells	with	those	with	an	
L.	 crispatus-dominated	 microbiota	 in	 this	 cohort.	 Previous	 in	 vitro	 studies	 have	suggested	 that	 L.	 crispatus	 inhibits	 inflammatory	 cytokine	 responses,	 which	 may	 be	
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important	in	the	context	of	lowering	HIV	risk	(Rizzo	et	al.,	2015;	Chetwin	et	al.,	2019).	A	recent	 study	 from	our	 group	 in	 adolescents	 from	 the	 same	 community	 in	Cape	Town	reported	 that	 a	 L.	 iners-dominated	 VMB	 was	 not	 associated	 with	 an	 inflammatory	cytokine	profile	compared	to	those	with	a	L.	crispatus-dominated	VMB	(Lennard	et	al.,	2017).	 The	 role	 of	 L.	 iners	 in	 vaginal	 health	 is	 unclear,	 since	 it	 is	 detected	 in	 normal	conditions	as	well	 as	during	vaginal	dysbiosis	 (Petrova	et	 al.,	 2017).	 Several	previous	studies	have	considered	L.	crispatus	 and	L.	iners	 to	 largely	be	 functionally	similar,	and	both	outcompete	other	vaginal	commensals	for	resources,	a	survival	strategy	needed	to	maintain	 a	 healthy	 vaginal	 microbiota	 (Yamamoto	 et	 al.,	 2009;	 France	 et	 al.,	 2016).	Others	have	also	argued	that	L.	iners	might	be	more	adaptable	to	survive	in	a	dysbiotic	vaginal	 state	 compared	 to	 L.	 crispatus,	 and	 might	 help	 to	 facilitate	 recovery	 to	 a	lactobacilli-dominated	microbial	community	(Ferris	et	al.,	2004;	Jakobsson	and	Forsum,	2007;	 Srinivasan	 et	 al.,	 2010;	 Lambert	 et	 al.,	 2013;	 Petrova	 et	 al.,	 2017).	 Of	 all	 the	
Lactobacillus	spp.	that	typically	colonize	the	lower	FRT,	L.	iners	has	the	smallest	genome	size	 (~1.3Mbps;	 Macklaim	 et	 al.,	 2011).	 In	 their	 comprehensive	 description	 of	 the	 L.	
iners	 genome,	 Macklaim	 and	 co-authors	 (2011)	 reported	 that	 766	 genes	 predicted	within	L.	iners	 genome	were	 shared	between	L.	crispatus,	L.	acidophilus	 and	L.	gasseri,	although	these	“core”	genes	represent	>60%	of	the	L.	iners	coding	sequence	compared	to	 only	 37%	 of	 L.	crispatus,	 and	 44%	 of	 L.	acidophilus	 and	 L.	gasseri	 sequence	 space.	Further	 studies	 are	needed	 to	 investigate	whether	 the	 reason	L.	iners	 is	 also	 found	 in	women	with	vaginal	dysbiosis	is	because	of	its	adaptable	nature	and	its	greater	ability	to	 compete	 with	 other	 organisms	 compared	 to	 L.	 crispatus,	 or	 perhaps	 it	 has	 a	pathogenic	nature	that	is	driving	dysbiosis.		Effector	cytokines	are	central	mediators	of	Th17	immunity	(Ouyang	et	al.,	2012),	and	it	was	therefore	important	to	know	if	alterations	in	the	VMB	influenced	the	production	of	these	cytokines.	It	was	interesting	to	note	therefore	that	all	of	the	cytokines	measured	were	 elevated	 in	 BV+	 adolescents	 and	 those	 with	 intermediate	 Nugent	 scores	 (4-6)	compared	to	BV-	adolescents,	and	most	of	these	remained	significant	after	adjusting	for	multiple	comparisons,	STIs,	reported	condom	use	and	yeast	infections.	Furthermore,	it	was	 surprising	 that	 adolescents	with	 intermediate	 VMB	had	 higher	 concentrations	 of	genital	 IL-17A,	 IL-17F	 and	 IL-10	 compared	 to	 BV+	 adolescents.	 In	 BV+	 AGYW,	 IL-10	correlated	 positively	 with	 both	 IL-17A	 and	 IL-17F.	 Previous	 studies,	 focusing	 on	
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inflammatory	 cytokines	 and	 chemokines,	 reported	 that	 BV	 (Nugent	 7-10)	 and	intermediate	 VMB	 (Nugent	 4-6)	 induced	 similar	 magnitudes	 of	 FRT	 inflammation	(Hedges	et	al.,	2006;	Masson	et	al.,	2014;	Guédou	et	al.,	2014;	Deese	et	al.,	2015).			Since	 Amsel	 et	 al.	 (1983)	 first	 defined	 the	 clinical	 criteria	 for	 diagnosing	 BV,	 which	included	 vaginal	 pH>4.5	 for	 the	 detection	 of	 women	 with	 BV,	 vaginal	 pH	 has	 been	evaluated	as	a	sensitive	but	non-specific	tool	to	diagnose	vaginal	dysbiosis	(Hemalatha	et	 al.,	 2013).	 In	 this	 cohort,	 a	 vaginal	 pH	 of	 4.7	 was	 observed	 in	 BV-	 (Nugent	 0-3)	adolescents,	 which	 was	 higher	 than	 the	 normal	 vaginal	 pH	 of	 4.5	 or	 less	 that	 is	considered	 normal	 (Amsel	 et	 al.,	 1983;	 Ravel	 et	 al.	 2011).	 Although	 BV-	 AGYW	 had	vaginal	pHs	above	what	is	considered	normal	internationally,	it	was	interesting	to	note	that	 adolescents	 with	 BV	 (Nugent	 7-10)	 or	 intermediate	 VMBs	 (Nugent	 4-6)	 had	significantly	higher	vaginal	pHs	 compared	 to	 their	BV-	 counterparts.	 Previous	 studies	have	 reported	 a	 positive	 correlation	 between	 vaginal	 pH	 and	 abnormal	 vaginal	microbiota	(Caillouette	et	al.,	1997;	Ravel	et	al.,	2011;	Hemalatha	et	al.,	2013;	O’Hanlon	et	al.,	 2013;	Krauss-Silva	et	 al.,	 2014),	which	was	 supported	by	 the	 findings	 from	 this	Chapter.	 The	 composition	 of	 the	 microbial	 ecosystem	 undoubtedly	 influences	 the	vaginal	pH	and	vice	versa.	Lactobacillus	species	have	been	shown	to	produce	lactic	acid,	which	 is	required	to	maintain	this	 low	vaginal	pH	(Tachedjian	et	al.,	2017;	Chetwin	et	al.,	 2019).	 In	 this	 adolescent	 cohort,	 vaginal	 pH	 was	 not	 associated	 with	 changes	 in	Th17-related	cytokines.		In	support	of	the	Nugent	scoring	analysis,	adolescents	in	this	study	with	more	diverse	vaginal	 microbiota	 (belonging	 to	 C1	 CT)	 also	 had	 elevated	 Th17-related	 cytokines	compared	to	those	with	L.	crispatus-	(C2)	or	L.	iners-dominated	VMB	(C3).	Gosmann	et	al.	(2017)	also	found	that	Th17-related	cytokines	IL-17,	IL-1β,	and	IL-23	were	elevated	in	 women	 with	 high	 diversity,	 low	 Lactobacillus	 abundance	 vaginal	 bacterial	communities.	 Anahtar	 et	 al.	 (2015)	 showed	 that	 altered	 vaginal	 microbiota	 increase	genital	inflammation	by	pattern	recognition	receptors	sensing	of	pathobionts	by	vaginal	epithelial	and	mucosal	antigen	presenting	cells	(APC).	Lower	Th17-related	cytokines	in	adolescents	with	Lactobacillus-dominated	microbiota	 (C2	 and	 C3)	 compared	 to	 those	with	 C1	 VMBs	 may	 also	 be	 a	 result	 of	 immune-regulatory	 properties	 of	 vaginal	
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lactobacilli	and	their	metabolites	like	lactic	acid	(Spurbeck	and	Arvidson,	2011;	Hearps	et	al,	2017).			
C.	 trachomatis	 was	 the	 most	 prevalent	 STI	 in	 this	 cohort	 of	 AGYW,	 with	 33%	 of	adolescents	being	 infected	at	baseline.	Previously,	BV	was	 found	 to	predict	 chlamydia	risk	 (Wiesenfeld	et	al.,	2003).	Hence,	 the	potential	 synergistic	effect	of	 chlamydia	and	BV	on	vaginal	immune	responses	in	adolescents	was	investigated.	Although	adolescents	co-infected	 with	 C.	 trachomatis	 and	 BV	 tended	 to	 have	 lower	 frequencies	 of	 cervical	Th17	 cells	 than	 those	 who	 only	 had	 BV,	 a	 greater	 proportion	 of	 these	 cells	 were	activated	 (CD38+).	 Moreover,	 concentrations	 of	 IL-17A,	 IL-17F,	 TNF-a	 and	 IL-10	cytokines	were	significantly	higher	 in	BV+	chlamydia+	adolescents	compared	to	 those	who	were	BV+	but	didn’t	have	chlamydia.			In	summary,	 the	frequency	and	activation	of	Th17	cells	was	similar	 irrespective	of	BV	status	or	vaginal	CT	profiles	of	the	adolescents.	However,	Th17-related	cytokines	were	elevated	 in	 adolescents	 who	 were	 BV+	 and	 had	 intermediate	 Nugent	 scores,	 which	reflected	the	diversity	revealed	by	vaginal	microbial	community	typing.	In	the	presence	of	the	other	prevalent	genital	condition	–	C.	trachomatis	infection	-	BV	appeared	to	have	an	additive	effect	on	Th17-related	cytokine	production.	This	study	adds	to	the	body	of	evidence	confirming	the	highly	 inflammatory	nature	of	an	altered	vaginal	microbiome	in	relation	to	Th17-related	cytokine	responses	although	not	in	frequencies	of	Th17	cells.		
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4.1 Abstract	Several	 studies	 have	 suggested	 that	 HCs	 may	 increase	 susceptibility	 to	 HIV	acquisition	in	women.	AGYW	in	SA	continue	to	be	at	a	heightened	risk	of	acquiring	HIV	compared	to	adolescent	boys	or	young	men.	Biological	mechanisms	are	likely	to	 contribute	 significantly	 to	 this	 high	 risk,	 including	 the	 number	 and	 activation	status	of	HIV	target	cells	available	in	the	lower	genital	tract	to	become	infected	in	adolescent	girls.	Since	Th17	cells	are	highly	susceptible	to	HIV	infection	compared	to	other	CD4+	T	subsets,	the	aim	of	this	Chapter	was	to	evaluate	whether	this	T	cell	subset	 and	 their	 related	 cytokines	 were	 altered	 in	 the	 FRT	 of	 adolescents	randomized	to	various	HC	methods,	including	NuvaRing,	NET-EN	and	COCPs.	One	hundred	and	 thirty	adolescent	girls	were	enrolled	and	 randomized	 to	one	of	 the	three	HCs.	After	four	months,	participants	crossed	over	to	another	HC	for	another	four	months	before	exiting	the	study.	In	an	intra-individual	analysis	at	crossover,	NuvaRing	 use	 was	 associated	 with	 increased	 proportions	 of	 cervical	 Th17	 cells	that	 expressed	 activation	markers	HLA-DR/CD38,	 despite	 decreased	 frequencies	of	Th17	cells	overall	compared	to	NET-EN	and	COCPs	use.	In	addition,	adolescents	on	 NuvaRing	 had	 increased	 concentrations	 of	 cervical	 Th17-related	 cytokines,	including	 IL-21,	 IL-1β,	TNF-α	and	IFN-γ.	Contraceptive	arms	at	crossover	did	not	differ	 by	 activation	 or	 chemokine	 receptor	 expression	 by	 cervical	 Th17	 cells,	although	 an	 increase	 in	 Th17-related	 cytokines	 (IL-21,	 IL-1β,	 IL-33,	 IL-4,	 TNF-α,	IFN-γ	and	sCD40L)	in	participants	on	NuvaRing	was	noted.	No	difference	in	genital	tract	 concentrations	 of	 Th17-related	 cytokines	 was	 noted	 between	 NET-EN	 and	COCPs	 users.	 Together,	 this	 data	 suggest	 that	 the	 use	 of	 the	 inserted	 vaginal	NuvaRing	 alters	 the	 frequency	 of	 Th17	 cells	 at	 the	 genital	 mucosa	 and	 Th17-related	cytokines	to	a	greater	extent	than	NET-EN	and	COCPs.							
	 104	
4.2 Introduction	It	 is	 undisputable	 that	 HCs	 are	 important	 in	 preventing	 unwanted	 pregnancies	(Kallner	 and	Danielsson,	2016).	The	 synthetic	progestins	DMPA	and	NET-EN	are	widely	 used	 in	 SSA	 because	 of	 their	 relatively	 long-acting	 nature,	 compared	 to	other	contraceptives	like	COCPs	which	need	to	be	taken	daily	(Heffron	et	al.,	2012;	UNDESA,	2015).	NET-EN	is	administered	bi-monthly,	while	DMPA	is	administered	every	 third	 month.	 Because	 of	 affordability,	 DMPA	 has	 been	 a	 popular	 product	offered	 in	 the	 public	 sector	 in	 developing	 countries,	 although	 NET-EN	 is	increasingly	being	used	at	higher	costs.			Despite	 the	 contraceptive	 benefits,	 there	 is	 public	 health	 concern	 that	 injectable	contraceptives	increase	a	woman’s	susceptibility	to	HIV	(Polis	et	al.,	2016).	It	has	been	 estimated	 that	 injectable	HCs	may	be	 responsible	 for	 up	 to	 130	000	HIV-1	infections	 per	 year	 globally	 (Butler	 et	 al.,	 2013).	 The	World	Health	Organization	recently	 reviewed	 their	 guidelines	 on	 the	 medical	 eligibility	 of	 DMPA	 for	contraceptive	use	and	stated	that	women	at	high	risk	for	HIV	acquisition	should	be	informed	of	 the	uncertainty	 regarding	 injectable	 contraceptives	 (WHO,	2015).	 In	support	 of	 this	 recommendation,	 the	 first	 multi-center,	 open-label,	 randomized	trial	 of	 DMPA	 versus	 other	 contraceptive	 methods	 (levonorgestrel	 implant	 and	copper	IUD)	on	HIV	outcomes	–	called	the	Evidence	for	Contraceptive	Options	and	HIV	Outcomes	(ECHO)	-	 is	under	way	and	the	eagerly	awaited	results,	which	will	be	announced	later	this	year,	will	provide	more	information	on	HIV	susceptibility	with	 the	 use	 of	 HCs	 (http://echo-consortium.com).	 Some	 of	 the	 biological	mechanisms	by	which	DMPA	use	is	thought	to	increase	HIV	susceptibility	include	suppression	 of	 local	 protective	 immunity,	 alteration	 in	 protective	 Lactobacilli-dominated	 vaginal	 microbiota,	 and	 elevated	 levels	 of	 mucosal	 inflammatory	cytokines	which	could	result	in	an	influx	of	HIV	target	cells	to	the	genital	mucosa	(Ghanem	et	al.,	2005;	Chandra	et	al.,	2013).		In	 contrast	 to	 injectable	 contraceptives	 like	 DMPA,	 a	 recent	 systematic	 review	found	 that	 COCPs	 did	 not	 similarly	 increase	 HIV	 risk	 (Polis	 et	 al.,	 2016).	 In	addition,	 this	 review	 also	 suggested	 that	 the	 available	 data	 on	 NET-EN	 do	 not	suggest	an	association	with	HIV	risk	in	women,	although	the	trend	was	positive.	In	
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a	population	that	has	a	high	HIV	prevalence,	it	is	important	to	answer	the	question	whether	HCs	increases	HIV	acquisition	and	provide	safer	options	for	women.	With	a	 variety	 of	 options	 to	 choose	 from,	 women	 should	 be	 able	 to	 make	 informed	decisions	 regarding	 the	 type	 of	 contraception	 to	 choose.	 The	 use	 of	 safe	 and	effective	 contraceptives	 in	 regions	 at	 the	 highest	 risk	 for	 HIV	 infections,	particularly	in	AGYW	is	a	global	health	priority.			NuvaRing®	 (containing	 etonogestrel	 and	 ethinyl	 estradiol),	 a	 hormonal	 vaginal	ring	 placed	 in	 the	 cervix	 for	 three	 weeks,	 has	 been	 recently	 licensed	 for	 use	 in	South	Africa,	adding	another	HC	option	for	women	in	South	Africa.	This	combined	contraceptive	vaginal	ring	(CCVR)	has	previously	been	found	to	increase	“healthy”	
Lactobacilli	abundance	 in	women	with	a	high	BV	prevalence	(Hardy	et	al.,	2017).	There	 is	 still	 limited	data	 on	how	CCVR	affect	 the	 immune	microenvironment	 of	the	genital	tract.		Stieh	 et	 al.	 (2016)	 recently	 reported	 that	 HIV	 preferentially	 infects	 Th17	 cells.	These	 cells	 are	 thought	 to	 be	 important	 in	 maintaining	 the	 mucosal	 epithelial	integrity,	 through	 cytokine	 and	 chemokine	 production	 (Dandekar	 et	 al.,	 2010).	Little	is	currently	known	about	how	this	highly	susceptible	CD4+	T	cell	population	in	the	genital	mucosa	is	affected	by	the	use	of	HCs.	The	primary	aim	of	this	Chapter	was	 therefore	 to	 compare	 the	 effects	 of	 NuvaRing,	 NET-EN	 and	 COCPs	 on	 Th17	cells	and	related	cytokines	in	the	genital	tract	of	adolescent	girls	in	an	open-label,	randomized	 crossover	 study	 conducted	 in	 Cape	 Town,	 South	 Africa.	 The	hypothesis	 is	 that	NuvaRing	would	 offer	 some	 safety	 advantage	 over	NET-EN	 in	terms	of	mucosal	inflammation	and	HIV	target	cell	activation.	
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4.3 Materials	and	Methods	
4.4.1 Study	design	
This	 cohort	 was	 a	 sub-study	 to	 an	 NIH-funded	 parent	 study	 called	 “Choices	 for	Adolescent	 Prevention	 Methods	 for	 South	 Africa	 (CHAMPS)”	 which	 aimed	 to	evaluate	 the	 acceptability,	 feasibility,	 and	 adherence	 to	 various	 HC	 choices	 in	AGYW,	with	the	view	to	extend	this	to	preferences	for	HIV	prevention	modalities	as	 more	 HIV	 prophylactic	 products	 are	 developed	 (PI:	 Prof	 Linda-Gail	 Bekker,	Desmond	 Tutu	 HIV	 Foundation,	 UCT).	 The	 study	 design	 was	 an	 open-label,	randomized	crossover	study	of	130	sexually	active	 female	adolescents	aged	15	–	19	years	from	Masiphumelele,	Cape	Town,	South	Africa.	Inclusion	criteria	included	being	HIV-negative,	non-pregnant,	seeking	hormonal	contraceptives	or	a	change	in	method,	 and	 willing	 to	 refrain	 from	 inserting	 non-study	 vaginal	 products	 or	objects	into	the	vagina	for	the	duration	of	the	study.	Exclusion	criteria	included	not	being	 sexually	 active,	 being	 HIV	 positive,	 having	 any	 symptomatic	 STIs	 or	 an	abnormal	Pap	smear,	a	positive	urine	pregnancy	test,	being	contra-indicated	to	any	study	 product,	 or	 if	 informed	 consent	 (adolescents	 ≥18	 years)	 or	 assent	 with	parental	consent	(adolescents	<18	years)	was	not	obtained.		After	the	screening	visit,	adolescents	who	met	the	inclusion	and	exclusion	criteria	returned	 within	 40	 days	 for	 enrolment	 into	 this	 study.	 After	 enrolment,	adolescents	were	randomly	assigned	in	a	1:1:1	ratio	to	one	of	the	three	study	arms,	according	to	the	following	schema	(Figure	4.1):		
• Arm	 1:	 Adolescents	 received	 injectable	 NET-EN	 (intramuscular	 injection	containing	200mg	of	progestogen	norethisterone	oenanthate)	once	every	8	weeks	for	4-months.	
• Arm	 2:	 Adolescents	 received	 the	 CCVR	 NuvaRingâ	 (Merck,	 Sharp	 and	Dohme,	 containing	 0.12mg	 etonogestrel	 and	 0.015mg	 ethinyl	 estradiol)	inserted	for	three	weeks	continuously	followed	by	one	ring	free	week	for	a	4-month	period.	The	 study	 clinicians	 carried	out	 vaginal	 examination	 and	removed	the	used	rings	(as	requested	by	participants).	
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• Arm	 3:	 Adolescents	 received	 COCPs	 (Nordetteâ	 or	 Triphasilâ).	 The	Triphasilâ	 regimen	 included	 six	 tablets	 containing	 30μg	 ethinyl	estradiol/50μg	 levonorgestrel	 (phase	 1),	 five	 tablets	 containing	 40μg	ethinyl	estradiol/75μg	levonorgestrel	(phase	2),	ten	tablets	containing	30μg	ethinyl	 estradiol/125μg	 levonorgestrel	 (phase	 3),	 and	 seven	 inert	 tablets.	The	 Nordetteâ	 regimen	 included	 26	 tablets	 containing	 30μg	 ethinyl	estradiol/150μg	 levonorgestrel,	 plus	 seven	 inert	 tablets.	 For	 both	 COCPs	products,	participants	were	required	to	take	a	daily	tablet	for	21	days	and	a	placebo	 tablet	 for	 seven	 days	 (day	 22-28)	 each	 month,	 for	 a	 16-week	period.			After	being	randomized	onto	each	of	these	contraceptive	methods	for	four	months,	adolescents	 crossed	 over	 to	 another	 form	 of	 HC	 (Figure	 4.1).	 Those	 receiving	either	NET-EN	or	the	daily	COCPs	(Arm	1	and	Arm	3,	respectively)	for	the	first	16	weeks	 of	 the	 study	 switched	 over	 to	 using	 the	 CCVR	 (Arm	2),	while	 adolescents	receiving	CCVR	as	the	first	method	were	given	the	choice	between	either	NET-EN	or	 the	 daily	 COCPs	 as	 their	 second	 method.	 After	 a	 total	 of	 32	 weeks,	 the	adolescents	returned	for	a	final	visit	at	the	clinic	and	exited	the	study.			
	
Figure	4.1.	Summary	of	the	randomized	cross	over	study	design	used	to	investigate	
the	effect	of	HCs	on	Th17	cells/Th17-related	 cytokines	 in	adolescents.	Adolescents	were	screened	and	the	eligible	ones	randomized	to	NET-EN,	NuvaRing	or	COCPs.	Samples	were	collected	at	the	screening	visit	(baseline),	after	four	months	on	randomized	product	(crossover),	and	after	crossover	to	an	alternative	HC	for	four	months	(exit).	
Screening		
Enrolment	&	
Randomization	(1:1:1)	
NET-EN	Arm	1	
NuvaRing	Arm	2	
COCPs	Arm	3	
NET-EN	Arm	1	
NuvaRing	Arm	1+3	
COCPs	Arm	3	
Crossover		
(Week	16)	
Exit	
(Week	32)	
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4.4.2 HIV	and	pregnancy	testing	
A	rapid	HIV	test	(Alere	DetermineTM	HIV-1/2	Ag/Ab	Combo;	Alere,	MA,	USA)	and	pregnancy	 test	 (U-test	 Pregnancy	 strip;	 Humor	 Diagnostica,	 Pretoria,	 SA)	 was	performed	 at	 all	 study	 visits	 (screening,	 enrolment,	 crossover	 and	 exit).	 If	 HIV	seroconversion	 occurred	 during	 the	 study,	 the	 participant	 was	 counselled	 and	referred	for	HIV	management	while	being	allowed	to	continue	her	participation	in	the	study.			
4.4.3 Sample	collection	
The	 following	 genital	 tract	 samples	 were	 collected	 in	 the	 following	 order	 at	screening,	crossover	and	exit:	1. Menstrual	 cup:	 Cervicovaginal	 secretions	 were	 collected	 by	 inserting	 a	menstrual	cup	(Softcup®)	for	30	minutes	(section	2.3.8).	These	were	used	to	analyse	Th17-related	cytokines	by	Luminex	(section	2.3.9).	2. STI	testing:	A	vulvovaginal	swab	was	collected	for	STI	testing	(section	2.3.4)	using	an	 in	house	validated	multiplex	PCR	assay,	which	was	performed	at	the	 STI	 Reference	 Laboratory	 at	 the	 NICD,	 Sandringham	 as	 previously	described	(Lewis	et	al.,	2012).	3. BV	Nugent	scoring:	Posterior	fornix	and	lateral	wall	swabs	were	collected	to	prepare	a	wet	mount	slide	for	BV	Nugent	scoring	by	Gram	staining,	and	for	detection	 of	 yeast	 hyphae	 and	 spores	 (section	 2.3.4).	 Nugent	 scoring	was	performed	 at	 the	 STI	 Reference	 Laboratory	 at	 the	 NICD,	 Sandringham,	Johannesburg.	4. Vaginal	microbiome:	A	lateral	vaginal	wall	swab	was	collected	for	16S	rRNA	and	shotgun	metagenomic	sequencing,	performed	by	Christina	Balle	(Dept	Immunology,	 UCT).	 The	 microbiome	 data	 will	 not	 be	 included	 in	 this	dissertation	as	it	formed	part	of	Christina	Balle’s	PhD	dissertation,	which	is	currently	being	examined.	5. Flow	 cytometry:	 An	 endocervical	 cytobrush	 (Digene®	 Corporation,	 MD,	USA)	 was	 collected	 for	 CMCs	 (section	 2.3.5),	 which	 were	 analysed	 using	flow	cytometry	(section	2.3.6).	
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4.4.4 BV	and	STI	diagnosis	
Collected	vulvovaginal	swabs	were	screened	for	C.	trachomatis,	N.	gonorrhoeae,	T.	
vaginalis	 and	M.	genitalium,	as	 described	 in	 section	 2.3.3.	 BV	 was	 diagnosed	 by	Gram	staining	using	Nugent’s	criteria,	as	described	in	section	2.3.4.		
4.4.5 Hormone	measurement	
Blood	 was	 collected	 using	 SST	 tubes	 to	 measure	 serum	 hormone	 levels.	Concentrations	of	E2,	LH	and	FSH	were	measured	in	blood	specimens,	which	was	measured	by	BARC,	as	described	previously	in	section	2.3.3.		
4.4.6 Flow	cytometry		
An	 endocervical	 cytobrush	 (Digene®	 Corporation)	 was	 collected	 from	 each	participant	 under	 speculum	 examination,	 and	 processed	 within	 4	 hours	 as	previously	 described	 in	 section	 2.3.4.	 CMCs	 were	 stained	 with	 the	 following	monoclonal	 antibodies:	 CD3,	 CCR6,	 CCR5	 (BD	 Biosciences);	 CD38	 (eBioscience);	CD4	 (Invitrogen);	 CD8,	 CCR10,	 HLA-DR	 (Biolegend)	 as	 previously	 described	 in	section	 2.3.5.	 A	 DUMP	 channel	 consisting	 of	 CD14,	 CD19	 (Invitrogen)	 and	 ViVid	(Life	 Technologies)	 was	 included	 to	 remove	 monocytes,	 B-cells	 and	 dead	 cells.	Th17-like	 cells	 were	 considered	 as	 those	 that	 expressed	 CCR6	 but	 not	 CCR10,	while	highly	activated	T	cells	were	considered	as	 those	that	expressed	CD38	and	HLA-DR.	CCR5	was	 included	as	 the	major	HIV	co-receptor	 involved	 in	viral	entry	during	 sexual	 transmission	 (Lopalco,	 2010).	A	 representative	 figure	 showing	 the	gating	strategy	is	shown	in	Chapter	2,	section	2.3.7.		
4.4.7 Cytokine	measurements	
The	concentrations	of	Th17-related	cytokines,	including	IL-17A,	IL-22,	IL-21,	IL-1β,	IL-4,	IL-6,	IL-10,	IL-17F,	IL-23,	IL-25,	IL-31,	IL-33,	IFN-γ,	sCD40L	and	TNF-α,	were	measured	 as	 described	 in	 section	 2.3.9,	 using	 the	 Bio-Plex	 Pro™	 Human	 Th17	cytokine	Luminex	kit	(Bio-Rad	Laboratories	Inc).	
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4.4.8 Statistical	analyses	
Statistical	 analysis	 was	 conducted	 using	 two	 different	 approaches:	 (1)	 within-subject	 assessment,	which	 compared	 intra-individual	 immunological	 phenotypes	before	and	after	initiation	of	contraception	method,	where	each	participant	served	as	 her	 own	 control;	 and	 (2)	 between	 study	 arms	 assessment,	 which	 compared	inter-individual	immunological	phenotypes	by	different	study	interventions	(NET-EN,	COCPs	and	NuvaRing).	A	Wilcoxon	matched-pairs	signed	rank	test	was	used	to	compare	individuals	within	each	study	arm	before	and	after	being	on	a	particular	contraceptive.	A	Mann-Whitney	U	test	was	applied	to	compare	the	three	HC	arms.	Data	were	analysed	as	both	intention	to	treat	(ITT)	and	per	protocol	(PP).	The	ITT	analysis	does	not	 take	 into	account	participants	who	deviated	 from	the	protocol,	and	analysis	is	based	on	the	arm	to	which	participants	were	initially	randomized.	The	PP	analysis	considered	participants	who	deviated	from	protocol,	and	they	are	analysed	according	to	the	actual	arm	(HC	product)	 they	used.	Statistical	analyses	were	performed	using	Prism	version	6	(GraphPad	Software,	CA,	USA),	and	STATA™	version	12	 (StataCorp,	TX,	USA).	All	 tests	were	 two	sided	and	a	p-value	of	≤0.05	was	 considered	 significant.	 Where	 stated,	 multiple	 comparisons	 were	 adjusted	using	the	Benjamini-Hochberg	procedure	(Benjamini	and	Hochberg,	1995).											
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4.4 Results	
4.4.1 Characteristics	of	study	participants	
One	 hundred	 and	 fifty-six	 adolescents	 were	 screened	 for	 this	 study.	 Of	 these,	130/156	 were	 enrolled.	 Of	 those	 that	 did	 not	 enroll,	 21/156	 (13%)	 were	 not	interested	 in	 the	 study,	 and	 5/156	 (3%)	 did	 not	 meet	 the	 enrolment	 criteria.	Reasons	for	not	including	these	five	adolescents	included	that	they	were	younger	than	15	years	at	the	time	of	screening	(n=1),	were	on	TB	treatment	(n=1),	anaemic	(n=1),	had	elevated	blood	pressure	(n=1),	or	raised	liver	function	(n=1).	The	130	adolescents	 who	 where	 eligible	 and	 enrolled	 were	 randomized	 to	 the	 three	hormonal	 contraceptive	 arms,	 with	 45/130	 being	 randomized	 to	 NuvaRing,	45/130	 to	 NET-EN,	 and	 40/130	 to	 COCPs	 (Figure	 4.2).	 Of	 these,	 108/130	completed	 visit	 2	 (83%),	 and	 93/130	 completed	 the	 final	 visit	 (72%).	 One	participant	assigned	to	the	NET-EN	arm	seroconverted	before	the	crossover	visit	and	mucosal	sampling	was	not	performed	at	the	crossover	and	exit	visits,	and	one	participant	withdrew	consent	 for	mucosal	 sample	collection	at	 the	exit	visit.	The	final	numbers	was	thus	107	at	crossover	and	92	at	exit.	A	total	of	nine	adolescents	deviated	 from	 the	 protocol:	 In	 the	 NuvaRing	 arm,	 one	 participant	 changed	 to	COCPs	and	three	changed	to	NET-EN	before	the	crossover	visit;	in	the	COCPs	arm,	one	 participant	 changed	 to	 NuvaRing	 and	 three	 changed	 to	 NET-EN	 before	 the	crossover	 visit;	 in	 the	 NET-EN	 arm,	 one	 participant	 deviated	 from	 protocol	 by	changing	 to	 COCPs.	 Some	 of	 the	 reasons	 for	 changing	 methods	 included	 poor	adherence	 (mainly	 in	 the	COCPs	arm),	discomfort	with	 study	product	 (mainly	 in	the	NuvaRing	arm)	and	spotting	(in	the	NET-EN	arm).		The	baseline	characteristics	of	the	cohort	are	summarized	in	Table	4.1.	There	was	no	 difference	 in	 baseline	 characteristics	 across	 arms	 (including	 age,	 endogenous	hormone	level,	BMI,	vaginal	pH,	genital	 infections,	BV,	prior	use	of	contraception,	sexual	 risk	 behaviour	 and	 intra-vaginal	 insertion	 practices).	 Although	 the	 initial	intent	was	to	recruit	adolescents	who	were	naïve	to	HCs	into	the	study,	very	few	adolescents	 in	 this	 age	 group	 in	 this	 community	 were	 not	 currently	 using	 HCs	(5/130).	As	a	result,	 the	protocol	had	to	be	amended	to	 include	adolescents	who	were	 otherwise	 eligible	 and	 considering	 method	 change,	 of	 whom	 none	 had	
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previously	used	NuvaRing	prior	to	study	initiation.	Within	the	age	group	enrolled,	the	majority	 of	 the	 adolescents	were	 not	 contraceptive	 naïve	 at	 enrolment,	with	the	majority	previously	using	NET-EN	(56%).				
	
Figure	4.2.	Flow	diagram	showing	number	of	the	adolescents	screened,	enrolled	and	
randomized	into	each	of	the	contraceptive	arms.	The	numbers	of	participants	excluded	or	 lost	 to	 follow	up	are	shown	 in	 the	dotted	rectangles.	Figures	 in	 red	 indicate	 the	 total	number	of	participants	at	each	visit.	
Enrolled	and	Randomized	
(n	=	130)	
COCPs	(n	=	40)																			NuvaRing	(n	=	45)															NET-EN	(n	=	45)	
35	at	crossover	*Received	allocated		intervention	(n	=	31)	
*Protocol	deviation	=	4		
Screening	(n	=156)	 Excluded:	26	-	5	failed	screening	-	17	unreachable	-	4	declined	participation	
Crossover	
(n	=	107)	
NuvaRing	
(n	=	47)	
NET-EN	
(n	=	33)	
COCPs	
(n	=	12)	
23	participants	were	lost	to	follow	up	
14	participants	were	lost	to	follow	up	
38	at	crossover	*Received	allocated		intervention	(n	=	34)	
*Protocol	deviation	=	4	
	
34	at	crossover	*Received	allocated		intervention	(n	=	33)	
*Protocol	deviation	=	1		
Exit	
(n	=	92)	
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	Table	4.1	Baseline	characteristics	of	adolescents	according	to	randomization	arm		
NuvaRing	n=45	 NET-EN	n=45	 COCPs	n=40	 P-value	Median	age	at	screening	 17	(16	–18)	 17	(16	–18)	 17	(16	–18)	 0.91	
Serum	hormone	concentration	
	 	 	 				E2	(pmol/l)	 97.0	(63.0–138.0)	 106.0	(85.2–157.8)	 90.5	(75.5–137.0)	 0.46				FSH	(U/L)	 4.7	(2.8–5.8)	 4.7	(3.6–5.8)	 5.5	(4.2–6.2)	 0.08				LH	(IU/l)	 4.4	(2.0–5.9)	 4.5	(2.0	–6.5)	 4.0	(2.0–5.4)	 0.93	BMI	(kg/m2)	 25.0	(22.1–27.8)	 25.0	(22.5–29.1)	 25.7	(21.5–28.3)	 0.75	Vaginal	pH	 4.7	(4.4–5.2)	 5.0	(4.7–5.3)	 4.7	(4.4–5.2)	 0.33	
Genital	infections	at	screening	
	 	 	 	
			Any	STIs	 19	(42.2%)	 22	(48.9%)	 15	(37.5%)	 0.48	
			Chlamydia	trachomatis	 14	(31.1%)	 17	(37.7%)	 12	(30.0%)	 0.70	
			Neisseria	gonorrhoeae	 5	(11.1%)	 5	(11.1%)	 3	(7.5%)	 0.97	
			Trichomonas	vaginalis	 4	(8.8%)	 5	(11.1%)	 4	(10.0%)	 0.75	
			Mycoplasma	genitalium	 0	(0.0%)	 2	(4.4%)	 1	(2.5%)	 0.36				HSV-2	serology	 12	(26.7%)	 13	(28.8%)	 14	(35.0%)	 0.49				Presence	of	yeast	hyphae	 10	(22.2%)	 4	(8.8%)	 6	(15.0%)	 0.22	
BV	status	
	 	 	 0.69				BV-	(Nugent	0-3)	 23	(51.1%)	 18	(40.0%)	 20	(48.8%)	 				Intermediate	(Nugent	4-6)	 3	(6.6%)	 7	(15.6%)	 4	(9.8%)	 				BV+	(Nugent	7-10)	 19	(43.2%)	 20	(44.4%)	 16	(40.0%)	 	
Prior	contraceptive	method	
	 	 	 0.44				Naive	 2	(4.4%)	 2	(4.4%)	 1	(2.5%)	 				Not	currently	 6	(13.3%)	 10	(22.2%)	 10	(25.0%)	 				DMPA	 5	(11.1%)	 7	(15.9%)	 7	(17.5%)	 				NET-EN	 28	(62.2%)	 21	(46.7%)	 20	(50.0%)	 				COCPs	 3	(6.7%)	 2	(4.5%)	 1	(2.5%)	 				Implanon	 1	(2.2%)	 2	(4.5%)	 0	(0.0%)	 	
Sexual	risk	behaviour	
	 	 	 				Age	of	sexual	debut	 15	(14	–16)	 15	(14	–16)	 15	(14	–16)	 0.97				Condom	use	always			 61.4%	 61.9%	 60.9%	 0.99				Multiple	sexual	partners	 0	(0.0%)	 1	(2.2%)	 0	(0.0%)	 1.00				Number	of	sexual	partners	 1	(1-1)	 1	(1-2)	 1	(1-1)	 0.16	
Vaginal	practices	
	 	 	 				Use	of	any	products	 1	(4.6%)	 4	(8.8%)	 2	(2.5%)	 0.50				Washing	with	soap	 4	(8.8%)	 6	(13.3%)	 2	(5.1%)	 0.47				Tampon	use	 2	(4.6%)	 5	(11.1%)	 1	(2.5%)	 0.28				Washing	with	water	 5	(11.1%)	 6	(13.3%)	 5	(12.8%)	 1.00				Douching	 0	(0.0%)	 1	(2.2%)	 0	(0.0%)	 1.00	BV,	 bacterial	 vaginosis;	 BMI,	 body	 mass	 index;	 E2,	 estradiol;	 S-FSH,	 follicle	 stimulating	 hormone;	 LH,	luitenizing	hormone	
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4.4.2 Baseline	genital	cytokine	profiles	by	randomization	arm	
To	evaluate	potential	differences	in	cytokine	profiles	in	adolescents	randomized	to	the	three	study	arms,	Th17-related	cytokine	concentrations	were	measured	in	menstrual	cup	secretions	at	baseline.	No	significant	differences	were	noted	in	the	concentration	of	any	of	the	fifteen	Th17-related	cytokine	between	study	arms	at	baseline	(Figure	4.3).			
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Figure	4.3.	Comparison	of	genital	Th17-related	cytokines	at	baseline,	stratified	by	
study	 arm.	Based	 on	 their	 functional	 relatedness	 to	 Th17	 cells,	 cytokines	 have	 been	divided	into	those	produced	by	Th17	cells	(first	column;	including	IL-17A,	IL-17F,	IL-21,	IL-22),	and	those	involved	in	their	differentiation	(second	column;	including	IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α)	and	those	involved	in	their	regulation	(third	column;	including	IL-4,	IL-10,	 IL-25,	 IL-31,	 IFN-γ).	 Pink	 boxes	 indicate	 adolescents	 randomized	 to	 NuvaRing,	blue	boxes	indicate	adolescents	randomized	to	NET-EN,	and	green	boxes	indicate	those	randomized	 to	 COCPs.	 A	 Mann-Whitney	 U	 test	 was	 used	 to	 compare	 medians	 with	p≤0.05	being	considered	significant.	No	significant	differences	were	noted.			
4.4.3 Baseline	genital	Th17	cell	frequencies	and	activation	did	
not	differ	by	study	arm	prior	to	randomization	
The	phenotype	and	 level	of	activation	of	genital	mucosal	Th17	cells	at	baseline	was	initially	characterized	to	confirm	that	Th17	cells	did	not	differ	by	study	arm,	prior	to	randomizations.	The	cell	count	(per	cytobrush)	and	relative	frequency	of	Th17	 cells	 (of	 total	 CD4+	 T	 cells)	 was	 the	 same	 across	 arms,	 with	 an	 overall	median	 frequency	 of	 54.0%	 (IQR	 44.0%	 -	 64.3%;	 Figure	 4.4)	 being	 R6+R10+	(Th17-like).	 Expression	 of	 CCR5	 and	 activation	 markers	 (CD38,	 HLA-DR)	 was	also	similar	across	arms	(data	not	shown).			
	
Figure	4.4.	Comparison	of	Th17	cell	frequency	and	number	at	baseline,	according	
to	 contraceptive	 arm.	 (A)	 Frequency	 of	 Th17	 cells	 (expressed	 as	 proportion	 of	R6+R10-	CD4+	T	cells	in	a	cytobrush).	(B)	Total	counts	of	Th17	cells	per	cytobrush.	Pink	boxes	 indicate	 adolescents	 randomized	 to	 NuvaRing,	 blue	 boxes	 indicate	 adolescents	
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randomized	to	NET-EN,	and	green	boxes	indicate	those	randomized	to	COCPs.	The	box	and	 whisker	 plots	 show	 the	 median	 (middle	 line),	 IQR	 (boxes)	 and	 whiskers	 extend	between	 the	 minimum	 and	 maximum	 values.	 A	 Mann-Whitney	 U	 test	 was	 used	 to	compare	medians	with	 a	 p	 value	 of	 ≤0.05	 being	 considered	 significant.	No	 significant	differences	were	noted.			
4.4.4 Impact	of	HC	arm	on	genital	Th17-related	cytokine	
concentrations:	the	crossover	visit		
Adolescents	were	randomized	to	one	of	the	three	HC	products	for	four	months,	returning	 to	 the	 clinic	 for	 an	 HC	 crossover	 visit.	 The	 following	 ITT	 and	 PP	analyses	focused	on	the	crossover	visit,	where	measurements	were	made	before	the	 adolescents	 crossed	over	 to	 another	product.	 In	 the	 ITT	analysis,	 data	was	analysed	according	to	randomization,	while	in	the	PP	analysis,	data	was	analysed	according	to	the	actual	HC	the	participants	were	on	(detailed	in	section	4.3.8).		Alteration	of	cytokines	in	the	genital	tract	may	have	significant	effect	on	HIV	risk	in	women	(Masson	et	al.,	2015a;	Passmore	et	al.,	2016;	McKinnon	et	al.,	2018).	Of	the	 cytokines	produced	by	Th17	 cells	 (IL-17A,	 IL-17F,	 IL-21,	 IL-22),	 IL-21	was	significantly	 elevated	 in	 genital	 secretions	 in	 adolescents	 who	 used	 NuvaRing	(p=0.009;	 Figure	 4.5A).	 In	 addition,	 several	 of	 the	 cytokines	 involved	 in	differentiation	 and	 regulation	 of	 Th17	 cells	 (including	 IL-1β	 [p=0.007],	 IL-33	[p=0.04],	 IL-4	 [p=0.02],	 TNF-α	 [p=0.01],	 IFN-γ	 [p=0.01],	 and	 sCD40L	 [p=0.02])	were	 significantly	 elevated	 in	 genital	 secretions	 from	 adolescents	 using	NuvaRing	 (Figure	 4.5B	 and	 C).	 IL-21,	 IL-1β,	 IFN-γ	 and	 TNF-α	 remained	significant	 after	 adjusting	 for	 multiple	 comparisons.	 Adjusting	 for	 protocol	violations	(early	change	in	HC),	the	PP	analysis	showed	similar	results	(data	not	shown).			In	 contrast	 to	 NuvaRing,	 NET-EN	 and	 COCPs	 use	was	 not	 associated	with	 any	significant	 changes	 in	 Th17-related	 cytokine	 concentrations	within	 individuals	before	 and	 after	 randomization	 (Figure	 4.6	 and	 4.7,	 respectively).	 In	 an	 ITT	
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analysis	comparing	these	three	HCs	cross-sectionally	at	week	16,	adolescents	on	NuvaRing	 had	 elevated	 IL-17A	 (p=0.009),	 IL-17F	 (p=0.03),	 IL-21	 (p=0.03)	 and	IL-33	 (p=0.03)	 compared	 to	 those	 on	 NET-EN;	 while	 IL-21	 (p=0.04),	 IL-6	(p=0.03),	 IL-1β	 (p=0.03)	 and	 TNF-α	 (p=0.04)	were	 elevated	 in	 adolescents	 on	NuvaRing	 compared	 to	 those	 on	 COCPs	 (Appendix	 Table	 A2).	 None	 of	 these	observations	remained	significant	after	adjusting	for	multiple	comparisons.			
	
Figure	 4.5.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	
(black	 dots)	 and	 after	 using	 NuvaRing	 for	 16	weeks	 (pink	 dots).	Cytokines	 have	been	divided	based	on	their	role	in	Th17	cell	regulation	or	differentiation:	(A)	Cytokines	produced	by	Th17	cells.	(B)	Cytokines	involved	in	the	differentiation	of	Th17	cells.	(C)	Cytokines	 involved	 in	 the	 regulation	 of	 Th17	 cells.	 Black	 circles	 indicate	 cytokine	concentrations	prior	to	using	NuvaRing	while	pink	circles	indicate	concentrations	after	four	months	of	NuvaRing.	Black	lines	link	paired	data	points	in	an	individual	adolescent	before	 and	 after	 using	 NuvaRing.	 Cytokine	 concentrations	 were	 compared	 using	 a	
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Wilcoxon	matched-pairs	signed	rank	test,	and	only	significant	p-values	are	displayed	(p	≤0.05).	 Cytokines	 highlighted	 by	 the	 grey	 shaded	 box	 remained	 significant	 after	adjusting	for	multiple	comparisons.						
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.6.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	
(black	dots)	and	after	using	NET-EN	for	16	weeks	(blue	dots).	Cytokines	have	been	divided	 based	 on	 their	 role	 in	 Th17	 cell	 regulation	 or	 differentiation:	 (A)	 Cytokines	produced	by	Th17	cells.	(B)	Cytokines	involved	in	the	differentiation	of	Th17	cells.	(C)	Cytokines	 involved	 in	 the	 regulation	 of	 Th17	 cells.	 Black	 circles	 indicate	 cytokine	concentrations	 prior	 to	 using	NET-EN	while	 blue	 circles	 indicate	 concentrations	 after	four	months	of	NET-EN.	Black	 lines	 link	paired	data	points	 in	an	individual	adolescent	before	 and	 after	 using	 NET-EN.	 Cytokine	 concentrations	 were	 compared	 using	 a	Wilcoxon	matched-pairs	 signed	 rank	 test,	 and	 only	 significant	 p-values	 are	 displayed	(p≤0.05).				
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Figure	 4.7.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	
(black	dots)	and	after	using	COCPs	for	16	weeks	(green	dots).	Cytokines	have	been	divided	 based	 on	 their	 role	 in	 Th17	 cell	 regulation	 or	 differentiation:	 (A)	 Cytokines	produced	by	Th17	cells.	(B)	Cytokines	involved	in	the	differentiation	of	Th17	cells.	(C)	Cytokines	 involved	 in	 the	 regulation	 of	 Th17	 cells.	 Black	 circles	 indicate	 cytokine	concentrations	 prior	 to	 using	 COCPs	while	 green	 circles	 indicate	 concentrations	 after	four	months	 of	 COCPs.	 Black	 lines	 link	 paired	 data	 points	 in	 an	 individual	 adolescent	before	and	after	using	COCPs.	Cytokine	concentrations	were	compared	using	a	Wilcoxon	matched-pairs	signed	rank	test.	Only	significant	p-values	are	displayed	(p≤0.05).			
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4.4.5 Impact	of	HC	arm	on	genital	Th17	cell	frequencies	and	
activation	status:	the	crossover	visit		
The	 impact	 of	NuvaRing	on	 genital	 Th17	 cell	 frequencies	 and	 activation	 status	within	participants	was	 investigated	next,	where	each	adolescent	was	her	own	baseline	 control.	 In	 the	 ITT	 analysis,	 a	 significant	 decrease	 in	 the	 frequency	 of	genital	 Th17	 cells	 was	 observed	 after	 four	months	 on	 NuvaRing	 (Figure	 4.8A;	p=0.001;	 adj.	 p=0.008).	 In	 addition,	 the	 frequency	 of	 CD4+	 T	 cells	 was	 also	reduced	within	the	NuvaRing	arm	(p=0.03;	data	not	shown).	While	the	frequency	of	 Th17	 cells	 were	 reduced	 following	 NuvaRing	 use,	 an	 increase	 in	 highly-activated	cervical	Th17	cell	 frequencies	was	noted	(HLA-DR/CD38;	p=0.02;	adj.	p=0.08),	 including	 those	expressing	 the	HIV	 co-receptor	 (HLA-DR/CD38/CCR5;	p=0.01;	adj.	p=0.04).	The	PP	analysis	showed	similar	results.		Cervical	Th17	frequencies	tended	to	be	lower	after	COCPs	use	within	individuals	(Figure	 4.8B),	 although	 their	 activation	 status	was	 similar.	 The	 use	 of	NET-EN	did	not	influence	the	frequency	or	the	expression	of	CCR5	on	Th17	cells	(Figure	4.8C);	however,	Th17	cells	 tended	 to	be	more	activated	after	being	on	NET-EN	(HLA-DR/CD38;	p=0.03;	adj.	p=0.1).			Although	 the	 impact	 of	 NuvaRing	 (Figure	 4.8A)	 on	 the	 frequency	 of	 cervical	CD4+	T	cells	 that	were	Th17	cells	and	their	 level	of	activation	(HLA-DR/CD38)	appeared	 to	 be	 more	 dramatic	 compared	 to	 NET-EN	 (Figure	 4.8C)	 or	 COCPs	(Figure	4.8B),	this	was	not	significant	across	HC	arms	(data	not	shown).				
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Figure	4.8.	Phenotype	of	Th17	cells	before	(baseline)	and	after	(16	weeks)	being	
on	 (A)	 NuvaRing	 (B)	 COCPs	 and	 (C)	 NET-EN.	 The	 frequencies	 of	 Th17	 cells	 and	expression	of	CCR5,	CD38	and	HLA-DR	on	these	cells	were	assessed	before	and	after	16	weeks	 of	 adolescents	 being	 on	 the	 randomized	 HC.	 Pink	 boxes	 indicate	 adolescents	randomized	 to	NuvaRing,	blue	boxes	 indicate	adolescents	randomized	 to	NET-EN,	and	green	boxes	indicate	those	randomized	to	COCPs.	A	Wilcoxon	matched-pairs	signed	rank	test	was	applied	and	a	p-value	≤0.05	was	considered	significant.						
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4.4.6 Changes	in	Th17	cells	and	Th17-related	cytokines	in	
participants	changing	between	HCs	
Changes	 in	 Th17-related	 cytokines	 in	 participants	 changing	 from	NuvaRing	 to	NET-EN,	 NuvaRing	 to	 COCPs,	 NET-EN	 to	 COCPs	 and	 vice	versa	at	 all	 the	 three	visits	 were	 investigated.	 After	 adjusting	 for	 multiple	 comparisons,	 IL-21	(p=0.011),	 IL-6	 (p=0.003),	 IL-1β	 (p=0.003),	 IL-33	 (p=0.010),	 TNF-α	 (p=0.025),	IL-25	 (p=0.028)	 and	 IFN-γ	 (p=0.025)	were	 elevated	 in	 participants	when	 they	were	 on	 NuvaRing	 compared	 to	when	 the	 same	 participants	were	 on	 NET-EN	(Figure	 4.9).	 Except	 for	 IL-4,	 all	 other	 Th17-related	 cytokines	 were	 elevated	when	 participants	were	 on	 NuvaRing	 compared	 to	when	 they	were	 on	 COCPs	(Figure	4.10).	In	contrast,	no	significant	differences	in	the	concentration	of	Th17-related	cytokines	 in	participants	changing	 from	NET-EN	to	COCPs	or	vice	versa	were	observed	(Figure	4.11).	
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Figure	 4.9.	 Th17-related	 cytokines	 (A)	 those	 produced	 by	 Th17	 cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	 cells,	 in	 adolescents	 changing	 from	NuvaRing	 to	NET-EN	and	
vice	versa.	A	Wilcoxon	matched-pairs	signed	rank	test	was	applied	and	a	p-value	≤0.05	was	 considered	 significant.	 Only	 significant	 p-values≤0.05	 are	 displayed	 and	 those	indicated	by	a*	remained	significant	after	adjusting	for	multiple	comparisons.	
0.01
0.1
1
10
100
1000
IL-17A
	(pg/m
l)
0.001
0.01
0.1
1
10
100
1000
10000
IL-1β	(
pg/ml)
*	p	=	0.003
0.001
0.01
0.1
1
10
100
1000
IL-10	(
pg/ml)
0.1
1
10
100
1000
IL-17F
	(pg/m
l)
0.1
1
10
100
1000
IL-23	(
pg/ml)
0.001
0.01
0.1
1
10
IL-25	(
pg/ml)
*	p	=	0.028
0.001
0.01
0.1
1
10
100
IL-21	(
pg/ml)
*	p	=	0.011
0.1
1
10
100
IL-33	(
pg/ml)
*	p	=	0.010
1
10
100
1000
IL-31	(
pg/ml)
*	p	=	0.028
0.01
0.1
1
10
100
1000
IL-22	(
pg/ml)
NuvaRing	
NET-EN
0.001
0.01
0.1
1
10
100
1000
10000
TNF-α	
(pg/ml
)
*	p	=	0.025
0.01
0.1
1
10
100
1000
sCD40L
	(pg/m
l)
0.001
0.01
0.1
1
10
100
1000
IL-6	(p
g/ml)
*	p	=	0.003
0.01
0.1
1
10
100
IL-4	(p
g/ml)
0.01
0.1
1
10
100
IFN-γ	(
pg/ml)
*	p	=	0.025
A	
B	
C	
Cytokines	produced	by	Th17	cells	
Cytokines	involved	in	Th17	differentiation	
Cytokines	involved	in	regulating	Th17	cells	
	 124	
	
	Figure	4.10.	Th17-related	cytokines	 (A)	 those	produced	by	Th17	cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	cells,	in	adolescents	changing	from	NuvaRing	to	COCPs	and	vice	
versa.	A	Wilcoxon	matched-pairs	signed	rank	test	was	applied	and	a	p-value	≤0.05	was	considered	 significant.	 All	 p-values	 remained	 significant	 after	 adjusting	 for	 multiple	comparisons	(indicated	by	*).			
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Figure	4.11.	Th17-related	 cytokines	 (A)	 those	produced	by	Th17	 cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	cells,	 in	adolescents	changing	from	NET-EN	to	COCPs	and	vice	
versa.	A	Wilcoxon	matched-pairs	signed	rank	test	was	applied	and	a	p-value	≤0.05	was	considered	significant.	Only	significant	p-values	are	displayed.				In	a	paired	analysis,	 the	phenotype	of	Th17	cells	 in	adolescents	 changing	 from	NuvaRing	to	COCPs,	NET-EN	to	COCPs	and	NuvaRing	to	NET-EN	or	vice	versa	was	assessed	 at	 all	 the	 three	 combined	 visits.	 Similar	 to	 the	 reduction	 in	Th17	 cell	frequencies	in	adolescents	initiated	on	NuvaRing	(at	crossover;	Figure	4.8A),	the	frequency	 of	 Th17	 cells	 was	 significantly	 reduced	 when	 participants	 were	 on	NuvaRing	compared	to	when	the	same	participants	were	on	NET-EN	(p=0.0002,	adj.	 p=0.001).	 Moreover,	 activated	 Th17	 cells	 expressing	 CCR5/HLA-DR/CD38	also	 tended	 to	be	elevated	when	participants	were	on	NuvaRing	 (p=0.020,	 adj.	p=0.1;	 Figure	 4.12A).	 There	 was	 no	 significant	 difference	 in	 participants	changing	 from	 NuvaRing	 to	 COCPs	 and	 vice	 versa	 (Figure	 4.12B),	 and	 those	changing	from	NET-EN	to	COCPs	and	vice	versa	(Figure	4.12C).		
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Figure	 4.12.	 Phenotype	 of	 Th17	 cells	 in	 participants	 who	 changed	 between	
different	HCs.	(A)	Participants	who	changed	from	NuvaRing	to	NET-EN	and	vice	versa.	Data	 from	 38	 participants	 is	 included.	 (B)	 Participants	 who	 changed	 from	 COCPs	 to	NuvaRing	 and	 vice	versa.	 Data	 from	 16	 participants	 is	 included.	 (C)	 Participants	 who	changed	 from	NET-EN	 to	COCPs	and	vice	versa.	Data	 from	19	participants	 is	 included.	Wilcoxon	 matched-pairs	 signed	 rank	 test	 was	 applied.	 Only	 significant	 p-values	 are	displayed	 on	 the	 graph,	 and	 those	 in	 bold	 remained	 significant	 after	 adjusting	 for	multiple	comparisons.	
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4.4.7 Longitudinal	changes	in	genital	Th17	cells	and	Th17-
related	cytokines	across	the	three	visits	
Changes	 in	 Th17	 cells	 and	 Th17-related	 cytokines	 with	 the	 use	 of	 HCs	 were	investigated	across	 the	 three	visits	 in	 all	 the	available	participants,	 and	also	 in	matched	participants	from	baseline	to	the	exit	visit,	to	evaluate	whether	the	shift	from	 one	 contraceptive	 method	 and	 back	 again	 influenced	 activation	 or	frequencies	 of	 Th17	 cells	 or	 changes	 in	 cytokine	 profiles.	 This	 longitudinal	analysis	focused	on	the	Th17-related	cytokines	that	changed	significantly	in	the	NuvaRing	arm	analyses	shown	 in	Figure	4.14	(including	 IL-17A,	 IL-21,	 IL-6,	 IL-1β,	IL-23,	IL-33,	IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ,	TNF-α,	and	sCD40L).			
4.4.7.1 	NuvaRing	first	(16	weeks)	to	NET-EN	or	COCPs	(32	weeks)	For	 adolescents	 randomized	 on	 NuvaRing	 and	 subsequently	 swopped	 to	 NET-EN,	 there	was	a	significant	difference	 in	 the	 frequency	of	Th17	cells	across	 the	three	visits	(p=0.0003;	Figure	4.13	left	panel),	and	increased	expression	of	HLA-DR/CD38	 and	 CCR5/HLA-DR/CD38	 (p=0.02	 and	 0.01,	 respectively).	 In	 the	matched	analysis,	a	decrease	in	the	frequency	of	Th17	cells	(p=0.04;	Figure	4.13	middle	panel)	and	increased	expression	of	HLA-DR/CD38	on	these	cells	(p=0.04)	at	 week	 16	 was	 observed,	 which	 did	 not	 return	 to	 baseline	 levels	 when	participants	 swopped	 to	 NET-EN	 (p=0.01	 and	 p=0.02,	 respectively).	 For	adolescents	randomized	on	NuvaRing	and	subsequently	swopped	to	COCPs,	due	to	sample	size,	only	matched	analysis	was	performed	(Figure	4.13	right	panel).	For	 the	 4	 participants	 available,	 there	 was	 a	 trend	 towards	 a	 decreased	frequency	of	Th17	cells	 at	week	16	on	NuvaRing,	 and	 this	was	not	 restored	 to	baseline	 levels	 when	 participants	 swopped	 to	 COCPs.	 However,	 these	 results	should	be	treated	with	caution	due	to	small	numbers.					
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Figure	 4.13.	 Longitudinal	 changes	 in	 phenotype	 and	 activation	 of	 cervical	 Th17	
cells	in	adolescents	randomized	to	use	NuvaRing	first	and	then	either	crossing	to	
NET-EN	(left	panel)	or	COCPs	 (right	panel).	 (A	 left	 panel)	 Participants	 that	 crossed	over	to	NET-EN	(baseline	n=21,	crossover	n=18,	exit	n=17).	Mann-Whitney	U	test	was	applied	to	compare	the	groups.	(A	middle	panel)	Paired	participants	for	all	visits	(n=14).	(B)	 Participants	 that	 crossed	 over	 to	 COCPs	 (n=4).	 Each	 line	 connects	 a	 single	participant	 across	 all	 the	 three	 visits.	 Box	 and	 whiskers	 show	 the	 median,	 IQR	 and	range.	 Wilcoxon	 matched-pairs	 signed	 rank	 test	 was	 applied	 to	 compare	 matched	samples.			In	matched	samples	from	adolescents	using	NuvaRing	first,	IL-6,	IL-1β	and	IL-33	were	 significantly	 elevated	 compared	 to	 baseline	 (p=0.02,	 p=0.04,	 p=0.05	
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respectively;	 Figure	 4.14),	 and	 subsequently	 decreased	when	 they	 swopped	 to	NET-EN	 even	 after	 adjusting	 for	multiple	 comparisons	 (p=0.001,	 adj.	 p=0.006;	p=0.006,	adj.	p=0.02;	p=0.001,	adj.	p=0.006,	respectively).	This	same	pattern	was	observed	in	the	unmatched	analysis	for	these	three	cytokines	(IL-6,	IL-1β,	IL-33).	Genital	 concentrations	 of	 INF-γ	 also	 increased	 at	 week	 16	 after	 NuvaRing	 use	(p=0.04)	and	decreased	at	week	32	after	NET-EN	use	(p=0.003,	adj.	p=0.01)	 in	the	 matched	 analysis.	 Furthermore,	 adolescents	 had	 a	 significant	 decrease	 in	genital	concentrations	of	 IL-21	(p=0.001),	 IL-23	(p=0.009),	 IL-4	(p=0.01),	 IL-10	(p=0.006),	 IL-25	 (p=0.006),	 IL-31	 (p=0.001),	 TNF-α	 (p=0.006)	 and	 sCD40L	(p=0.05)	when	they	swopped	from	NuvaRing	to	NET-EN	in	the	matched	analysis,	and	they	remained	significant	after	adjusting	for	multiple	comparisons	except	for	IL-4	and	sCD40L.		
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Figure	 4.14.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	NuvaRing	and	who	subsequently	crossed	over	
to	 NET-EN.	 Matched	 samples	 were	 compared	 from	 baseline	 to	 exit	 (n=14)	 using	 a	
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Wilcoxon	matched-pairs	sign	ranked	test.	Unmatched	samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=24,	crossover	n=22,	exit	n=22).				In	adolescents	who	initially	used	NuvaRing	and	subsequently	swopped	to	COCPs,	no	significant	changes	in	genital	cytokine	concentrations	were	observed	(Figure	4.15).	Numbers	were	small	for	this	analysis	and	should	be	treated	with	caution	(n=4	 matched;	 n=7-8	 all).	 However,	 cytokine	 concentrations	 appeared	 to	 be	elevated	after	using	NuvaRing	for	16	weeks	and	these	appeared	to	be	lower	after	switching	 to	 COCPs	 for	 only	 a	 subset	 of	 cytokines	 (including	 IL-4,	 IL-10,	 IL-1β	and	sCD40L,	Figure	4.15),	although	not	significantly.		
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Figure	 4.15.	 Longitudinal	 changes	 in	 cervical	 Th17-related	 cytokine	
concentrations	 in	 adolescents	 initially	 randomized	 to	 NuvaRing	 and	 who	
subsequently	crossed	over	to	COCPs.	Matched	samples	were	compared	from	baseline	
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to	 exit	 (n=4)	using	a	Wilcoxon	matched-pairs	 signed	 ranked	 test.	Unmatched	 samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=7,	crossover	n=8,	exit	n=8).				
4.4.7.2 NET-EN	first	(16	weeks)	to	NuvaRing	(32	weeks)	For	adolescents	initially	randomized	to	NET-EN	and	then	swopped	to	NuvaRing,	no	significance	difference	in	the	frequency	of	Th17	cells	was	observed	in	NET-EN	users	 compared	 to	baseline,	 although	Th17	 cells	were	 reduced	 in	 frequency	at	week	32	after	switching	to	NuvaRing	(p=0.02;	Figure	4.16	left	panel).	Moreover,	expression	 of	 activation	markers	 (HLA-DR/CD38)	 on	 cervical	 Th17	 cells	 were	significantly	higher	at	week	16	(p=0.01)	than	baseline	and	week	32	on	NuvaRing	(p=0.006).	 In	 a	 paired	 analysis,	 adolescents	 who	 swopped	 to	 NuvaRing	 at	crossover	 (using	 the	CCVR	 from	16-32	weeks)	 tended	 to	have	decreased	Th17	frequencies	 at	 study	 exit	 and	 elevated	 co-expression	 of	 HLA-DR/CD38	 and	CCR5/HLA-DR/CD38	(Figure	4.16	right	panel).																									
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Figure	4.16.	Changes	in	phenotype	and	activation	of	cervical	Th17	cells	across	the	
three	visits	[baseline	(0),	crossover	(16)	and	exit	(32)]	of	adolescents	randomized	
to	NET-EN	first	and	then	crossing	over	to	NuvaRing.	Left	panel	shows	the	data	for	all	participants	 from	 baseline	 to	 exit	 visit	 (baseline	 n=31,	 crossover	 n=21,	 exit	 n=21).	Mann-Whitney	 U	 test	was	 applied	 to	 compare	 the	 groups.	 Right	 panel	 column	 shows	only	 paired	 participants	 for	 all	 visits	 (n=8	 for	 each	 visit).	 Each	 line	 connects	 a	 single	participant	 across	 all	 the	 three	 visits.	 Box	 and	 whiskers	 show	 the	 median,	 IQR	 and	range.	 Wilcoxon	 matched-pairs	 signed	 rank	 test	 was	 applied	 to	 compare	 matched	samples.		
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	In	adolescents	randomized	to	NET-EN	and	subsequently	swopped	to	NuvaRing,	no	 significant	 changes	 in	 genital	 cytokine	 concentrations	 were	 observed	compared	to	baseline,	and	when	they	swopped	over	to	NuvaRing	(Figure	4.17).	Although	IL-6	and	IL-33	tended	to	be	elevated	when	matched	participants	were	on	 NuvaRing	 at	 week	 32	 compared	 to	 week	 16	 and	 baseline.	 Due	 to	 a	 small	sample	size,	participants	changing	from	NET-EN	to	COCPs	were	not	investigated.	
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Figure	 4.17.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	NET-EN	and	who	subsequently	crossed	over	to	
NuvaRing.	 Matched	 samples	 were	 compared	 from	 baseline	 to	 exit	 (n=12)	 using	 a	
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Wilcoxon	matched-pairs	sign	ranked	test.	Unmatched	samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=23,	crossover	n=26,	exit	n=23).				
4.4.7.3 COCPs	first	(16	weeks)	to	NuvaRing	(32	weeks)	For	participants	 randomized	 to	COCPs	 first	 and	who	 then	 crossed	 to	using	 the	NuvaRing,	frequencies	of	cervical	Th17	cells	remained	unchanged	after	16	weeks	of	COCPs	although	 these	decreased	after	 swopping	 to	NuvaRing	 for	 the	second	phase	of	 the	study	 (to	32	weeks;	p=0.01;	Figure	4.18	 left	panel).	Expression	of	CCR5	 on	 Th17	 cells	 was	 elevated	 after	 using	 COCPs	 for	 16	 weeks	 (p=0.006),	which	remained	elevated	to	32	weeks	(after	swopping	to	NuvaRing).	While	this	increase	 in	 expression	 of	 CCR5	 was	 significant	 in	 the	 unpaired	 analysis	 that	included	all	participants,	 it	was	not	significant	 in	the	paired	analysis	(including	12	 adolescents	 for	 whom	matched	 samples	 were	 available	 at	 all	 visits,	 Figure	4.17	right	panel).		For	Th17-related	cytokines,	no	significant	changes	were	observed	from	baseline	to	 week	 16	 after	 participants	 have	 been	 on	 COCPs	 (Figure	 4.19).	 However,	 a	significant	 increase	 in	 IL-6	 and	 IL-1β	 was	 observed	 in	 both	 the	 matched	(p=0.007	 and	 p=0.0003,	 respectively)	 and	 unmatched	 analyses	 (p=0.03	 and	p=0.04,	respectively)	at	week	32	when	adolescents	have	swopped	and	been	on	NuvaRing.	 IL-17A	 (p=0.01,	 adj.	 p=0.01),	 IL-21	 (p=0.003,	 adj.	 p=0.009),	 IL-23	(p=0.0007,	 adj.	 p=0.002),	 IL-33	 (p=0.02,	 adj.	 p=0.02),	 IL-25	 (p=0.008,	 adj.	p=0.01),	 IL-31	 (p=0.03,	 adj.	 p=0.03),	 IFN-γ	 (p=0.0005,	 adj.	 p=0.002),	 TNF-α	(p=0.01,	adj.	p=0.01)	and	sCD40L	(p=0.003,	adj.	p=0.009)	were	elevated	at	week	32	on	NuvaRing,	and	those	with	adjusted	p-values	(adj.	p)	remained	significant.	Only	3	samples	were	available	for	adolescents	who	swopped	from	COCPs	to	NET-EN,	and	therefore,	no	analysis	was	performed	(data	not	shown).						
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Figure	4.18.	Changes	in	the	phenotype	and	activation	of	cervical	Th17	cells	across	
the	 three	 visits	 [baseline	 (0),	 crossover	 (16)	 and	 exit	 (32)]	 in	 adolescents	
randomized	 initially	 to	 use	 COCPs	 and	 who	 subsequently	 crossed	 over	 to	
NuvaRing.	 Left	 panel	 shows	 the	 data	 from	 all	 participants	 from	 baseline	 to	 exit	(baseline	 n=20,	 crossover	 n=22,	 exit	 n=16).	 A	 Mann-Whitney	 U	 test	 was	 applied	 to	compare	 the	 groups.	 Right	 panel	 shows	 only	 paired	 participants	 for	 all	 visits	 (n=12).	Each	line	connects	a	single	participant	across	all	the	three	visits.	Box	and	whiskers	show	the	median,	 IQR	and	range.	A	Wilcoxon	matched-pairs	signed	rank	test	was	applied	to	compare	matched	samples.			
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	Figure	 4.19.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	COCPs	and	who	subsequently	crossed	over	to	
NuvaRing.	 Matched	 samples	 were	 compared	 from	 baseline	 to	 exit	 (n=20)	 using	 a	Wilcoxon	matched-pairs	sign	ranked	test.	Unmatched	samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=22,	crossover	n=20,	exit	n=15).		
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4.5 Discussion	The	aim	of	this	Chapter	was	to	investigate	the	impact	of	various	HC	products	on	genital	tract	CD4+	T	cell	activation	and	numbers	in	adolescents,	in	a	randomized	crossover	trial	comparing	NuvaRing,	NET-EN	and	COCPs,	focusing	on	Th17	cells	because	they	are	thought	to	be	highly	susceptible	to	HIV	infection	(Brenchley	et	al.,	2008;	Kim	et	al.,	2013;	Stieh	et	al.,	2016).	This	may	provide	valuable	insight	into	mechanisms	 underlying	 increased	HIV	 risk	 in	 adolescent	 girls.	 One	 of	 the	major	 findings	 was	 that	 genital	 tract	 IL-21,	 IL-1β,	 TNF-α	 and	 IFN-γ	concentrations	were	elevated	in	those	randomized	to	use	NuvaRing	at	crossover	compared	 to	 baseline.	 In	 contrast,	 no	 such	 changes	 in	 genital	 tract	 cytokines	were	observed	in	adolescents	initially	randomized	to	NET-EN	or	COCPs.			One	of	 the	many	 functions	of	Th17-related	cytokines,	 including	 IL-17A,	 IL-17F,	IL-6,	 IL-23	and	 IL-1β	 is	 to	 recruit	Th17	cells	 to	mucosal	 surfaces	 including	 the	genital	tract	(Conti	et	al.,	2009;	Sandquist	and	Kolls,	2018).	Therefore,	how	HCs	altered	 the	 frequency	 and	 activation	 of	 Th17	 cells	 within	 individuals	 was	investigated.	Adolescents	using	NuvaRing	had	significantly	elevated	frequencies	of	 highly	 activated	 cervical	 Th17	 cells	 (expressing	 both	 CD38	 and	 HLA-DR),	although	 these	 were	 present	 at	 lower	 frequencies	 compared	 to	 baseline.	Frequencies	 of	 highly	 activated	 Th17	 cells	 also	 tended	 to	 be	 elevated	 in	adolescents	 initially	 randomized	 to	 NET-EN,	 although	 not	 after	 adjusting	 for	multiple	 comparisons.	 No	 differences	 in	 the	 frequency	 or	 activation	 status	 of	cervical	 Th17	 cells	 were	 observed	 in	 adolescents	 changing	 from	 NuvaRing	 to	COCPs	 or	 those	 changing	 from	 NET-EN	 to	 COCPs	 at	 crossover	 and	 exit	 visits.	Adolescents	 using	 COCPs	 tended	 to	 have	 a	 decreased	 frequency	 of	 Th17	 cells,	with	 a	 significant	 increase	 of	 CCR5	 expression	 on	 these	 cells	 compared	 to	baseline,	 although	 this	 was	 not	 confirmed	 in	 the	 paired	 analysis.	 Overall,	 this	data	 suggests	 that	 all	 three	 HCs	 investigated	 altered	 Th17	 cells	 in	 the	 genital	tract	compared	to	when	these	young	girls	came	into	the	study.		The	median	age	of	sexual	debut	in	this	cohort	was	15	years,	and	having	had	sex	at	 or	 before	 the	 age	 of	 16	 has	 been	 reported	 to	 be	 a	 strong	marker	 for	 future	poor	sexual	health	patterns	(Cavazos-Rehg	et	al.,	2010;	Zuma	et	al.,	2014).	Unlike	
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in	 older	 women,	 the	 underdeveloped	 cervix	 of	 adolescents	 is	 going	 through	physical	 changes	 including	 changes	 in	 the	 vaginal	 epithelium	 (Moscicki	 et	 al.,	1999).	In	addition,	adolescent	girls	are	at	a	stage	of	hormonal	changes	associated	with	 sex	 maturation.	 These	 changes	 in	 addition	 to	 initiating	 HCs	 might	 all	contribute	to	perturbations	seen	in	the	genital	tract.	In	this	study,	the	range	of	E2	serum	levels	(74-142	pmol/L)	were	lower	than	the	reported	reference	ranges	in	older	 women	 (161-774	 pmol/L;	 Smritee	 Dabee	 PhD	 thesis).	 It	 would	 be	interesting	 to	 see	 whether	 NuvaRing	 perturbs	 the	 vaginal	 immune	microenvironment	 in	older	women	at	 the	same	extent	seen	 in	adolescent	girls,	given	the	differences	in	their	biological	sexual	maturity	of	the	genital	tract.		Overall,	 the	 results	 observed	 in	 this	 study	 show	 elevated	 genital	 Th17-related	cytokine	 concentrations	 in	 adolescents	 using	 NuvaRing	 but	 not	 in	 those	 using	NET-EN	and	COCPs.	Amongst	the	cytokines	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21	and	IL-22),	IL-17F	was	less	affected	by	the	use	of	NuvaRing.	Although	both	cytokines	play	a	critical	role	in	tissue	inflammation	by	inducing	the	release	of	 proinflammatory	 cytokines,	 IL-17F	 has	 been	 reported	 to	 be	 less	 potent	 at	inducing	cytokines	(Sueki	et	al.,	2008;	Ouyang	et	al.,	2012;	Brembilla	et	al.,	2018;	Glatt	et	al.,	2018).	Increased	Th17-related	cytokines	observed	when	participants	were	 on	NuvaRing	might	 suggest	 both	 hormonal	 and	mechanical	 responses	 to	the	copolymer	evatane	vaginal	ring	(forming	the	NuvaRing)	in	the	vagina.	Early	studies	suggested	local	leukocytic	inflammatory	responses	after	IUD	insertion	in	the	endometrium	and	 fallopian	 tubes	 (Moyer	and	Mishell,	1971).	Furthermore,	the	 presence	 of	 an	 LNG-IUD	 in	 the	 genital	 tract	 has	 been	 associated	 with	inflammatory	cytokines	including	IL-1β,	TNF-α,	IFN-γ,	GM-CSF,	and	IFN-α	in	the	endocervical	 canal	 (Shanmugasundaram	et	 al.,	 2016;	 Sharma	 et	 al.,	 2018),	 and	insertion	of	the	copper	IUD	was	associated	with	increase	in	IL-1α,	IL-1β,	IL-6	and	TNF-α	 (Sharma	 et	 al.,	 2018).	 This	 shows	 that	 changes	 in	 cytokines	 can	 be	induced	both	mechanically	and	hormonally.		With	elevated	inflammatory	cytokines	including	IL-1β	noted	in	adolescents	using	NuvaRing,	 one	 would	 expect	 increased	 numbers	 and/or	 frequencies	 of	 Th17	cells	or	total	CD4+	T	cells	in	these	participants.	It	was	therefore	surprising	that	
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the	overall	frequency	of	total	genital	CD4+	and	Th17-like	T	cells	were	reduced	in	adolescents	assigned	to	the	NuvaRing	arm.	Alteration	in	Th17	cells	was	observed	in	 all	 HCs	 compared	 to	 baseline,	 indicating	 that	 exogenous	 hormones	 partly	caused	these	perturbations.	Highly	activated	genital	tract	T	cells	are	more	likely	to	die	by	apoptosis	than	resting	T	cells	(Nkwanyana	et	al.,	2009),	and	one	could	hypothesize	that	the	reduction	in	frequencies	of	cervical	Th17	cell	in	adolescents	using	 NuvaRing	 and	 NET-EN	might	 reflect	 cell	 death	 of	 these	 highly	 activated	cells.	 IL-10,	 IL-25,	 IL-4	 and	 IFN-γ	 negatively	 regulate	 Th17	 cells,	 and	 these	cytokines	 might	 also	 contribute	 to	 the	 dramatic	 decrease	 in	 Th17	 cell	frequencies	 seen	 in	 the	 NuvaRing	 arm,	 in	 addition	 to	 other	 immune	 cells	including	Tregs	 not	measured	 in	 this	 study,	 but	 are	 known	 to	 be	 important	 in	suppressing	 Th17	 responses	 (Lee	 et	 al.,	 2015b).	 In	 one	 study,	 NuvaRing	 and	COCPs	 users	 were	 found	 to	 have	 reduced	 frequencies	 of	 CD207+	 Langerhans	cells	in	the	vagina	(Mitchell	et	al.,	2014).	Langerhans	cells	are	antigen-presenting	cells	 that	 are	 known	 to	 activate	 cutaneous	 Th17	 responses	 in	 response	 to	bacterial	infections	(Deckers	et	al.,	2018).	Perhaps	participants	on	NuvaRing	also	had	 a	 reduction	 in	 these	 antigen-presenting	 cells	 thereby	 decreasing	 the	presence	 of	 Th17	 cells	 at	 the	 genital	 tract.	 Furthermore,	 the	 vaginal	 ring	 is	recognized	as	a	foreign	object	in	the	lower	reproductive	tract,	thereby	inducing	microbial	and	 immune	changes.	The	 localised	hormones	delivered	directly	 into	the	vagina	by	NuvaRing	might	also	contribute	to	this	effect.		Hardy	 et	 al.	 (2017)	 recently	 reported	 that	 the	 NuvaRing	 acquires	 a	 complex	bacterial	 biomass	 after	 insertion,	 including	 several	 BV-associated	 bacterial	strains.	 They	 postulated	 that	 even	 though	 the	 delivered	 hormones	 from	NuvaRing	 increased	 the	 concentration	 and	 relative	 abundance	 of	 vaginal	
Lactobacillus	spp.,	metabolites	and	bacteriocins	produced	by	Lactobacillus	were	not	effective	against	a	poly	microbial	biofilm.	While	the	microbial	composition	of	the	 biofilms	 associated	 with	 CCVRs	 in	 this	 study	 was	 not	 determined,	 it	 is	possible	that	these	bound	microbial	products	on	the	ring	bind	to	TLRs	expressed	on	 different	 epithelial	 and	 immune	 cells	 including	 T	 cells	 and	 neutrophils,	thereby	 initiating	 cytokine	 and	 chemokine	 production.	 Although	 neutrophil	infiltration	was	 not	measured,	 Th17	 cells	 are	 known	 to	 recruit	 neutrophils	 by	
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producing	 IL-17A	 and	 IL-17F	 (Roussel	 et	 al.,	 2010;	 Schofield	 et	 al.,	 2016).	Activation	 of	 Th17	 cells	 has	 been	 reported	 to	 result	 in	 a	 large	 amount	 of	inflammatory	cytokine	production	including	IL-17A,	IL-17F,	IL-21	and	IL-22	and	this	 partially	 explains	 why	 NuvaRing	 had	 increased	 Th17-related	 cytokine	concentrations	due	to	highly	activated	Th17	cells	observed	(Tesmer	et	al.,	2008;	Ouyang	et	al.,	2012).	The	use	of	NuvaRing	had	been	reported	to	increase	vaginal	wetness,	and	some	have	 linked	 this	 to	 inflammation	due	 to	a	 slight	 increase	 in	vaginal	white	blood	cells	in	CCVR	users	(Schwan	et	al.,	1983;	Veres	et	al.,	2004).	Vaginal	wetness,	however,	was	not	determined	in	this	study.			Aside	from	CCVRs,	vaginal	rings	containing	HIV	drugs	have	also	been	assessed	as	pre-exposure	prophylaxis	(PrEP)	modalities,	although	genital	tract	immune	cells	are	typically	not	measured	in	these	clinical	studies	(Johnson	et	al.,	2012;	Smith	et	al.,	 2015;	Baeten	 et	 al.,	 2016).	However,	 insertion	of	 a	 silicon	 intravaginal	 ring	into	female	macaques	was	not	associated	with	inflammatory	cytokines	IL-6	and	IL-8.	 Both	 tenofovir-medicated	 and	 unmedicated	 rings	 in	macaques	 have	 been	shown	to	form	biofilms	(Gunawardana	et	al.,	2011).		This	 study	 has	 several	 limitations.	 Although	 the	 initial	 plan	 was	 to	 recruit	adolescents	 who	 are	 contraceptive	 naïve	 into	 the	 study,	 the	 age	 range	 of	 this	young	 cohort	 (15-19	 years)	 biased	 recruitment	 to	 those	 who	 were	 already	sexually	 active	 and	 had	 initiated	 HCs.	 Moreover,	 these	 participants	 were	recruited	 from	a	 family	planning	clinic	 rather	 than	 from	a	broader	community.	For	participants	<18	years	of	age,	the	recruitment	process	was	difficult,	as	they	had	 to	 get	 a	 parental	 consent	 and	 expose	 that	 they	 were	 sexually	 active	 in	 a	culture	 where	 it	 is	 not	 typically	 widely	 accepted.	 Importantly,	 there	 was	 no	washout	period	due	 to	 the	nature	of	 the	 study	assuring	 that	participants	were	protected	 from	 unwanted	 pregnancies.	 Sexual	 risk	 behaviour	 and	 vaginal	practices	was	self-reported,	however,	these	were	similar	across	HC	arms	thereby	excluding	 possible	 confounders.	 Another	 important	 limitation	 is	 the	 small	sample	 size,	 decreased	 further	 by	 sub-analyses,	 and	 hence	 underpowered	 to	detect	some	changes.		
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In	conclusion,	results	 in	this	part	of	the	study	show	a	perturbation	of	Th17	cell	frequencies	 and	 increased	 concentrations	 of	 genital	 Th17-related	 cytokines	 in	the	 lower	 reproductive	 tract	 of	 adolescents	who	were	 using	 NuvaRing.	 To	my	knowledge,	this	is	the	first	study	to	compare	NuvaRing,	NET-EN	and	COCPs	in	a	randomized	 crossover	 designed	 trial	 in	 adolescents	 around	 sexual	 debut.	Further	investigation	to	understand	the	changes	seen	in	Th17	cells	 in	response	to	 the	 various	 HCs	 is	 urgently	 needed.	 It	 was	 concerning	 that	 Th17-related	cytokine	changes	localised	primarily	to	adolescents	in	the	NuvaRing	arm.					
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5.1 	Abstract	
Cytotoxic	CD8+	T	cells	are	the	primary	adaptive	immune	mechanism	responsible	for	 controlling	 HIV.	 Although	 it	 is	 widely	 accepted	 that	 Th17	 cells	 (CD4+)	 are	more	 susceptible	 to	HIV	 infection,	 a	 subset	 of	 CD8+	T	 cells	 are	 also	 capable	of	producing	IL-17	and	therefore	considered	T	cytotoxic	IL-17	cells	(Tc17	cells).	IL-17	 is	 associated	 with	 inflammation	 and	 Th17	 cells	 are	 susceptible	 to	 HIV	infection,	nonetheless,	the	relative	role	of	Tc17	cells	in	HIV	infection	and	risk	is	less	well	understood.	Here,	the	impact	of	HCs	on	CD8+	T	cells	generally	and	on	the	frequencies	of	Tc17	cells	(CD8+CCR6+)	was	investigated	in	adolescents.	In	a	paired-analysis	 comparing	 baseline	 to	 the	 crossover	 visit,	 adolescents	 using	NuvaRing	had	lower	frequencies	of	cervical	CD8+	T	cells,	which	expressed	lower	levels	 of	 HLA-DR,	 but	 had	 higher	 frequencies	 of	 CD38	 and	 CCR5/CD38.	Moreover,	 frequencies	 of	 Tc17	 cells	 were	 decreased	 in	 these	 adolescents.	Similarly	 to	 NuvaRing,	 adolescents	 using	 NET-EN	 had	 reduced	 frequencies	 of	CD8+	with	elevated	frequencies	expressing	CD38	and	CCR5/CD38,	and	reduced	HLA-DR,	 in	 addition	 to	 reduced	 Tc17	 frequencies.	 The	 use	 of	 COCPs	 was	associated	with	 reduced	 frequencies	of	Tc17	cells,	 and	 increased	expression	of	CCR5/CD38	 and	 reduced	 expression	 of	 HLA-DR	 on	 cervical	 CD8+	 T	 cells.	 In	adolescents	 changing	 between	 HCs,	 those	 using	 NuvaRing	 had	 decreased	frequencies	of	Tc17	cells	compared	to	when	the	same	participants	were	on	NET-EN	or	COCPs.	This	data	suggests	that	HCs	reduced	the	frequencies	of	Tc17	cells,	while	altering	activation	markers	on	CD8+	T	cells,	which	may	have	implications	for	mucosal	immune	control	in	relation	to	HIV	infection.									
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5.2 Introduction	Alteration	 of	 immune	 cells	 in	 the	 FRT	 may	 have	 a	 significant	 effect	 of	 HIV	acquisition	and	transmission.	Like	CD4+	T	cells,	CD8+	T	cells	continue	to	play	a	central	 role	 in	mucosal	 immunity	 (Luckheeram	 et	 al.,	 2012).	 CD8+	 T	 cells	 are	needed	in	the	FRT	to	protect	against	infections	including	protozoal,	bacterial	and	viral	pathogens	(Levy	et	al.,	1996;	Brinza	et	al.,	2016).	Mouse	studies	have	shown	that	 intravaginal	 HSV-2	 infections	 induced	 high-affinity	 memory	 CD8+	 T	 cells	that	were	needed	to	control	epithelial	pathogens	infecting	the	genital	tract	(Tang	and	Rosenthal,	2010;	Anjuère	et	al.,	2012).	These	memory	CD8+	T	cells	are	also	critical	 in	 controlling	 HSV-2	 reactivation	 and	 maintaining	 latency.	 Similar	 to	CD4+	T	cells,	CD8+	T	cells	are	classified	into	various	memory	subsets	based	on	expression	 of	 different	 receptors	 and	 cytokine	 production	 (Golubovskaya	 and	Wu,	2016),	and	expression	of	CCR6	was	predominantly	associated	with	memory	CD8+	T	cells	(Kondo	et	al.,	2007).	Based	on	their	ability	to	produce	IL-17,	these	CD8+	T	cells	expressing	CCR6	are	known	as	Tc17	cells	(Kondo	et	al.,	2009).	CCR6	and	its	 ligand	CCL20	act	as	chemotactic	 immune-modulatory	envoy	that	attract	lymphocytes	and	other	immune	cells	to	the	mucosal	tissues	including	the	genital	tract	(Ranasinghe	and	Eri,	2018).			Given	the	importance	of	CD8+	T	cells	in	FRT	protective	immunity,	it	is	important	to	 understand	 how	 the	 use	 of	 HCs	 altered	 them.	 HCs	 containing	 the	 synthetic	progestin	MPA	have	been	shown	to	inhibit	protective	CD8+	T	cell	responses	by	promoting	HSV-1	 reactivation	 (Cherpes	et	al.,	2008).	Although	most	 studies	on	HCs	 have	 focused	 on	 CD4+	 T	 cells,	 it	 is	 also	 important	 to	 investigate	 their	potential	 effects	 on	 CD8+	 T	 cells.	 Alteration	 in	 CD8+	 T	 cells	 may	 compromise	immune	responses	 to	pathogens	 in	 the	genital	 tract.	However,	 there	have	been	few	 studies	 focusing	 on	 how	 HCs	 affect	 CD8+	 T	 cells	 in	 the	 genital	 tract,	particularly	 in	 adolescent	 girls.	 The	 aim	 of	 this	 Chapter	 was	 therefore	 to	investigate	the	effect	of	NuvaRing,	NET-EN	and	COCPs	use	on	CD8+	and	Tc17	cell	frequencies	in	adolescents	in	the	uCHOOSE	cohort.				
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5.3 Materials	and	Methods	
5.3.1	Study	design	
As	 described	 in	 Chapter	 4	 (section	 4.3.1),	 the	 study	 design	was	 an	 open-label,	randomized	crossover	study	of	130	sexually	active	female	adolescents	aged	15–19	years	from	Masiphumelele,	Cape	Town,	South	Africa.	Inclusion	and	exclusion	criteria	 are	 described	 in	 Section	 4.3.1.	 Adolescents	 were	 randomized	 1:1:1	 to	three	arms:	 (1)	 injectable	NET-EN;	 (2)	 the	CCVR	NuvaRingâ;	 or	 (3)	COCPs	 (as	described	 in	 Chapter	 4).	 After	 being	 randomized	 onto	 each	 of	 these	contraceptive	 methods	 for	 four	 months,	 participants	 crossed	 over	 to	 another	form	of	HC	(as	shown	in	Figure	4.1).	Participants	receiving	either	NET-EN	or	the	daily	COCPs	(Arm	1	and	Arm	3,	respectively)	for	the	first	16	weeks	of	the	study	switched	over	to	using	NuvaRing	(Arm	2),	while	participants	receiving	NuvaRing	as	 the	 first	method	were	 given	 the	 choice	between	either	NET-EN	or	 the	daily	COCPs	 as	 their	 second	 method.	 After	 a	 total	 of	 32	 weeks,	 the	 participants	returned	for	a	final	visit	at	the	clinic	and	exited	the	study.		
5.3.2	HIV	and	pregnancy	testing	
As	described	 in	 Chapter	 4	 (section	 4.3.2),	 a	 rapid	HIV	 test	 (Alere	DetermineTM	HIV-1/2	Ag/Ab	Combo;	Alere,	MA,	USA)	 and	pregnancy	 test	 (U-test	 Pregnancy	strip;	 Humor	 Diagnostica,	 Pretoria,	 SA)	 was	 performed	 at	 all	 study	 visits	(screening,	enrolment,	crossover	and	exit).			
5.3.3	Sample	collection	
An	 endocervical	 cytobrush	 (Digene	 Corporation,	 MD,	 USA)	 was	 collected	 for	CMCs,	which	were	analysed	using	flow	cytometry	(section	2.3.5	and	2.3.6).		
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5.3.4	Flow	cytometry		
Endocervical	 cytobrushes	 (Digene®	 Corporation)	 were	 collected	 from	 each	adolescent	 under	 speculum	 examination,	 and	 processed	 within	 4	 hours	 as	previously	 described	 in	 section	 2.3.5.	 CMCs	 were	 stained	 with	 the	 following	monoclonal	antibodies:	CD3,	CCR6,	CCR5	(BD	Biosciences);	CD38	(eBioscience);	CD4	 (Invitrogen);	 CD8,	 CCR10,	HLA-DR	 (Biolegend)	 as	 previously	 described	 in	section	2.3.5.	A	DUMP	channel	consisting	of	CD14,	CD19	(Invitrogen)	and	ViVid	(Life	Technologies)	was	 included	 to	 remove	monocytes,	 B-cells	 and	dead	 cells.	The	gating	strategy	is	described	in	Chapter	2,	section	2.3.6.		
5.3.5	Statistical	analyses	
A	 Wilcoxon	 matched-pairs	 signed	 rank	 test	 was	 used	 to	 compare	 individuals	within	 each	 study	 arm	 at	 baseline	 and	 after	 being	 on	 the	 randomized	contraceptive.	A	Mann-Whitney	U	test	was	used	for	unmatched	comparisons.	For	comparison	between	more	than	two	groups,	the	Kruskal-Wallis	one-way	analysis	of	variance	was	used.	Statistical	analyses	were	performed	using	GraphPad	Prism	version	6	(GraphPad	Software,	CA,	USA),	and	STATA™	version	12	(StataCorp,	TX,	USA).	All	tests	were	two	sided	and	a	p-value	of	≤0.05	was	considered	significant.	Where	stated,	 the	Benjamini-Hochberg	method	was	used	 to	adjust	 for	multiple	comparisons.			
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5.4 Results		
 Effect	of	HCs	on	CD8+	T	cells	after	HC	use		
Cervical	 CD8+	 T	 cell	 frequencies	 and	 activation	 status	 were	 compared	 within	 each	contraceptive	arm,	using	each	adolescents	baseline	and	crossover	visit	 time	points,	 to	determine	 whether	 they	 were	 altered	 by	 use	 of	 HCs.	 For	 NuvaRing,	 29/35	 genital	samples	 were	 available	 for	 paired	 analysis.	 Intra-individual	 analysis	 within	 the	NuvaRing	arm	showed	a	reduction	 in	the	 frequencies	of	Tc17	(p<0.0001)	and	CD8+	T	cells	(p=0.03),	with	decreased	expression	of	HLA-DR	(p=0.02)	and	increased	expression	of	 CD38	 (p=0.01)	 and	 CCR5/CD38	 (p<0.0001)	 on	 CD8+	 T	 cells	 after	 NuvaRing	 use	(Figure	 5.1A).	 All	 phenotypic	 changes	 on	 CD8+	 T	 cells	 remained	 significant	 after	adjusting	for	multiple	comparisons.		In	the	NET-EN	arm,	22/32	adolescents	had	paired	genital	samples	available	for	analysis.	Unlike	NuvaRing,	the	use	of	NET-EN	was	not	associated	with	a	reduction	in	frequencies	of	 total	 CD8+	 T	 cells	 although	 the	 Tc17	 cell	 subset	 was	 significantly	 decreased	(p<0.0001;	Figure	5.1B).	Increased	frequencies	of	cervical	CD8+	T	cells	expressed	CD38	(p=0.01)	 and	 CCR5/CD38	 (p=0.0001)	 after	 NET-EN	 use,	 while	 lower	 frequencies	 of	these	cells	expressed	HLA-DR	(p=0.002).		In	the	COCPs	arm,	27/37	adolescents	had	paired	genital	samples	available	for	analysis.	While	 cervical	 CD8+	 T	 cell	 frequencies	 remained	 unchanged	 after	 using	 COCPs	 for	 4	months,	the	frequency	of	Tc17	cells	was	significantly	reduced	(p<0.0001;	Figure	5.1C).	However,	 the	 frequency	 of	 cervical	 CD8+	 T	 cells	 expressing	 CCR5/CD38	 was	significantly	 higher	 post-COCP	 use	 (p<0.0001).	 The	 frequency	 of	 CD8+	 T	 cells	expressing	HLA-DR	decreased	significantly	compared	to	baseline	(p<0.0001).	
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Figure	5.1.	Impact	of	(A)	NuvaRing,	(B)	NET-EN,	and	(C)	COCPs	on	cervical	Tc17	cells	and	
CD8+	 frequencies	 and	 activation	 state.	 CCR5	 and	 activation	 markers	 (CD38	 and	 HLA-DR)	
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were	analysed	within	CD8+	T	cell	populations.	The	clear	squares	show	participants	at	baseline	and	 the	 circles	 show	 participants	 at	 crossover.	 Each	 black	 line	 link	 paired	 data	 points	 in	 an	individual	participant.	 Samples	were	 compared	using	 the	Wilcoxon	matched-pair	 signed	 rank	test,	and	a	p-value≤0.05	was	considered	significant.			Next,	the	activation	and	co-receptor	expression	characteristics	of	cervical	CD8+	T	cells	were	 compared	across	arms	at	 crossover.	 In	an	 ITT	analysis,	 there	was	no	 significant	difference	 in	 the	 frequencies	 of	 cervical	 Tc17	 and	 CD8+	 T	 cells,	 according	 to	randomization	arm	(Figure	5.2).	Expression	of	CCR5	and	activation	markers	on	CD8+	T	cells	was	also	similar	across	the	HC	arms.	At	the	exit	visit,	the	frequency	and	phenotype	of	CD8+	T	cells	was	also	similar	across	the	three	arms	(data	not	shown).																						
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Figure	 5.2.	 Comparison	 of	 the	 frequency	 and	 activation	 status	 of	 cervical	 CD8+	 T	 cells	
from	adolescents	using	NuvaRing	(pink	circles),	NET-EN	(blue	circles)	and	COCPs	(green	
circles).	 Tc17	 cells,	 CCR5	 and	 activation	 markers	 were	 analysed	 within	 the	 CD8+	 T	 cell	population.	 The	 middle	 line	 represents	 the	 median,	 and	 the	 error	 bars	 represent	 the	 IQR.	Groups	were	compared	using	the	Kruskal-Wallis	test.			
5.4.2	Analysis	of	CD8+	T	cell	frequencies	and	activation	after	changing	
between	NuvaRing	to	NET-EN	
The	 changes	 in	CD8+	T	 cells	 in	 adolescents	 changing	between	NET-EN	and	NuvaRing	were	evaluated.	Swopping	from	NET-EN	to	NuvaRing	resulted	in	increased	frequencies	of	cervical	CD8+	T	cells	expressing	CCR5	(p=0.04),	CD38	(p=0.003)	or	both	CCR5/CD38	together	(p<0.0001),	although	Tc17	cell	frequencies	were	lower	(p=0.0004;	Figure	5.3).				
	
Figure	5.3.	Comparison	of	cervical	CD8+	T	cells	in	participants	changing	between	NET-EN	
and	NuvaRing.	Tc17	cells,	CCR5	and	activation	markers	were	analysed	within	the	CD8+	T	cell	population.	A	blue	circle	denotes	the	matched	time	point	when	adolescents	were	using	NET-EN,	
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while	a	purple	circle	denotes	the	NuvaRing	time	point.	The	bar	shows	the	median	frequency	for	each	 subset	 analysed.	 Samples	were	 compared	 using	 the	Wilcoxon	matched-pair	 signed	 rank	test.	P-value≤0.05	was	considered	significant	and	those	that	were	significant	are	shown.	
		
5.4.3	Analysis	of	CD8+	T	cell	frequencies	and	activation	after	changing	
between	COCPs	and	NuvaRing	
The	phenotype	of	CD8+	T	cells	 in	adolescents	changing	between	COCPs	and	NuvaRing	was	 investigated	 (Figure	5.4).	 The	 frequency	 of	 CD8+	T	 cells	 expressing	HLA-DR	was	significantly	 lower	 when	 adolescents	 used	 NuvaRing	 compared	 to	 when	 they	 were	using	COCPs,	in	a	matched	analysis	(p=0.02).	In	contrast,	the	frequency	of	CD8+	T	cells	expressing	 both	 CCR5/CD38	 was	 significantly	 elevated	 (p=0.003)	 when	 participants	were	 using	 NuvaRing	 compared	 to	 COCPs.	 In	 addition,	 Tc17	 cells	 were	 significantly	reduced	after	NuvaRing	use	(p=0.0003).			
Figure	 5.4.	 Comparison	 of	 cervical	 CD8+	 T	 cell	 phenotype	 and	 activation	 status	 in	
adolescents	 changing	 between	 COCPs	 and	 NuvaRing.	 Tc17	 cells,	 CCR5	 and	 activation	markers	were	analysed	within	the	CD8+	T	cell	populations.	A	green	circle	denotes	the	matched	time	 point	 when	 adolescents	were	 using	 COCPs,	 while	 a	 purple	 circle	 denotes	 the	 NuvaRing	
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time	 point.	 The	 bar	 shows	 the	 median	 frequency	 for	 each	 subset	 analysed.	 Samples	 were	compared	 using	 the	 Wilcoxon	 matched-pair	 signed	 rank	 test.	 	 P≤0.05	 were	 considered	significant	and	those	that	were	significant	are	shown.		
	
5.4.4	Analysis	of	CD8+	T	cell	frequencies	and	activation	after	changing	
between	NET-EN	and	COCPs		
While	 the	 frequencies	 of	 cervical	 CD8+	 T	 cells	 expressing	 HLA-DR	 was	 significantly	higher	when	adolescents	were	using	NET-EN	compared	 to	when	 the	 same	adolescent	were	 using	 COCPs	 (p=0.004),	 the	 frequency	 of	 CD8+	 T	 cells	 expressing	 CCR5/CD38	together	was	significantly	lower	(p=0.0008).	Moreover,	Tc17	cells	were	increased	when	the	same	participants	used	NET-EN	(p=0.001;	Figure	5.5).			
Figure	 5.5.	 Comparison	 of	 cervical	 CD8+	 T	 cell	 frequencies	 in	 adolescents	 changing	
between	COCPs	and	NET-EN.	Tc17	cells,	CCR5	and	activation	markers	were	analysed	within	the	CD8+	T	 cell	 population.	A	 green	 circle	denotes	 the	matched	 time	point	when	 adolescents	were	 using	 COCPs,	 while	 a	 blue	 circle	 denotes	 the	 NET-EN	 time	 point.	 The	 bar	 shows	 the	median	 frequency	 for	 each	 subset	 analysed.	 Samples	 were	 compared	 using	 the	 Wilcoxon	
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matched-pair	 signed	 rank	 test.	 P≤0.05	 were	 considered	 significant	 and	 those	 that	 were	significant	are	shown.			
5.4.5	Longitudinal	changes	in	CD8+	T	cells	across	all	three	study	visits	
Finally,	changes	in	CD8+	T	cell	frequencies	and	activation	between	baseline,	crossover	and	exit	were	assessed	to	determine	whether	profiles	that	were	changed	in	response	to	a	 particular	 HC	 reverted	 to	 pre-HC	 phenotypes	 after	 that	 particular	 HC	 was	discontinued.	As	shown	in	the	previous	analyses	(Figure	5.1A),	NuvaRing	use	appeared	to	 decrease	 both	 Tc17	 and	 total	 CD8+	 T	 cell	 frequencies	 in	 adolescents	 compared	 to	pre-NuvaRing	 (0	week)	baseline.	 It	was	 therefore	 interesting	 to	 assess	whether	 these	returned	to	baseline	levels	after	the	adolescents	swopped	to	NET-EN	or	COCPs.		NuvaRing	use	decreased	Tc17	cell	 frequencies	 (visible	at	 crossover	visit).	These	Tc17	cell	 frequencies	 did	 not	 return	 to	 baseline	 frequencies	 after	 adolescents	 changed	 to	NET-EN	 (p<0.0001	 compared	 to	baseline;	Figure	5.6A),	 and	Tc17	 cells	 at	 the	NET-EN	use	time	point	(week	32)	were	comparable	to	 frequencies	at	 the	NuvaRing	time	point	(week	 16).	 Similarly,	 frequencies	 of	 Tc17	 cells	 were	 not	 restored	 in	 those	 swopping	from	NuvaRing	to	COCPs	(p=0.03	compared	to	baseline;	Figure	5.6B),	and	Tc17	cells	at	the	COCPs	use	time	point	(week	32)	were	comparable	to	 frequencies	at	 the	NuvaRing	time	point	(week	16).	However,	it	should	be	noted	that	only	four	participants	on	COCPs	at	week	32	were	available	for	this	comparison.					
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Figure	 5.6.	 Comparison	 of	 cervical	 CD8+	 T	 cells	 at	 baseline	 (0	 weeks),	 crossover	 (16	
weeks)	and	exit	visit	(32	weeks)	for	adolescents	initially	randomized	to	NuvaRing	(until	
16	weeks)	and	who	subsequently	crossed	over	to	either	NET-EN	(panel	A;	baseline	n=22,	
week	16	n=19,	week	32	n=17)	or	COCPs	(panel	B;	baseline	n=7,	week	16	n=8,	week	32	
n=4)	 until	 32	weeks.	The	 baseline	 time	 points	 are	 shown	 as	 clear	 dots,	 the	 NuvaRing	 time	point	 as	 pink	 dots,	 and	 either	 the	 NET-EN	 or	 COCPs	 time	 points	 as	 blue	 or	 green	 dots,	respectively.	Tc17	 cells,	 CCR5	 and	 activation	markers	 were	 analysed	 within	 the	 CD8+	 T	 cell	population.	The	mid	 line	represents	 the	median,	and	 the	error	bars	represent	 the	 IQR.	Mann-Whitney	 U	 tests	were	 used	 to	 compare	 groups.	 P≤0.05	 were	 considered	 significant	 and	 only	significant	differences	are	shown.			Adolescents	 randomized	 to	 NET-EN	 similarly	 had	 higher	 frequencies	 of	 Tc17	 cells	 at	baseline	that	significantly	declined	at	week	16	after	NET-EN	use,	and	further	decreased	after	 adolescent’s	 swopped	 to	 NuvaRing	 (p<0.0001;	 Figure	 5.7).	 Expression	 of	
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CCR5/CD38,	CCR5/HLA-DR	and	CD38/HLA-DR	on	CD8+	T	cells	were	also	increased	at	week	16	after	NET-EN	use,	and	more	so	at	week	32	post-NuvaRing	(p<0.0001,	p<0.0001	and	p=0.04,	respectively).	Due	to	a	small	sample	size	of	3,	participants	randomized	to	NET-EN	and	crossed	over	to	COCPs	were	not	compared.				
	
Figure	5.7.	 Comparison	of	 cervical	 CD8+	T	 cells	 at	 baseline	 (0	weeks,	 n=17),	 crossover	
(16	weeks,	n=18)	and	exit	visit	(32	weeks,	n=21)	for	adolescents	initially	randomized	to	
NET-EN	 (until	 16	 weeks)	 and	 who	 subsequently	 crossed	 over	 to	 NuvaRing	 (until	 32	
weeks).	The	baseline	time	points	are	shown	as	clear	dots,	the	NET-EN	time	point	as	blue	dots,	and	 the	 NuvaRing	 time	 point	 as	 pink	 dots.	 Tc17	 cells,	 CCR5	 and	 activation	 markers	 were	analysed	within	the	CD8+	T	cell	population.	The	mid	line	represents	the	median,	and	the	error	bars	 represent	 the	 IQR.	 Mann-Whitney	 U	 tests	 were	 used	 to	 compare	 groups.	 P≤0.05	 were	considered	significant	and	only	significant	differences	are	shown.			For	adolescent	randomized	to	COCPs,	baseline	frequencies	of	Tc17	cells	declined	post-COCPs,	 and	 declined	 further	 post-NuvaRing	 (p<0.0001;	 Figure	 5.8).	 While	 the	expression	of	HLA-DR	on	CD8+	T	cells	decreased	at	week	16	post-COCPs,	 this	slightly	increased	 post-NuvaRing	 although	 not	 restored	 to	 the	 baseline	 levels.	 Expression	 of	CCR5/CD38	and	CCR5/HLA-DR	on	CD8+	T	cells	 tended	 to	be	higher	at	week	16	post-COCPs	 (p<0.0001	 for	 CCR5/CD38)	 and	 at	 week	 32	 post-NuvaRing	 (p=0.003).	 For	
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adolescents	randomized	onto	COCPs	and	crossed	over	to	NET-EN,	only	3	samples	were	available	and	therefore	no	comparisons	were	performed.			
Figure	5.8.	 Comparison	of	 cervical	 CD8+	T	 cells	 at	 baseline	 (0	weeks,	 n=22),	 crossover	
(16	weeks,	n=21)	and	exit	visit	(32	weeks,	n=15)	for	adolescents	initially	randomized	to	
COCPs	(until	16	weeks)	and	who	subsequently	crossed	over	to	NuvaRing	(32	weeks).	The	baseline	 time	 points	 are	 shown	 as	 clear	 dots,	 the	 COCPs	 time	 points	 as	 green	 dots,	 and	 the	NuvaRing	 time	 point	 as	 pink	 dots.	 Tc17	 cells,	 CCR5	 and	 activation	 markers	 were	 analysed	within	 the	 CD8+	 T	 cell	 population.	 The	 mid	 line	 represents	 the	 median,	 and	 the	 error	 bars	represent	 the	 IQR.	 Mann-Whitney	 U	 tests	 were	 used	 to	 compare	 groups.	 P≤0.05	 were	considered	significant	and	only	significant	differences	are	shown.											
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5.5 Discussion	In	 this	chapter,	 the	effect	of	NuvaRing,	NET-EN	and	COCPs	on	overall	cervical	CD8+	T	cells	 and	 Tc17	 cell	 subsets	 in	 the	 reproductive	 tracts	 of	 adolescent	 females	 was	evaluated.	Baseline	 frequencies	 and	 activation	of	CD8+	T	 cells	were	 similar	 across	 all	arms,	 confirming	 that	 randomization	was	 effective	 in	 excluding	possible	 confounders.	Overall	frequencies	of	Tc17	and	CD8+	T	cells	were	reduced	in	NuvaRing,	while	only	the	frequency	of	Tc17	cells	 in	NET-EN	and	COCPs	users	were	reduced	by	16	weeks	of	HC	use.	 While	 the	 expression	 of	 CD38	 on	 CD8+	 T	 cells	 was	 only	 reduced	 within	 the	NuvaRing	 arm,	 all	 HCs	 had	 a	 significant	 reduction	 in	 HLA-DR	 and	 an	 increased	expression	 of	 CCR5/CD38	 on	 their	 cervical	 CD8+	 T	 cells	 after	 16	 weeks.	 Therefore,	intra-individual	 analysis	 (where	 each	 young	woman	was	 her	 own	 control)	 suggested	that	all	three	HCs	altered	cervical	CD8+	T	cells,	although	neither	the	frequency	nor	the	activation	 of	 these	 cells	 differed	 between	 arms	 after	 16	 to	 32	 weeks	 of	 HC	randomization.		Furthermore,	 extending	 the	 intra-individual	 analysis	 of	 those	 adolescents	 who	subsequently	 changed	 from	 one	 HC	 form	 to	 another,	 they	 tended	 to	 have	 lower	frequencies	 of	 Tc17	 cells,	 and	 higher	 expression	 of	 CCR5,	 CD38,	 CCR5/CD38	 and	CCR5/HLA-DR	on	their	CD8+	T	cells	when	they	were	using	NuvaRing	compared	to	when	they	 swopped	 to	 NET-EN,	 although	 NET-EN	 use	 did	 not	 restore	 expression	 levels	 to	baseline.	 Similarly,	 those	 that	 changed	 from	 NuvaRing	 to	 COCPs	 also	 had	 lower	frequencies	 of	 Tc17	 cells	 reduced	 expression	 of	 HLA-DR	 and	 increased	 expression	 of	CCR5/CD38	on	their	CD8+	T	cells	when	they	were	on	NuvaRing,	although	swopping	to	COCPs	 did	 not	 appear	 to	 restore	 their	 CD8+	 T	 cell	 frequencies	 to	 baseline.	 In	participants	 changing	 from	 NET-EN	 to	 COCPs,	 there	 was	 a	 decrease	 in	 Tc17	 cells,	reduced	expression	of	HLA-DR	and	increased	expression	of	CCR5/CD38	on	CD8+	T	cells	when	participants	were	on	COCPs.	Although	NET-EN	and	COCPs	use	tended	to	have	less	impact	 on	 the	 frequency	 of	 Tc17	 cells	 than	NuvaRing,	 activated	 CD8+	T	 cells	 did	 not	return	to	baseline	levels	after	adolescent’s	swopped	to	NET-EN	or	COCPs.	This	suggests	that	 all	 progestin-based	 contraceptives	 increase	 activated	CD8+	T	 cells.	 Expression	of	activation	markers	 during	 HIV	 infection	 has	 differential	 significance,	 such	 that	 single	expression	of	HLA-DR	on	CD8+	T	cells	is	associated	with	a	better	survival	of	these	cells,	that	are	polyfunctional	and	have	higher	cytolytic	and	proliferative	ability	compared	to	
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HLA-DR+CD38+	CD8+	T	cells	(Saez-Cirion	et	al.,	2007;	Hua	et	al.,	2014;	Gonzalez	et	al.,	2016).	 On	 the	 contrary,	 CD38+	 CD8+	 T	 cells	 are	 prone	 to	 apoptosis,	 and	 have	 been	associated	 with	 residual	 HIV	 viral	 replication	 in	 patients	 on	 ART	 (Chun	 et	 al.,	 2004;	Miguel	 Benito	 et	 al.,	 2004).	 Whether	 these	 characteristics	 apply	 in	 HIV-uninfected	individuals	and	at	the	genital	mucosa	is	yet	to	be	investigated.		A	 consistent	 trend	 that	 was	 observed	 in	 this	 cohort	 was	 the	 reduction	 in	 Tc17	 cells	frequencies	observed	from	baseline	to	week	16	and	32	of	using	HCs,	irrespective	of	the	HC	that	was	being	used.	Implications	of	decreased	frequencies	of	Tc17	cells	in	women	are	 not	 yet	 known.	 Tc17	 cells	 (CD8+	 T	 cells	 that	 express	 CCR6,	which	 is	 involved	 in	lymphocyte	 mucosal	 homing)	 have	 been	 shown	 not	 to	 be	 cytotoxic	 upon	 antigen	recognition	 so	 they	do	not	 kill	 target	 cells;	 rather	 they	produce	 several	 inflammatory	cytokines	 including	 IL-17,	 IFN-γ,	 TNF-α,	 and	 IL-2,	 and	 largely	 have	 a	 similar	 cytokine	profile	to	Th17	cells	(Kondo	et	al.,	2009;	Srenathan	et	al.,	2016).			Several	studies	have	shown	that	the	presence	of	CD8+	T	cells	in	the	vagina	is	required	for	protection	against	various	viral	pathogens	such	as	HIV	and	HSV,	through	the	release	of	cytotoxic	granules	containing	perforin	and	granzymes	(Musey	et	al.,	1997;	Nelson	et	al.,	2011).	Anti-HIV	specific	CD8+	T	cells	are	crucial	in	controlling	viremia	by	increasing	responses	 to	 on-going	 viral	 replication	 (Keoshkerian	 et	 al.,	 2003).	 MPA	 have	 been	reported	 to	 reduce	 the	 capacity	of	CD8+	T	 cells	 to	 release	 lytic	 granules	 and	produce	IFN-γ	 (Cherpes	 et	 al.,	 2008).	 In	 support	 of	 this,	 increased	 endogenous	 progesterone	levels	 in	 pregnant	 women	 have	 been	 associated	 with	 hypermethylation	 of	 the	 IFN-γ	gene,	an	underlying	mechanism	reported	to	increase	susceptibility	of	pregnant	women	to	 intracellular	 pathogens	 during	 pregnancy	 (Yao	 et	 al.,	 2017).	 Since	 the	 Tc17	 cell	subset	appear	to	be	more	effective	at	cytokine	production	than	cytolytic	capacity,	their	reduction	 in	 the	 cervix	 might	 suggest	 lower	 production	 of	 cytokines	 by	 these	 cells,	including	IFN-γ	which	is	thought	to	be	indispensable	to	host	defense	against	pathogens	(Tajima	et	al.,	2011).	Although	Tc17	cells	cytokine	production	was	not	assessed	in	this	study.		Tc17	cells	have	been	defined	for	the	purposes	of	this	Chapter	as	CD8+	T	cells	expressing	CCR6,	as	have	several	previous	studies	(Kondo	et	al.,	2007,	2009).	However,	others	have	
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characterized	them	functionally	by	their	ability	to	produce	IL-17	directly	(Zhuang	et	al.,	2012;	Perdomo-Celis	et	al.,	2018).	As	IL-17	production	by	these	cervical	Tc17	cells	was	not	evaluated,	it	is	not	known	whether	the	Tc17	cells	detected	here	are	producing	IL-17.	Since	 an	 overall	 decrease	 of	 CCR6	 on	 CD4+	 and	 CD8+	 T	 cells	 was	 observed	 in	 the	NuvaRing	arm,	the	downregulation	might	be	part	of	a	regulation	process	caused	by	the	excessive	 production	 of	 Th17-related	 cytokines.	 CCR6	 deficient	 mice	 have	 impaired	mucosal	 but	 not	 systemic	 humoral	 responses	 to	 rotavirus	 infection	 in	 the	 intestinal	mucosa,	 elucidating	 the	 importance	 of	 this	 chemokine	 receptor	 in	 lymphocyte	homeostasis	at	mucosal	surfaces	(Cook	et	al.,	2000).	Thus,	reduced	expression	of	CCR6	cells	on	CD8+	T	cells	may	contribute	to	increased	susceptibility	to	pathogens	on	the	one	hand,	 although	 decreased	 expression	 of	 CCR6	 at	 the	 genital	 mucosa	 may	 blunt	 HIV	target	 cell	 recruitment	 and	 lower	 the	 inflammatory	 state	 of	 the	mucosa	 on	 the	 other	hand.	Furthermore,	 these	CCR6+	CD8+	T	cells	would	need	 to	be	 further	characterized	and	 compared	 to	 CCR6-	 CD8+	 T	 cells	 to	 differentiate	 the	 two	 subsets.	 Perdomo-Celis	and	colleagues	(2018)	recently	reported	higher	 IL-17	production	by	activated	CD8+	T	cells	(co-expressing	CD38	and	HLA-DR)	from	HIV-negative	individuals,	and	that	CD8+	T	cells	 from	 non-viremic	 HIV	 positive	 individuals	 tended	 to	 produce	 less	 IL-17	 after	polyclonal	stimulation.	Moreover,	their	study	reported	activated	CD8+	T	cells	to	be	the	main	source	of	IL-17	among	the	CD8+	T	cell	population.	Matched	analysis	in	Chapter	4	showed	 an	 increase	 in	 genital	 concentrations	 of	 IL-17A	 when	 adolescents	 were	 on	NuvaRing	compared	to	when	they	were	on	NET-EN	or	COCPS.	Increased	activated	CD8+	T	cells	might	be	one	of	the	many	reasons	why	adolescents	had	increased	Th17-related	cytokines	when	they	were	on	NuvaRing.		A	limitation	of	this	study	was	that	blood	was	not	stored	for	measuring	circulating	CD8+	T	cell	frequencies,	to	determine	whether	this	was	a	localised	effect	of	HCs	at	the	genital	mucosa,	or	more	a	general	effect	that	could	be	detected	in	the	blood.	One	study	found	women	using	COCPs	to	have	elevated	blood	CD8+	T	cells	compared	to	those	not	using	HCs	(Auerbach	et	al.,	2002).	It	was	also	not	possible	to	determine	whether	the	changes	in	total	CD8+	T	cells	or	Tc17	cells	that	were	observed	in	adolescent	girls	in	this	Chapter	related	to	their	young	age,	since	older	women	were	not	part	of	this	study.		
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In	summary,	HCs	use	was	associated	with	reduced	Tc17	frequencies,	irrespective	of	the	type	of	HC	being	used,	although	these	changes	were	more	dramatic	with	NuvaRing	use.	The	 importance	 of	 these	 cells	 in	 the	 genital	 tract	 should	 be	 studied	 further	 to	understand	 their	 implication	 in	 HIV	 risk,	 and	 for	 rational	 designs	 of	 effective	 HIV	vaccines.	
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 Chapter	6	
 Discussion	and	Conclusion		
6.1 Discussion	Adolescence	 is	 a	 time	 of	 significant	 endocrine	 and	 biomedical	 change	 in	 females,	associated	with	increased	production	of	female	sex	hormones	(estrogen,	progesterone,	Luitenizing	 and	 follicle	 stimulating	 hormones),	 development	 of	 secondary	 sexual	characteristics,	 menarche,	 and	 sexual	 debut	 (Sehested	 et	 al.,	 2000).	 Adolescent	 girls,	particularly	 in	 SSA,	 face	 double	 vulnerabilities	 of	 unintended	 pregnancies	 and	 HIV	infection.	Despite	 the	 enormous	 benefits	 offered	 by	HCs,	 public	 health	 concerns	 have	been	 raised	 because	 of	 the	 heightened	 risk	 to	 HIV	 seen	 in	 women	 using	 long-acting	injectable	 HCs	 (Polis	 et	 al.,	 2016;	 Hapgood	 et	 al.,	 2018),	 especially	 in	 SSA,	 where	injectable	HCs	are	a	popular	choice	(Kleinschmidt	et	al.,	2007,	UNDESA,	2015)	and	HIV	risk	is	highest	(UNAIDS,	2017).	While	HCs	are	particularly	necessary	in	adolescence,	to	prevent	unwanted	pregnancies,	it	is	also	critical	to	provide	advice	and	HC	options	that	do	 not	 increase	 risk	 for	 HIV.	 In	 light	 of	 these	 related	 mandates,	 the	 aim	 of	 this	dissertation	was	to	first	characterize	the	immune	environment	in	the	adolescent	genital	tract	focusing	on	highly	HIV	susceptible	Th17	cells	and	their	related	cytokines,	and	then	to	 investigate	 whether	 the	 use	 of	 injectable	 NET-EN,	 COCPs	 or	 NuvaRing	 (newly	introduced	into	SA)	influenced	either	the	frequency	or	activation	status	of	these	highly	susceptible	CD4+	T	cells.	Through	Chapters	2	to	5,	this	dissertation	revealed	four	major	findings:	(i)	that	Th17	cells	are	a	major	subset	in	the	genital	tract	of	adolescent	girls;	(ii)	that	 the	 presence	 of	 BV	 and	 vaginal	 dysbiosis	 did	 not	 alter	 cervical	 Th17	 cell	frequencies,	however	BV	appeared	to	significantly	increase	Th17-related	cytokines,	by	favouring	 a	 pro-inflammatory	 immune	 microenvironment;	 (iii)	 that	 the	 use	 of	 HCs	tended	 to	 decrease	 cervical	 Th17	 frequencies,	 however,	 NuvaRing	 also	 increased	activation	markers	 (HLA-DR+CD38+)	 on	 Th17	 cells,	 and	 also	 increased	 Th17-related	cytokines;	and	(iv)	All	HCs	reduced	the	frequencies	of	Tc17	cells,	and	they	all	affected	expression	of	activation	markers	on	CD8+	T	cells.		
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6.1.1	 Activated	Th17	 cells	 are	 a	major	 subset	 in	 the	 genital	 tract	 of	 adolescent	
girls	
	Susceptibility	to	HIV	infection	is	influenced	by	many	factors,	including	the	availability	of	target	 cells	 at	 the	 genital	 mucosa	 (Trifonova	 et	 al.,	 2014).	 Chapter	 2	 focused	 on	characterizing	the	highly	HIV	susceptible	Th17	cells	and	Th17-related	cytokines	in	the	lower	reproductive	tract	of	adolescent	girls.	Th17	cells	(defined	by	expression	of	CCR6	and	 absence	 of	 CCR10;	McKinnon	 et	 al.,	 2015)	were	 found	 to	 be	 a	major	CD4+	T	 cell	subset	 in	 cervical	 cytobrushes,	 followed	 by	 CCR6-CCR10-	 CD4+	 T	 cells	 (which	 are	thought	to	be	a	mixture	of	Th1	and	Th2	cells;	Zhong	et	al.,	2017).	Moreover,	Th17	cells	found	 in	 the	 genital	 tract	 were	 highly	 activated	 (expressing	 CD38	 and	 HLA-DR),	 and	expressed	 high	 levels	 of	 the	 CCR5	 receptor	 compared	 to	 CCR6-CCR10-	 CD4+	 T	 cells.	Although	Th22	cells	also	express	CCR6	like	Th17	cells,	CCR10	had	been	reported	to	be	preferentially	 expressed	 by	 these	 cells,	 allowing	 one	 to	 differentiate	 them	 from	Th17	cells	 (CCR6+CCR10-;	 Duhen	 et	 al.,	 2009;	 McKinnon	 et	 al.,	 2015).	 In	 vitro	 studies	confirmed	 that	 majority	 of	 CCR6+	 CD4+	 T	 cells	 produced	 IL-17,	 although	 it	 was	 not	stained	 for	 in	 this	 study.	 Moreover,	 other	 chemokines	 receptors	 such	 as	 CCR4	 and	CXCR3	not	measured	in	this	study	allows	for	sub-classification	into	Th17	and	Th1/Th17	subsets,	respectively	(Liu	and	Rohowsky-Kochan,	2008;	Alvarez	et	al.,	2013;	Rodriguez-Garcia	et	al.,	2014).			Different	 cytokines,	 including	 those	 produced	 by	 Th17	 cells,	 are	 involved	 in	 their	differentiation	and	regulation,	such	as	IL-21	and	IL-22	(Guglani	and	Khader,	2010).	All	Th17-related	 cytokines	 in	 the	 different	 classes	 were	 detected	 in	 the	 genital	 tract	including	 IL-17A	and	 IL-17F.	Although	overall	 frequencies	of	 cervical	Th17	cells	 (as	a	proportion	 of	 CD4+	 T	 cells)	 did	 not	 correlate	 with	 concentrations	 of	 Th17-related	cytokines	 measured	 in	 genital	 secretions,	 highly	 activated	 cervical	 Th17	 cells	(expressing	 CD38)	 correlated	 positively	 with	 several	 cytokines,	 including	 IL-17A,	 IL-17F,	 IL-6,	 IL-10	 and	 sCD40L.	 Activation	 of	 Th17	 cells	 is	 known	 to	 induce	 them	 to	produce	cytokines,	which	could	partly	explain	the	correlation	observed	in	this	study.	In	
vitro	studies	have	reported	endogenous	hormones	to	alter	immune	functions	(Correale	et	al.,	1998;	Kanda	and	Watanabe,	2003;	Fahey	et	al.,	2008;	Seillet	et	al.,	2011).	In	this	study,	genital	Th17-related	cytokines	did	not	correlate	with	serum	E2	and	LH,	however,	
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activated	Th17	cells	were	negatively	associated	with	these	hormones.	Interestingly,	the	presence	 of	 STIs	 (including	 C.	 trachomatis,	 N.	 gonorhoeae,	 M.	 genitalium	 and	 T.	
vaginalis)	 did	 not	 alter	 Th17	 cell	 frequencies	 or	 activation	 status,	 although	 IL-17A	concentrations	were	elevated.	In	contrast,	yeast	 infections	were	associated	with	lower	frequencies	of	cervical	Th17	cells.			
6.1.2	 BV	 and	 an	 altered	 vaginal	 microbiota	 are	 associated	 with	 increased	
concentrations	of	Th17-related	cytokines		
	In	 Chapter	 3,	 the	 relationship	 between	 BV	 and	 cervical	 Th17	 cell	 frequencies	 and	activation	 status	 was	 investigated.	 The	 prevalence	 of	 BV	 was	 high	 in	 this	 cohort	 of	AGYW	 from	Cape	Town,	with	>40%	of	 adolescents	 classified	 as	having	BV	by	Nugent	scoring.	Others	 from	our	group	similarly	 found	high	BV	rates	 in	adolescent	girls	 from	this	community,	suggesting	that	this	is	a	persistent	problem	(Barnabas	et	al.,	2017).	In	this	same	community	of	adolescents	from	Cape	Town,	Lennard	et	al.	(2017)	described	three	major	VMB	clusters	in	the	vagina,	with	majority	of	adolescents	falling	in	the	non-Lactobacilli-dominant	 C1	 diverse	 microbiome	 cluster.	 Despite	 previous	 studies	suggesting	 a	 relationship	 between	 Th17	 cells	 and	 certain	 segmented	 filamentous	commensal	microbes	 in	 the	 gut	 from	mouse	 studies	 (Ivanov	et	 a.,	 2009),	 the	 findings	from	Chapter	 3	 show	 that	 the	 presence	 of	 BV	 or	 the	 C1	 non-Lactobacillus	 dominated	VMB	did	not	influence	the	frequency	of	Th17	cells	in	the	FRT	of	adolescents.	However,	BV	as	well	as	intermediate	or	C1	non-Lactobacillus-dominated	VMB	was	associated	with	elevated	 concentrations	 of	 Th17-related	 cytokines.	 This	 data	 suggests	 that	 vaginal	dysbiosis	alters	Th17-related	cytokine	production	 in	 the	adolescent	genital	 tract,	with	an	overall	increase	in	the	cytokines	measured,	including	the	regulatory	cytokines	IL-10,	IL-4	 and	 IL-25.	Although	no	 significant	 difference	was	observed	 in	 the	 frequency	 and	activation	of	Th17	cells	according	to	BV	status	or	microbiome	community	type,	vaginal	dysbiosis	undoubtedly	favoured	the	production	of	Th17-related	cytokines.	
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6.1.3	 All	HCs	altered	cervical	Th17	cells	frequencies	
	The	 WHO	 called	 for	 more	 randomization	 trials	 to	 better	 understand	 how	 HCs,	particularly	 the	 long-acting	 progestin-only	 injectable	 products	 (like	 DMPA),	 increase	women’s	susceptibility	to	HIV	(WHO,	2015).	The	aim	of	Chapter	4	was	to	investigate	the	impact	of	the	injectable	NET-EN,	COCPs	and	NuvaRing	(newly	licensed	in	South	Africa)	on	 the	 immune	environment	of	 the	adolescent	FRT,	 focusing	on	Th17	cells	defined	 in	Chapters	2	and	3.	NuvaRing	use	was	accompanied	by	a	marked	decrease	in	frequencies	of	cervical	Th17	cells,	although	these	were	highly	activated	compared	to	when	the	same	individuals	joined	the	study.	Although	adolescents	on	NET-EN	and	COCPs	also	tended	to	have	reduced	Th17	cell	 frequencies	after	16	weeks	of	HC	use,	 the	changes	seen	in	the	NuvaRing	arm	were	more	substantial.	The	highly	activated	genital	tract	Th17	cells	seen	in	the	NuvaRing	are	more	likely	to	die	by	apoptosis	than	resting	T	cells	(Nkwanyana	et	al.,	2009),	which	could	explain	their	reduced	frequencies.	Little	is	known	of	how	CCR6	is	regulated	 on	 T	 cells;	 however,	 a	 stable	 expression	 of	 CCR6	 on	 human	 T	 cells	 is	associated	with	promoter	demethylation	(Steinfelder	et	al.,	2011).	Molecular	studies	are	needed	 to	 investigate	whether	 the	changes	seen	 in	NuvaRing	might	also	be	related	 to	DNA	methylation.	 In	 summary,	 the	 use	 of	 NuvaRing	 promoted	 highly	 activated	 Th17	cells,	although	the	frequencies	were	reduced.	These	findings	are	summarized	in	Figure	6.1	below.			
	
Figure	 6.1.	 Summary	 of	 cervical	 Th17	 cells	 changes	 observed	 in	 the	 genital	 tract	 of	
adolescents	 using	 COCPs,	 NET-EN	 and	 NuvaRing	 compared	 to	 baseline.	 There	 was	 an	overall	 trend	 in	 the	 reduction	 of	 Th17	 cell	 frequencies,	 significantly	 so	 for	 NET-EN	 and	
NET-EN	Baseline	 COCPs	 NuvaRing	
CCR5+	 CD38+HLA-DR+	other	
Th17	cells	
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NuvaRing,	although	these	cells	were	highly	activated	compared	to	baseline.	Expression	of	CCR5	tended	to	be	elevated	in	participants	on	COCPs	compared	to	baseline,	but	not	across	HC	arms.				
6.1.4	 Only	NuvaRing	altered	Th17-related	cytokines			Th17-related	 cytokines	were	 upregulated	 in	 the	 NuvaRing	 arm	 compared	 to	 NET-EN	and	 COCPs	 arms.	 Pro-inflammatory	 cytokines	 including	 IL-17A,	 IL-β,	 IL-6	 and	 TNF-α	were	among	the	elevated	Th17-related	cytokines	in	adolescents	using	NuvaRing	(Figure	6.2).	 These	 cytokines	 are	 involved	 in	 activation,	 differentiation	 and	 recruitment	 of	immune	 cells	 including	T	 cells,	 neutrophils,	DCs	and	macrophages	 to	 the	genital	 tract	(Dubin	 and	 Kolls,	 2008;	 Arnold	 et	 al.,	 2016;	 Revu	 et	 al.,	 2018).	 Other	 important	cytokines	and	chemokines	involved	in	the	Th17	pathway	such	as	TGF-β,	and	the	CCR6	ligand	MIP-3a	were	not	measured,	and	 this	would	have	provided	more	 insight	on	 the	effect	of	NuvaRing	on	these	cytokines.	Interesting,	IL-1β	that	positively	regulate	MIP-1a	was	 elevated	 in	 adolescents	 using	 NuvaRing.	 Therefore,	 elevated	 cytokines	 in	adolescents	on	NuvaRing	might	increase	adolescent’s	susceptibility	to	HIV	acquisition.				
	
Figure	6.2.	Summary	of	changes	seen	 in	 the	concentration	of	Th17-related	cytokines	 in	
the	genital	tract	of	adolescent	girls.	Cytokines	including	IL-17A,	IL-1β	and	IL-6	were	elevated	after	NuvaRing	use	compared	to	NET-EN	and	COCPs.					
NET-EN	Baseline	 COCPs	 NuvaRing	
IL-17A	 IL-1β		 IL-6	 Other	cytokines		
Th17-related	cytokines	
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6.1.5	 CD8+	T	cells	were	altered	by	the	use	of	HCs	
	In	Chapter	5,	 the	effect	of	NuvaRing,	NET-EN	and	COCPs	on	vaginal	CD8+	T	cells	was	investigated.	The	 frequency	of	Tc17	cells,	 a	 subset	of	CD8+	T	cells	known	 to	promote	inflammation	 was	 also	 included	 in	 the	 analysis.	 Notably	 in	 humans,	 the	 clinical	relevance	of	Tc17	cells	is	a	new	field,	and	not	much	is	known	about	these	cells.	In	mice,	Tc17	cells	displayed	antitumor	 immunity	through	the	production	of	 IL-17,	 IFN-	 γ	and	TNF-α	(Garcia-Hernandez	et	al.,	2010).	Although	no	significant	differences	in	the	overall	frequency	of	CD8+	T	cells	were	observed	across	arms	at	the	crossover	and	exit	visits,	a	significant	decreased	in	the	frequency	of	Tc17	cells	was	observed	within	each	HC	arm	(Figure	6.3).	Moreover,	expression	of	activation	markers	on	CD8+	T	cells	were	generally	affected	by	the	use	of	HCs,	but	NuvaRing	appeared	to	be	associated	with	more	dramatic	alterations	compared	to	either	NET-EN	or	COCPs.		
	
Figure	6.3.	Summary	of	CD8+	T	cells	changes	in	the	genital	tract	of	adolescents	on	COCPs,	
NET-EN	and	NuvaRing	compared	to	baseline.	There	was	an	overall	trend	in	the	reduction	of	Tc17	cell	frequencies,	although	the	overall	frequencies	of	CD8+	T	cells	were	the	same	compared	to	baseline.							
NET-EN	Baseline	 COCPs	 NuvaRing	
CD8+CCR6+	
Tc17	
CD8+	
	 170	
6.2 Limitations	and	future	directions		This	 study	 defined	 Th17	 cells	 by	 chemokine	 receptor	 expression	 (CCR6+CCR10-)	 as	opposed	 to	 cytokine	 production.	 It	 could	 be	 that	 CCR6+CCR10-	 Th17	 cells	measured	here	are	not	 all	 able	 to	produce	 IL-17,	 therefore	overestimating	 these	 cells.	However,	identifying	Th17	cells	using	cytokine	production	represent	technical	challenges	because	of	the	low	cell	yield	and	fragility	of	cervical	cells,	and	the	plasticity	of	Th17	cells	(Boily-Larouche	 et	 al.,	 2017).	 Although	 this	 study	 aimed	 to	 recruit	 contraceptive	 naïve	adolescents,	most	of	 the	study	participants	were	on	NET-EN	at	baseline,	and	this	may	have	biased	the	study.	In	addition,	most	of	these	young	adolescents	had	asymptomatic	BV	 and	 STIs.	 However,	 given	 the	 randomized	 nature	 of	 this	 study,	 there	 was	 equal	distribution	between	arms	on	previously	used	methods	of	contraception,	BV	and	STIs.	The	 vaginal	 microbiome	 forms	 part	 of	 another	 PhD	 study,	 and	 was	 therefore	 not	presented	in	Chapter	4	and	5,	which	could	have	explained	some	of	the	differences	seen	between	 contraceptive	 arms.	 Self-reported	 behavioural	 data	 was	 limited,	 as	 some	adolescents	anecdotally	reported	to	have	tempered	with	their	rings,	and	this	might	have	contributed	to	the	high	inflammation	observed	with	the	use	of	NuvaRing.				The	main	disadvantage	of	a	crossover	study	is	the	potential	for	carry	over	between	the	HC	 interventions.	 Since	 this	was	a	 study	 in	young	girls	 seeking	 to	prevent	pregnancy,	there	was	no	washout	period	as	 the	risk	 for	unintended	pregnancies	during	wash	out	was	 high.	 However,	 intraindividual	 analysis	 looking	 within-person	 provided	participants	 to	 be	 their	 own	 control	 minimizing	 natural	 variation,	 and	 allowing	evaluation	of	longitudinal	changes	from	baseline,	which	further	confirmed	some	of	the	alterations	 seen	with	 the	use	of	NuvaRing	 compared	 to	NET-EN	and	COCPs.	Although	these	sexually	active	adolescent	girls	were	past	menarche	and	not	in	their	early	tanner	stages,	 having	 older	women	 as	 a	 reference	would	 have	 helped	 explain	 some	 immune	changes	 observed	 in	 this	 study.	 Other	 limitations	 included	 a	 small	 sample	 size	 and	adolescents	being	only	on	two	out	of	the	three	HCs.	Future	studies	should	aim	to	recruit	contraceptive	naïve	women,	and	have	each	participant	on	all	the	HC	options.	Recruiting	HC	naïve	adolescent	girls	would	help	to	link	changes	seen	to	the	use	of	HCs.			
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6.3 Conclusion		In	 summary,	 the	presented	data	 suggests	 that	HCs	appear	 to	 alter	 cervical	Th17	 cells	and	CD8+	T	cells,	while	only	NuvaRing	had	elevated	Th17-related	cytokines.	This	adds	to	the	body	of	evidence	on	the	biological	effect	of	progestins	on	vaginal	 immune	cells,	more	 importantly	 in	 adolescent	 girls	 who	 are	 one	 of	 the	 HIV	 key	 populations.	 The	dramatic	 changes	 of	 Th17	 and	 Tc17	 cells	 in	 addition	 to	 Th17-related	 cytokines	 seen	with	the	use	of	NuvaRing	warrants	further	investigation	of	potential	mechanisms.	Using	a	 placebo	 copolymer	 evatane	 vaginal	 ring	 and	 another	 silicon	 vaginal	 ring	may	 help	delineate	 how	 the	 hormonal	 and	 mechanical	 components	 of	 the	 CCVR	 impact	 the	vaginal	immune	microenvironment.																												
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	Appendix	1		
Table	A1.	Percentage	of	Th17-related	cytokines	detected	in	the	vaginal	secretions	
					
Cytokine	 Percentage	
detected	
Concentration	(pg/ml)	
Median	(IQR)	IL-1β	 98	 10.81	(1.23	–	73.99)	IL-4	 37	 0.05	(0.05	–	0.99)	IL-6	 98	 0.98	(0.32	–	5.17)	IL-10	 42	 0.01	(0.01	–	1.08)	IL-17A	 98	 1.33	(0.87	–	3.81)	IL-17F	 56	 3.46	(0.34	–	8.89)	IL-21	 78	 4.78	(0.02	–	10.85)	IL-22	 97	 6.44	(4.44	–	10.93)	IL-23	 56	 0.60	(0.12	–	9.16)	IL-25	 63	 0.16	(0.005	–	0.46)	IL-31	 94	 31.83	(16.84	–	57.44)	IL-33	 80	 5.01	(1.22	–	11.76)	IFN-γ	 92	 1.93	(1.01	–	3.50)	sCD40L	 59	 0.87	(0.07	–	6.54)	TNF-α	 87	 0.64	(0.11	–	3.26)	
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Table	A2.	Concentrations	of	Th17-related	cytokines	according	to	randomization	arm	at	crossover	
	
		 NuvaRing	(n=34)	 NET-EN	(n=34)	 COCP	(n=37)	 	Kruskal	Wallis	 NuvaRing	vs	NET-EN	 NuvaRing	vs	COCP	 NET-EN	vs	COCP		 	 Median	and	IQR	 	 																											P-value	Produced	by	Th17	cells	 	 	 	 		 Adj.	 	 Adj.	 	 Adj.	 	 Adj.	IL-17A	 3.24	(0.91	-	7.69)	 1.05	(0.62	-	2.50)	 1.48	(1.01	-	2.24)	 0.029	 0.185	 0.009	 0.135	 0.110	 0.196	 0.225	 0.970	IL-17F	 6.83	(0.34	-	23.86)	 0.34	(0.34	-	10.80)	 0.80	(0.34	-	10.14)	 0.090	 0.192	 0.033	 0.142	 0.118	 0.196	 0.658	 0.970	IL-21	 12.12	(3.75	-	23.59)	 4.51	(0.01	-	16.10)	 7.22	(2.35	-	11.43)	 0.060	 0.185	 0.039	 0.142	 0.049	 0.147	 0.519	 0.970	IL-22	 9.22	(4.57	-	21.83)	 7.00	(4.05	-10.81)	 6.43	(4.32	-	11.73)	 0.363	 0.161	 0.173	 0.196	 0.285	 0.328	 0.852	 0.970		 	 	 	 		 	 	 	 	 	 	 	Differentiation	of	Th17	cells	 	 	 	 		 	 	 	 	 	 	 	IL-6	 3.43	(0.69	-	28.10)	 1.01	(0.17	-	13.56)	 1.01	(0.36	-	6.51)	 0.074	 0.185	 0.076	 0.483	 0.030	 0.147	 0.943	 0.970	IL-1β	 61.12	(2.70	-	152.0)	 10.68	(0.25	-	76.34)	 11.32	(0.36	-	56.51)	 0.067	 0.185	 0.061	 0.142	 0.032	 0.147	 0.970	 0.970	IL-23	 4.56	(0.12	-	13.27)	 3.99	(0.12	-	11.43)	 0.59	(0.12-9.54)	 0.408	 0.408	 0.387	 0.142	 0.184	 0.243	 0.735	 0.970	IL-33	 8.51	(3.43	-	22.19)	 3.50	(0.23	-	10.13)	 3.65	(1.08	-	9.84)	 0.066	 0.185	 0.034	 0.142	 0.063	 0.156	 0.605	 0.970	TNF-α	 1.21	(0.29	-	6.69)	 1.38	(0.03	-	3.62)	 0.32	(0.13	-	2.41)	 0.177	 0.279	 0.344	 0.396	 0.045	 0.147	 0.583	 0.970		 	 	 	 		 	 	 	 	 	 	 	Regulators	of	Th17	cells	 	 	 	 		 	 	 	 	 	 	 	IL-4	 0.52	(0.05	-	5.42)	 0.05	(0.05	-	1.38)	 0.05	(0.05	-	1.51)	 0.170	 0.279	 0.074	 0.142	 0.168	 0.243	 0.777	 0.970	IL-10	 0.31	(0.01	-	1.81)	 0.01	(0.01	-	1.17)		 0.01	(0.01	-	0.56)	 0.186	 0.279	 0.483	 0.483	 0.073	 0.156	 0.248	 0.970	IL-25	 0.37	(0.01	-	1.51)	 0.01	(0.01	-	0.62)	 0.01	(0.01	-	0.45)	 0.067	 0.185	 0.059	 0.142	 0.037	 0.147	 0.817	 0.970	IL-31	 54.09	(19.30	-	108.10)	 26.63	(17.14	-	61.97)	 34.99	(21.03	-	65.77)	 0.272	 0.358	 0.131	 0.196	 0.360	 0.370	 0.373	 0.970	IFN-γ	 2.95	(1.21	-	8.73)	 2.25	(0.51	-	3.99)	 1.81	(0.84	-	4.03)	 0.347	 0.388	 0.226	 0.282	 0.195	 0.243	 0.947	 0.970	sCD40L	 6.70	(0.07-11.93)	 0.07	(0.07	-	8.90)	 0.32	(0.13	-	2.41)	 0.286	 0.358	 0.121	 0.196	 0.370	 0.370	 0.447	 0.970	Intention	to	treat	analysis	(ITT).	P-value	adjusted	(Adj.)	using	the	Benjamini-Hochberg.	
